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Abstract 
Biocatalysis complements the classical organic synthesis, and in many cases the superior selectivity of a 
biocatalyst is a strong driver explaining why there are an increasing number of processes where traditional 
organic synthesis has been replaced or combined with biocatalytic industrial process steps. An important fact 
is also that different types of selectivity make biocatalysis an excellent tool for overcoming difficulties typically 
associated with organic synthesis. Regioselectivity of the biocatalysts offers potential process simplification 
compared to the organic synthesis routes (reduction of the number of protective/deprotective steps), and 
stereoselectivity of the biocatalyst enables production of the desired chiral compounds, which often are 
building blocks of APIs. Currently there are many established processes in the industry using biocatalysis (≈ 
300), e.g the usage of lipases, esterases, ketoreductases and proteases and many more emerging biocatalysts 
such are monoamine oxidases, transaminases and P450 monooxygenases to name a few. 
The focus of this thesis is the biocatalytic synthesis of small molecule pharmaceuticals (Mw<1000), and in 
particular the production of optically pure amines via ω-transaminases, which is an interesting class of reactions 
for the pharmaceutical industry. There are many challenges related to the realization and implementation of 
these technologies, and attempts of tackling them have been numerous. In some cases ω-transaminase 
catalyzed reactions are thermodynamically challenged and equilibrium shifting strategies are required. The 
proposed equilibrium shifting strategies are selection of an amino donor, excess of an amino donor, in-situ 
product removal (ISPR) and in-situ co-product removal. (ISCPR). For severely thermodynamically challenged 
reactions ISCPR by enzymatic cascades often provides the only viable option as equilibrium shifting strategy. 
In the literature several enzymatic cascades have been reported as an ISCPR for the ω-transaminase systems, 
however in most cases no process considerations have been made and the consequences of using a givens 
cascade in an industrial process context have thus not been considered properly. 
In this research lactate dehydrogenase (LDH) (E.C. 1.1.1.27), alanine dehydrogenase (E.C. 1.4.1.1) (AlaDH) and 
yeast alcohol dehydrogenase (E.C. 1.1.1.1) (YADH) have been researched as co-product degrading enzymes 
and glucose dehydrogenase (GDH) (E.C. 1.1.1.47) and formate dehydrogenase (E.C. 1.2.1.2) (FDH) as co-factor 
regeneration enzymes. Additionally pyruvate decarboxylase (E.C. 4.1.1.1) (PDC) and acetolactate synthase (E.C. 
2.2.1.6) (ALS) have been considered as co-product degrading options. 
This work presents a procedure for cascade selection based on process considerations: thermodynamics, 
selectivity and operational stability while the final selection is further supported by the use of kinetic models. 
From the above presented cascade system options, the selection procedure identified the LDH/FDH cascade 
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system as the system that is most promising for future industrial implementation. Furthermore, the required 
improvements of the ω-transaminase have been identified as a function of the added cascade enzymes and 
for the case γLDH = 11 g L-1, γFDH = 11 g L-1 and cNADH = 0.1 mmol L-1, it was found that the ω-transaminase 
activity expressed as Vmax_f,r is required to be 55.33 mmol min-1 L-1 to achieve 95 % conversion within 24 h. 
Further investigation concluded that a significant LDH concentration reduction is possible if inhibition by 
lactate is alleviated (preferably by protein engineering). This thesis identified the UFMR (UltraFiltration 
Membrane Reactor) as a viable process design option and charge analysis showed that ISPR is possible via ion 
exchange resins or electrodialysis. An ISPR example showed that process intensification could yield significant 
reductions in the required ω-transaminase activity improvement (up to five fold improvement) needed to 
achieve a viable industrial process, as well as reduction of required tolerance toward product inhibition. 
Although this thesis has been based on a specific case of a severely thermodynamically challenged ω-
transaminase reaction (Keq = 4.03∙10-5), the selection framework can be transferred to any thermodynamically 
challenged reaction where the use of ISCPR by enzymes is considered to shift the equilibrium. Therefore, this 
work delivers: a) a method for initial investigation of thermodynamic limitations and viability of one or more 
equilibrium shifting strategies; b) a method for selecting a viable cascade option for ISCPR based on industrial 
conditions; c) information on the required enzyme performance e.g. the activity of the ω-transaminase, and 
potentially required compromises using process intensification tools and methods. 
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Résumé på dansk 
Det ses i stigende grad at processer der traditionelt er baseret på organisk syntese udskiftes eller kombineres 
med biokatalytiske procestrin. Dette skyldes i høj grad biokatalysatorers generelt fortræffelige selektivitet. 
Derudover giver de forskellige former for selektivitet, et enzym kan have (f.eks. regio-selektivitet, stereo-
selektivitet og substrat selektivitet), fremragende muligheder til at overvinde vanskeligheder der typisk er 
forbundet med selektiv organisk syntese. Biokatalysatorers regio-selektivitet kan potentielt forenkle organisk 
syntese baserede processer, da der i mindre grad vil være behov produkt beskyttende og ikke beskyttende 
proces trin. Biokatalysatorers stereo-selektivitet gør det muligt at producere de ønskede chirale molekyler i 
højere grad. Chirale molekyler er meget ofte brugt som byggesten til aktive farmaceutiske komponenter (APIs), 
hvor det er vigtigt at have det chirale molekyle i så ren form som muligt. Nu til dags er der relativt mange 
industrielle processer der benytter biokatalyse (~300).  Disse processer benytter typisk biokatalysatorer som 
lipaser, esteraser, ketoreductaser og proteaser. Ydermere, er der udsigt til industriel brug af mange flere nye 
typer af biokatalysatorer, f.eks. monoaminooxidaser, transaminaser og P450 monooxygenaser.  
Denne afhandling fokuserer på syntesen af lægemidler baseret på små molekyler (MW<1000) ved brug af 
biokatalysatorer. Der fokuseres især på syntesen af optisk rene chirale aminer ved brugen af ω-transaminaser, 
der har stor interesse for den farmaceutiske industri. Der er mange udfordringer forbundet med brugen af ω-
transaminase katalyserede reaktioner, og antallet af forsøg på overkomme disse udfordringer har også været 
talrige. En udfordring er bland andet at ω-transaminase reaktioner i nogle tilfælde er termodynamisk 
udfordrede, hvilket gør det nødvendigt at benytte diverse strategier for at skifte reaktionsligevægten. Oftest 
for at skifte reaktionsligevægten benyttes strategier, som at udskifte amindonoren, tilføre et overskud af 
amindonoren, samt fjerne produktet og/eller biproduktet in-situ (ISPR / IScPR).   I de tilfælde hvor reaktionerne 
er ekstremt termodynamisk udfordret, er det oftest kun muligt at benytte IScPR med enzymatiske 
kaskadereaktioner til at skifte reaktionsligevægten. I den videnskabelige litteratur findes der flere eksempler 
på ω-transaminase processer, der benytter flere forskellige enzymatiske kaskadereaktioner som IScPR strategi. 
Dog i mange af disse rapporterede tilfælde mangler der at blive taget højde for hvordan implementeringen af 
kaskadereaktioner influerer de industrielleprocesser.  
Det forskningsmæssige fokus for denne afhandling er baseret på enzymatiske kasakadereaktioner med 
laktatdehydrogenase (LDH) (EF 1.1.1.27), alanindehydrogenase (AlaDH) (EF 1.4.1.1) og 
gæralkoholdehydrogenase (YADH) (EF 1.1.1.1) til nedbrydning af biprodukter, IScPR strategi. Ydermere, er 
brugen af glukosedehydrogenase (GDH) (EF 1.1.1.47) og formiatdehydrogenase (FDH) (EF 1.2.1.2) blevet 
undersøgt for deres potentiale til at regenerere enzym co-faktorer.  Derudover, er brugen af 
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pyruvatdecarboxylase (PDC) (EF 4.1.1.1) og acetolactatsyntase (ALS) (EF 2.2.1.6) som IScPR strategier også 
undersøgt. 
I denne afhandling præsenteres en procedure der er yderst nyttig til at udvælge kaskadesystemer, til at skifte 
reaktionsligevægten, baseret på procesovervejelser. Procesovervejelserne inkluderer termodynamikken for den 
givne reaktion, selektiviteten og stabilitet ved drift. Den endelige udvælgelse er yderligere understøttet af 
brugen af kinetiske modeller. Fra de foroven præsenterede kaskade systemer indikerede den foreslåede 
procedure, at LDH/FDH kaskadesystemet er det mest lovende system, for potentiel fremtidig industriel 
implementering. Derudover, blev det observeret at forbedringerne i ω-transaminase synteseruten kunne 
beskrives som en funktion af mængden af tilsat kaskade enzym. I et tilfælde med γLDH = 11 g L-1, γFDH = 11 g 
L-1 and cNADH = 0.1 mmol L-1, blev det fundet at ω-transaminase aktiviteten udtrykt ved Vmax_f,r er nød til at være 
55.33 mmol min-1 L-1, for at opnå 95% omdannelse indenfor 24 timer. Yderligere undersøgelser indikerede, at 
der er muligt væsentligt at reducere LDH koncentrationen, hvis inhiberende effekter fra laktat på LDH mindskes, 
f.eks. ved protein engineering. Denne afhandling fandt frem til at en ultrafilteringsmembranreaktor (UFMR) er 
en lovende procesløsning. Analyse af polariteten af komponenterne i de benyttede reaktionssystemer 
indikerede at det potentielt vil være muligt at foretage ISPR fjernelse ved brug af enten ionbytnings partikler 
eller elektrodialyse. Et ISPR casestudy viste at denne form for procesintensivering, betydeligt kan mindske 
industrille proceskrav for ω-transaminase aktivitet, op til fem gange mindre, samt markant reducere produkt 
inhiberende effekter. 
På trods af denne afhandling er baseret på et konkret casestudy for en termodynamisk udfordret ω-
transaminase reaktion (Keq = 4.03∙10-5), så kan den foreslåede kaskadeudvælgelsesprocedure ligeledes 
benyttes til andre termodynamiske udfordrede reaktioner. Det kræver dog at der overvejes IScPR 
implementering ved brugen af kaskadeenzymer til at forskydereaktionsligevægten. Gennem dette arbejde 
leveres der derfor følgende: a) en metode til at lave indledende undersøgelser af termodynamiske 
begrænsninger, samt brugbarheden af en eller flere strategier til at forskyde reaktionsligevægten; b) en metode 
til at udvælge brugbare IScPR kaskadereaktioner baseret på industrielt relevante procesforhold; c) og 
oplysninger om påkrævet ydeevne for enzymer, f.eks. aktiviteten af ω-transaminase, og potentielt mulige 
proceskompromiser der kan foretages ved brugen af procesintensiveringsværktøjer og metoder.
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Abreviations 
ABREVIATIONS DESCRIPTION 
ADP Adenosine diphosphate 
AHAS Acetohydroxyacid synthase 
AlaDH Alanine dehydrogenase 
ALS Acetolactate synthase 
API Active pharmaceutical ingredient 
ATA ω-transaminase 
CCS-IONP Catechol-chitosan iron oxide nanoparticles 
CDW Cell dry weight 
CS-IONP Chitosan iron oxide nanoparticles 
DMSO Dimethyl sulfoxide 
DSP Downstream processing 
e.e. Enantiomeric excess 
E-PLP Enzyme – pyridoxal-5-phosphate complex 
E-PMP Enzyme – pyridoxaamine-5-phosphate complex 
EtOH Ethanol 
FAD Flavin adenine dinucleotide 
FDH Formate dehydrogenase 
FMN Flavin mononucleotide 
GDH Glucose dehydrogenase 
IONP Iron oxide nanoparticles 
i-PrNH2 i-Propylamine 
ISCPR in-situ co-product removal 
ISPR in-situ product removal 
ISSS in-situ substrate supply 
LDH Lactate dehydrogenase 
MBA Methylbenzylamine 
MTBE Methyl tert-butyl ether 
NAD+ Nicotinamide adenine dinucleotide 
NADP+ Nicotinamide adenine dinucleotide phosphate 
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ABREVIATIONS DESCRIPTION 
PAT Process analytical technology 
PDC Pyruvate decarboxylase 
PLP Pyridoxal-5-phosphate 
PMP Pyridoxaamine-5-phosphate 
PSE Process system engineering 
Ribo Ribose ring 
ThDP Thiamine diphosphate 
ThPP Thiamine pyrophosphate 
UFMR Ultrafiltration membrane reactor 
YADH Yeast alcohol dehydrogenase 
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Symbols 
ABREVIATIONS DESCRIPTION UNIT 
[A], cA Concentration of component A [mmol L-1] 
e Natural logarithm [-] 
F Flow rate [L min-1] 
I Inhibitor concentration [mmol L-1] 
kd Dissociation constant [h-1] 
Keq Thermodynamic equilibrium constant [-] 
k Reaction rate constant [min-1] 
Ki Inhibition constant [mmol L-1] 
Km Michaelis-Menten constant [mmol L-1] 
logP Partitioning coefficient [-] 
Mw Molar weight [g mol-1] 
na Amount of component a [mmol L-1] 
pKa Acid dissociation constant [-] 
pvap Vapor pressure [mm Hg] 
R Gas constant [J mol-1 K-1] 
r0 Initial reaction rate [mmol min-1 g-1] 
rt Reaction rate at time t [mmol min-1 g-1] 
Saq Aqueous solubility [g L-1] 
t Time [min, h] 
T Temperature [K, °C] 
Tm Melting temperature [°C] 
t1/2 Half-life time [h] 
V Volume  [L] 
Vmax 
Maximum velocity [mmol min-1 g-1] 
X 
Amino donor excess [-] 
α 
Stoichiometric coefficient [-] 
γ 
Mass concentration [g L-1] 
ΔG° 
Gibbs free energy change [J mol-1] 
τ 
Residence time [min] 
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1 Introduction 
1.1 Background 
Indeed, biocatalysis complements the classical organic synthesis in many ways and its regio- stereo- and 
substrate selectivity led to the combination with or replacement of more classical organic synthesis approaches. 
The usage of the biocatalysis is continuously increasing in the pharmaceutical industry due to the greater 
availability of the enzymes and the diversity of the reactions enzymes can catalyze1. The new potentials for the 
pharmaceutical industry now lies in the stereoselectivity and application of biocatalysis of valuable 
components, e.g. optically pure amines. In some cases these reactions are severely thermodynamically 
challenged and a strategy for shifting of the equilibrium is imperative, e.g. excess substrate, in-situ product 
removal (ISPR) or in-situ co-product removal (ISCPR). For the cases where the co-product causes inhibition or 
it is preferable that the product remains in the reaction mixture, a possible strategy is in-situ co-product 
removal (ISCPR). There are two major requirements for ISCPR of severely thermodynamically limited reactions: 
to reduce selectively the concentration of co-product to very low concentration and to maintain it low over the 
course of the reaction. In such cases the use of enzymes for ISCPR purposes offers a clear advantage over other 
techniques. Enzymes are selective towards the desired molecule (co-product) which causes the thermodynamic 
shift only to the product side of the reaction and are extremely successful at removing the co-product at 
already low concentrations.  
1.2 Motivation 
In the particular case of biocatalytic synthesis of chiral components a synthesis of optically pure amines as 
pharmaceutical building blocks catalyzed by ω-transaminase is of high interest to the pharmaceutical industry. 
As the necessity for this process is increasing, it is extremely important for overcoming different challenges to 
develop a toolbox, e.g. expanding ω-transaminase libraries, increasing the library of enzymes capable of 
removing different co-products or other process related tools.  
In some cases ω-transaminase catalyzed reactions are thermodynamically challenged and it is believed that 
reactions with low Keq values (< 0.1) are too severely thermodynamically challenged and, as a consequence, 
that the process development is impractical. The hypothesis that is tested in this thesis is to show that reactions 
with Keq values lower than 0.1 can be successfully implemented into a process, and that the cascades are a 
viable solution for this challenge. A case study was chosen where acetophenone and alanine are used as 
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substrates in reactions where a severe thermodynamic challenge is present (Keq = 4.03∙10-5). The severity of the 
thermodynamic equilibrium of this particular system makes it a very interesting model case for an investigation 
of methods that are suitable for overcoming the thermodynamically challenged reactions. Additionally, it has 
been found that the co-product pyruvate can be removed by several different cascade options. Although these 
cascades have been reported in the literature no systematic comparison or guidelines for selection of specific 
cascades has been developed. Therefore, it is of high importance and the main focus of this thesis to develop 
methods for comparison and selection of different cascade systems with the final aim of achieving industrial 
implementation. 
1.3 Objectives 
The main objectives of this thesis was to develop a strategy for comparison of possible cascade enzymes and 
to select a specific process setup best suited to the characteristics of the selected cascade system. While 
pursuing the main objectives, following points were also addressed: 
 The selection of cascade candidates was based on industrial conditions 
 Final cascade selection was supported by developing and using kinetic models 
 Further debottlenecking of selected cascade was possible investigating kinetic behavior identifying 
product inhibition of co-product consuming enzyme as possible challenge of process development 
 While discussing a process setup several major topics were addressed 
o Formulation of all biocatalytically active components (enzymes and co-factors) plays an 
important role in process development and a part of the discussion is dedicated to this 
strategy. 
o Batch vs continuous, one pot vs two pots, feeding strategies, process control and downstream 
processing are some of the process considerations that are discussed. 
o The decision for choosing one process implementation option over another is motivated on 
the basis of simulations with the developed models or literature suggestions of similar process 
implementations. 
o The use of process intensification techniques, e.g. ISPR can successfully overcome some of the 
process challenges, e.g. ω-transaminase with product inhibition can be used or lower activity 
of ω-transaminase is required for successful process implementation or the combination of 
those two enzyme characteristic. 
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1.4 Structure of the PhD Thesis 
The thesis has been divided into 6 main chapters: 
 Chapter 2 (Literature Overview) provides an overview of the current developments in the field of 
synthesis of optically pure amines by ω-transaminases. The overview focuses on the reported cascade 
systems used for removing the co-product in ω-transaminase system, process implementations and 
biocatalyst formulation, to name a few. The objective of this overview is to summarize the current 
knowledge and state of the art of the research in the field of cascade systems, but also to indicate 
clearly that no decision making tools for cascade selection has been developed. 
 Chapter 3 (Considerations for a Cascade Selection) is a framework designed to select a cascade 
system for thermodynamically challenged ω-transaminase system and ISCPR by enzymes is 
equilibrium shifting strategy of choice. The selection process is focused on guidelines for successful 
implementation of biocatalytic processes focusing mainly on final product concentration (> 50 g L-1) 
and it is based on three important process considerations: thermodynamics of the system, substrate 
selectivity and operational stability of cascade enzymes. The objective of this chapter is to investigate 
the viability of proposed cascade candidates and select feasible candidates for further investigation. 
 Chapter 4 (Developing Kinetic Models of LDH, GDH and FDH Enzymes to Assist the Selection 
Process) discusses further selection of feasible cascade candidates. Kinetic models describing enzymes 
behavior in a very complex reaction media re develop to facilitate decision and to optimize enzyme 
concentrations. Detailed kinetic study also predicts the required ω-transaminase activity for a 95 % 
conversion within 24 h while debottlenecking of the overall cascade system identifies product 
inhibition of co-product removing enzyme (LDH) one of the mayor hurdles for rational enzyme 
consumption. 
 Chapter 5 (Industrial Perspectives and Process Strategies for Implementation of ω-
transaminase/LDH/FDH System) discusses the process implementation of the selected cascade 
candidate. Several process options are proposed based on process considerations and requirements, 
such as pH regulation, biocatalyst formation, one vs two pot system to name a few. Every process 
configuration is discussed and either backed by process simulations or examples from the literature. 
Finally, downstream processing strategies are discussed and the benefits of possible ISPR techniques 
are highlighted. The objective of this chapter is to give a better overview of possible process 
implementation options and to discuss choices made based on the process conditions. 
 Chapter 6 and 7 conclude the thesis, identify open challenges and discuss future perspectives. 
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2 Literature Overview 
2.1 Introduction 
The production of optically pure amines is an interesting topic for the pharmaceutical industry, particularly via 
biocatalysis when using e.g. ω-transaminases, an emerging technology. There are many challenges following 
the realization and implementation of these technologies and attempts of tackling them have been numerous. 
It is therefore the aim of this overview to give a comprehensive overview of the work that has been published 
in the literature by describing the challenges which can be placed into two groups: biocatalytic and 
thermodynamic challenges. The focus of this thesis is primarily on the latter challenge, and in this literature 
overview several relevant equilibrium shifting strategies have been discussed. The focus has been placed on 
the ISCPR by enzymes which have been extensively documented in the literature. However, no guidelines have 
been reported on how to choose a cascade for shifting the thermodynamic equilibrium, and how to perform 
its implementation to an industrial process. Another question that arises is what are the consequences of using 
a particular cascade in the industrial process? This literature overview lays the foundation for understanding 
the current state of research on the production of optically pure chiral amines by ω-transaminase in general, 
and more specifically the cascade options for shifting the equilibrium. The literature overview is a prelude for 
more detailed analysis described in the following chapters. 
The case study of asymmetric synthesis of optically pure amines by ω-transaminase places this work in the 
domain of the pharmaceutical industry. However the intent was that the conclusions made from observation 
of this system can be generic and implemented for a wide range of processes facing thermodynamic 
limitations. Currently, the enzymatic strategies for shifting the equilibrium are still not well established in the 
industry, and all investigated cases are so-called 1st generation processes, meaning all processes are still not 
industrially established. However, in the future these equilibrium shifting technologies will be part of a common 
process toolbox, and for achieving the well-defined and established industrial implementation as 2nd 
generation processes further research has to be conducted and an improved understanding of the cascade 
processes has to be obtained. 
2.2 Biocatalysis in the Pharmaceutical Industry 
Biocatalysis is already an established technology for some processes in the pharmaceutical industry, especially 
for the production of small-molecule pharmaceuticals. However continuous development of the biocatalysts 
and increased documentation on the broader substrate range they can catalyze makes biocatalysis applicable 
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for an increasing number of processes, not only in the pharmaceutical industry, but also for the production of 
fine and bulk chemicals. Biocatalysis is an interesting alternative to the current traditional metalo- and 
organocatalysis methods for several reasons. The biggest advantage is the outstanding selectivity of the 
biocatalyst, both with respect to regio- and stereoselectivity. This in turn decreases the complexity of classical 
synthetic routes by removing the need for multiple protection and deprotection steps. High selectivity also 
leads to higher yields. Reactions are usually performed under mild conditions, neutral pH, at room 
temperatures and in water medium without the need for organic solvents which in many cases can be 
carcinogenic and/or flammable. 
Enzymes have been developing in nature for millions of years and are very well adapted to their natural 
surroundings: the conditions inside the cell. The natural enzymes are somewhat selective towards their natural 
substrate2, tolerate small concentrations of substrates and products and operate under neutral pH and mild 
temperatures. However, these conditions are not suitable for the industrial processes. Traditionally, in the 
synthetic route a biocatalytic step was defined and a biocatalyst identified. The design of the process and 
process solutions were tailored to suit the biocatalyst properties and to overcome its shortcomings. In addition 
to the reaction engineering, attempts were made to stabilize and reuse enzymes by immobilization3. Nowadays 
however, it is possible to tailor the biocatalyst with specific properties (the ideal biocatalyst)4 to the needs of 
the process. The protein engineering methods e.g. directed evolution enabled the development of enzymes 
suited to the specific industrial process. This, so-called third wave of biocatalysis5 together with the 
development of other supporting technologies such as miniaturization technologies for high-speed screening 
and mathematical modelling, makes biocatalysis a rapidly expanding technology in the pharmaceutical 
industry and beyond. 
The industrial biocatalytic process has to be economically viable, and should therefore be comparable to the 
values and economic parameters of a competing chemical process for producing the same product. Depending 
on the complexity of the biocatalytic process, there are many factors which determine the economic viability, 
and the published data on the economics of biocatalytic processes is scarce. However, the literature identifies 
two very important parameters for every biocatalytic process6-8. The first parameter is the added value of the 
biocatalyst and can be linked to the biocatalytic productivity [gproduct/genzyme]. The higher the biocatalyst 
productivity, the lower the quantities that have to be used to achieve the desired amount of the product. The 
second parameter is the concentration of the product which determines the type of downstream equipment 
and the effectiveness of the product recovery. A more detailed and comprehensive list of process metrics which 
can be used for the comparison of the biocatalytic processes is given in the Table 1 which was presented by 
Tufvesson et al.8 The authors point out that these metrics should be considered more as general 
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recommendations and that factor listing and evaluation for economic feasibility is determined on a case-to-
case basis. 
Table 1 Guidelines for successful biocatalytic processes adapted from 8 
Fermentation  
Cell titer 50 – 100 g CDW L-1 (if intra cell.) 
Protein titer 1-10 g L-1 
Biocatalyst formulation  
Retention of activity High 
Stabilization Improve catalyst productivity > 5 times 
Reaction  
Product concentration > 50 g L-1 
Catalyst productivity 
10 – 35 g product g-1 whole cell (CDW) 
100 – 250 g product g-1 free enzyme (crude) 
50 – 100 g product g-1 immob. enzyme 
Stereoselectivity > 98 % ee 
Yield > 90 % 
There has been much effort in making the pharmaceutical processes greener. Several guidelines for achieving 
greener processes have been published, and biocatalysis provides certain opportunities to address some of 
these guidelines. Unlike chemocatalysis where catalysts are often heterogeneous and the catalytically active 
components are usually transition metals, biocatalysts are completely made from renewable materials. 
Furthermore, certain pharmaceutical processes involve long synthetic routes which result in a high E-factor 
[kgwaste/kgproduct]9, 10. Due to the exquisite selectivity of the biocatalysis and the ability to skip protection and 
deprotection steps (stereoselectivity), the E-factor can be significantly lowered, thus implying a greener 
process. The biocatalytic reactions are usually performed at ambient temperatures, at mild pH values in 
aqueous systems and other environmental benefits can also be achieved, e.g. the replacement of hazardous 
reagents or organic solvents in reactions11. 
2.3 Synthesis of Optically Pure Amines 
The reactions in the human body are based on chirality, and therefore one stereoisomer of a certain compound 
is usually much more active than another. Moreover, the undesired stereoisomer can lead to reactions 
generating unwanted side effects. This is, therefore, one of the motivations of the pharmaceutical industry to 
produce optically pure compounds or building blocks. Out of many functional groups, synthesis of optically 
pure amines represents one important segment in the production of optically pure compounds. 
One of the most widely used chemocatalytic approaches for production of chiral amines is crystallization of 
racemic amines with chiral carboxylic acids12. This method starts from the racemic mixture, and therefore the 
maximum yield is only 50 %. Another chemocatalytic method relies on the reduction of the C=N double bond 
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from the prochiral precursor13. However, as described previously in the chapter 2.2 the biocatalytic approach 
gives an interesting alternative to the traditional methods of preparing chiral amines and it is the focus of this 
thesis. There are two main strategies of biocatalytic synthesis of chiral amines: (dynamic) kinetic resolution and 
asymmetric synthesis. 
2.3.1 Enzymatic Kinetic Resolution of Racemic Amines 
Kinetic resolution of racemic amines is a method that differentiates between the two enantiomers in the 
racemic mixture. The undesired enantiomer is reacted away thus increasing the optical purity of the racemic 
mixture. The major drawback of this method is the maximum conversion of only 50 % in a single kinetic 
resolution step. To improve this method and achieve higher yields, a racemization step was introduced to 
return the undesired product to the starting racemic mixture. This method is then called dynamic kinetic 
resolution. Either kinetic resolution or dynamic kinetic resolution of racemic amines can be achieved by using 
several enzymes. The overview of these technologies and applications is shown in the Table 2. 
Table 2 The overview of kinetic resolution methods for production of chiral amines 
enzyme reaction scheme literature 
hydrolyases 
(E.C. 3.x.x.x) 
 
Figure 1 (Dynamic) kinetic resolution with hydrolases adapted from Höhne et. al.14 
15-18 
monoamine 
oxidases 
(E.C. 1.4.3.4) 
 
Figure 2 Deracemization with monoamine oxidase adapted from Höhne et. al.14 
14, 19-21 
ω-transaminases 
(E.C. 2.6.1.18) 
 
Figure 3 Kinetic resolution by ω-transaminase adopted from Höhne et. al.14 
22-35 
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2.3.2 Asymmetric Synthesis of Optically Pure Amines 
Asymmetric synthesis, also called enantiomeric or chiral synthesis, is defined as a method that favors the 
formation of a specific enantiomer. The starting material is non-chiral and the enzyme is (R) or (S) selective, 
resulting in (R) or (S) chiral product respectively. The theoretical yield is 100 % which makes this method very 
interesting. The overview of possible biocatalytic methods is given in the Table 3. 
Table 3 The overview of asymmetric synthesis methods for the production of chiral amines 
enzyme Reaction scheme literature 
ketimine 
reductases 
(E.C. 1.5.1.25)  
Figure 4 Asymmetric reduction of aryl imines adopted from Höhne et. al.14 
36 
decarboxylases 
(E.C. 4.1.x.x)  
Figure 5 Combined use of L-threonine aldolase and L-tyrosine decarboxylase 
adapted from Turner et. al.37 
38 
amine 
dehydrogenases 
(E.C. 1.4.99.3) 
 
Figure 6 Asymmetric synthesis with amine dehydrogenase adapted from Höhne 
et. al.14 
39, 40 
ω-transaminases 
(E.C. 2.6.1.18) 
 
Figure 7 Asymmetric synthesis with ω-transaminase adopted from Höhne et. al.14 
41, 42 
 
2.3.2.1 Asymmetric Synthesis of Chiral Amines by ω-transaminase 
The first work regarding the production of optically pure amines by ω-transaminase was done by Stirling et. 
al24 describing a kinetic resolution of a racemic mixture of amines. This research continued until 1999, favoring 
the (dynamic) kinetic resolution due to the faster reaction rates and favorable equilibrium. In 1999, the 
groundbreaking work by Shin and Kim41 was published, involving the asymmetric synthesis of chiral amines by 
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the ω-transaminase. The asymmetric synthesis approach started to become a hot topic as the need for cheaper 
and simpler methods for production of chiral amines arose. Compared to the kinetic resolution technologies 
which require prior synthesis of racemic amines14, asymmetric synthesis is usually favored due to the theoretic 
yield of 100 % and the fact that non chiral substrates are much more affordable than racemic mixtures43. 
Although the asymmetric synthesis approach promises a simpler method that achieves higher yields, there are 
challenges which are still being addressed today and will be discussed extensively in this thesis. 
Much work has been done to solve the crystal structure of the ω-transaminases44-49. The reaction catalyzed by 
the ω-transaminases follows the Ping Pong Bi Bi mechanism which will be described in more detail in chapter 
2.3.2.3.1.1. However, ω-transaminase requires pyridoxyl-5-phosphate co-factor (PLP) to transfer the amino 
group from an amino donor to acceptor50. The overall reaction can be divided into two half reactions where 
the first half reaction is the oxidative deamination of an amino donor. As shown in Figure 8 the PLP binds to 
the enzyme, forming an enzyme-PLP complex. The amino group from the amino donor is transferred to the E-
PLP complex forming an enzyme - pyridoxamine-5-phosphate (E-PMP) complex while the residual amino 
donor is transferred to a corresponding ketone. The second half reaction is the reductive amination of the 
amino acceptor. The amino group from the E-PMP complex is transferred to the ketone substrate and chiral 
amine is produced, whilst the E-PMP complex is regenerated to the E-PLP. Such co-factor recycling system 
within the same reaction and using a single enzyme gives an outstanding advantage compared to the co-factor 
recycling systems of oxidation and reduction reactions, e.g. using dehydrogenases51. 
 
Figure 8 The mechanism of ω-transaminase reaction: oxidative deamination and reductive amination adapted from 52 
A diversity of primary amines show reactivity towards the ω-transaminases as amino donors. Both alkyl and 
arylalkyl amines are accepted by the ω-transaminase whilst the latter amines show surprisingly higher 
reactivities53. In the literature, α-MBA has been identified as an amino donor with high reactivity and several 
cases where other amino donors showed higher reactivity were reported, e.g. 1-aminoindan53, 54, 1-
aminotetralin53, 1-methyl-3-phenylpropylamine54, benzylamine54 and L-α-alanine54. Reactivity of the ketones 
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varies depending on the type of the ketone used, e.g. the highest reactivities have been found for the α-keto 
acids (pyruvate) and aldehydes (propanal, benzaldehyde)52. However, the reactivity of prochiral ketones, which 
are the substrates for the production of the highly desires chiral amines, have been found to be lower than the 
pyruvate. This is the reason why the asymmetric synthesis of arylalkyl amines, e.g. (S)-α-MBA when using 
alanine as amino donor is challenging at best. 
The potential usage of the ω-transaminases in the production of industrially valuable chiral components is 
significant. Components containing a chiral amine moiety are used as building blocks in a wide range of 
pharmaceutical or bioactive components and one such example is the production of (R)-amphetamine55, 56. (R)-
4-phenylbutan-2-amine is the precursor for the antihypertensive dilevalol57 and (R)-p-metoxyamthetamine is 
a building block for the bronchodilator (R,R)-formoterol58. 1-phenyl-1-propylamine is a precursor for a potent 
antidepressant59 and (S)-2-amino-1-methoxypropane is a building block for the herbicides metolachor or 
Outlook®23. (S)-Rivastigmine {(S)-3-[1-(dimethylamino)-ethyl]phenyl ethyl-(methyl)carbamate} is one of the 
most potent drugs for treatment of Alzheimer’s desease60. The possibility of the synthesis of β-amino acids by 
the ω-TA has also been reported in the literature61-64. These amino acids are the building blocks of many natural 
and synthetic drugs like antibiotics, enzyme inhibitors or peptide mimicking compounds with pharmaceutical 
properties, e.g. taxol65. 
As seen from these examples both enantiomers of chiral amines do have significant use, and it is therefore 
important for the pharmaceutical industry to find and develop both (R)-selective and (S)-selective ω-
transaminases. The majority of the transaminases reported are (S)-selective23, however a few were reported to 
be (R)-selective66, 67 including the excellent example of enhanced ω-transaminase by directed evolution 
resulting in an enzyme capable of taking a bulky substrate in the case of Sitagliptin production68. 
2.3.2.2 Process Overview 
One of the most extensive reviews regarding the process considerations of ω-transaminase and its 
implementation was reported by Tufvesson et al.42 The authors show that the process of production of optically 
pure amines by ω-transaminases consists of four major steps as shown in Figure 9: fermentation, biocatalyst 
formulation, reaction and product recovery. 
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Figure 9 Overview of the process of production of optically pure amines by ω-transaminase adapted from Tufvesson et. al.42 
In the fermentation process the biocatalyst is expressed in the host organism which produces the desired 
enzyme activity. The enzyme is then transferred into the required biocatalytic form. This form can be either 
whole-cell form or crude extract, depending on the process requirements, while the stability and reusability of 
the biocatalyst can be enhanced by various immobilization techniques69. However, the fermentation process 
and the biocatalyst formulation are optional processes and can be circumvented by purchasing the biocatalyst 
in the desired form from an external supplier. After the biocatalytic reaction is carried out under the desired 
conditions the biocatalyst is removed. In the last step the product is recovered and purified from the reaction 
mixture. 
2.3.2.3 Process Challenges and Strategies 
There are many challenges described in the literature concerning the implementation of an ω-transaminase 
catalyzed processes. These challenges can be divided into two major groups: challenges arising from the 
biocatalyst characteristics and thermodynamic equilibrium related challenges. The overview of those 
challenges and possible strategies to overcome them is given in the Table 4. 
Table 4 The overview of process challenges and strategies in an ω-transaminase catalyzed reactions 
group challenge Strategy 
BIOCATALYST 
Substrate inhibition ISSS, protein engineering 
Product inhibition ISPR, protein engineering 
Stability 
Immobilization, protein 
engineering 
THERMODYNAMICS Unfavorable Keq value 
Excess substrate, choice of amino 
donor, ISPR, ISCPR 
 
Fermentation Biocatalyst 
formulation
Reaction
Downstream 
Product Separation
Substrates
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2.3.2.3.1.1 Biocatalyst Challenges 
As mentioned before, wild-type enzymes are often not applicable to the industrial bioconversions due to their 
inability to cope with high substrate or product concentrations and unnatural substrates. To overcome these 
challenges, biocatalytic improvements have to be made and, while improving the biocatalyst, multiple 
improvement targets are often set. However, it is difficult to screen for multiple desired properties 
simultaneously4 and a stepwise improvement strategy may be required. One of the most important properties 
that usually has to be improved is the enzyme activity which in turn decreases enzyme load and the added cost 
of the enzyme. Such attempts have been made for the ω-transaminase and one excellent example is the work 
by Martin et al.70 where the authors managed to increase the activity of the enzyme by a factor of almost 300 
while at the same time improving the stability of the enzyme towards the reaction conditions. 
The ω-transaminase follows a Ping-Pong Bi Bi mechanism described in the literature71, 72 and shown in the 
Figure 10. The enzyme exists in the E form and binds to the PLP forming the E-PLP complex followed by the 
bonding of the substrate A. Product P is then released and the enzyme form is changed from the E form to the 
F form which represents the E-PMP complex. The product B binds to the F form of the enzyme releasing the 
co-product Q and the enzyme reverts back to the E form. However, the E and the F form of the enzyme are not 
significantly different and it is not surprising that the substrate A could have some affinity towards the F form 
of the enzyme, as well as the substrate B might have some affinity towards the E form. These undesired affinities 
will result in a lower reaction rate at certain substrate concentrations. A similar effect can be observed with the 
products, e.g. Q can bind to the F form of the enzyme forming the dead-end complex. 
 
Figure 10 Ping-Pong Bi Bi mechanism adopted from the literature72 
Product and substrate inhibition were reported in the literature as a major challenge in the kinetic resolution 
approach where both amine enantiomers can act as inhibitors forming a dead-end complex73. The ketone 
produced from the amine also showed high product inhibition26, 74 and to overcome this challenge a significant 
research effort was done and numerous process solutions have been proposed. One of the proposed process 
solutions for alleviating the product inhibition in the kinetic resolution approach was applied by Shin and Kim 
by utilizing an auxiliary phase (organic solvent) for the extraction of the ketone25. There were other instances 
E-PLP = E E
(EA ↔ FP) (FB ↔ EQ)
E-PMP = F
A P B Q
k1 k2 k3 k4 k5 k6 k7 k8
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where the separation of the ketone was performed using a hollow-fiber membrane26, an enzyme membrane 
reactor26 or packed-bed reactor31. However, these examples show product inhibition of the ketone, e.g. for the 
acetophenone product for the kinetic resolution approach. In the asymmetric synthesis the acetophenone is 
usually the prochiral substrate and substrate inhibition in this case can be alleviated by substrate feeding75-78 
or by other in-situ substrate supply (ISSS) techniques from an auxiliary phase, liquid or solid. Product inhibition 
also poses a significant challenge for the asymmetric synthesis approach and there have been several proposed 
in-situ product removal (ISPR) strategies. One strategy by Yun and Kim proposed an organic solvent bridge 
(isooctanol) for continuous removal of the product (S)-α-methylbenzylamine79. Another strategy by Truppo et 
al. involved selective adsorption of the same product to the ion-exchange resin80. The authors also suggested 
another approach involving a change of the overall chemistry of the process in such a way that the product of 
the ω-transaminase reaction would auto cyclize, and therefore would no longer fit into an active site of the 
enzyme and cause product inhibition80. All of these strategies are examples of process/chemistry manipulations 
to avoid substrate or product inhibition. However, another strategy that holds much promise and could 
overcome inhibition problems elegantly is protein engineering. One such example involved the production of 
Sitagliptin by ω-transaminase ATA-11768. Numerous mutations of the enzyme enabled higher substrate             
(i-PrNH2) concentrations, but also higher stability in organic solvent and higher temperature with a wider range 
of substrate specificity, for example also accepting bulky substrates. The reports from Rothman et al.81 and Yun 
et al.74 also demonstrated that directed evolution of enzymes can alleviate product inhibition. Another, more 
recent study by Park and Shin identified ω-transaminase from Ochrobactrum anthropi which showed no 
product or substrate inhibition in the case of kinetic resolution82. According to the authors, this new ω-
transaminase should be beneficial for the asymmetric synthesis approach as well. 
2.3.2.3.1.2 Stability 
The reaction conditions in the industrial process are usually far away from the conditions found in a cell. The 
concentrations of chemicals are much higher in the process and pH may be different from neutral. Non-natural 
substrates or products often have low water solubility and in many cases reactions are run in slurry conditions. 
In some cases, it is required to avoid emulsions, and co-solvents are used to increase solubility of reaction 
components. All these reaction conditions often decrease the stability of the enzyme, and to maintain the 
desired rate of the reaction additional quantities of enzyme must be added. However, if the stability of the 
enzyme can be improved sufficiently such that the required rate remains adequate throughout the reaction, 
the biocatalyst loading could be reduced. The deactivation of enzymes is often caused by unfolding or chemical 
modification and can be described as a first order kinetic reaction83 as shown in Equation 2.1. 
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 𝑟𝑡 = 𝑟0𝑒
−𝑘𝑑∙𝑡 2.1  
rt – reaction rate at given time; r0 – initial reaction; kd – deactivation coefficient; t - time 
Several strategies for increasing the stability have been described advocating the economic benefits based on 
the reusability of the biocatalyst. One of the most commonly used strategies for enzyme stabilization is the 
immobilization. This method mimics nature in a way that native intracellular enzymes seem to be bound to the 
cell membrane or localized in the gel-like surroundings of a cellular organelle84. The first industrial application 
of the method was continuous optical resolution of D,L-amino acids by immobilized aminoacylase85 in 1969. 
The advantages of an immobilized compared to the free enzyme are improved operational and storage 
stability, easy recovery and reuse, possibility of continuous operation in a packed bed reactor and the potential 
of minimizing the protein impurities in the product86. However, known issues of enzyme immobilization are 
the loss of activity due to mass transfer limitations and the loss of the active enzyme69. 
There have been several reports on immobilization of the ω-transaminase in the soluble enzyme form. One of 
the first reports was made by Yi et al. where the ω-transaminase was covalently linked to different solid support 
materials87. The chitosan beads showed improved stability and retained 77 % activity after 5 cycles, however a 
severe substrate and product inhibition was present. The entrapment by sol-gel matrices was reported by 
Koszelewski et al.88 and Lee et al.89 where immobilization yields of 20-50 % and less than 20 % activity were 
reported. Immobilized enzyme showed improved activity at higher pH values and temperatures88. Another, 
more recent example of immobilization of free enzyme by covalent linkage to the catechol-chitosan (CCS) – 
iron oxide nanoparticles (IONPs) was reported by Ni et al.90 The retained activity was dependent on the carrier 
and was 93, 95.7 and 87.5 % for the IONPs, CS-IONPs and CCS-IONPs respectively. The authors reported ~ 90 
% activity after 5 cycles and improved activity for wider pH and temperature value ranges. The use of magnetic 
nanoparticles for immobilization purposes makes this method highly desirable due to the easy biocatalyst 
recovery and reuse. 
Immobilization of whole cells or permeabilized cells containing ω-transaminase attracted some attention as 
well. Shin and Kim performed the entrapment of the whole cells in calcium alginate beads used in the kinetic 
resolution of racemic amines in a packed bed reactor31. This approach showed diffusion limitations and 
substrate and product inhibition, and it was later demonstrated by Martin et al. that Vmax and Km changed after 
immobilization70. Research by Cardenas-Fernandez et al. showed an easy and robust method of immobilization 
of whole and permeabilized cells with LentiKats®91. The authors showed that no diffusional limitations were 
found as well as no activity loss. Stability of the immobilized whole and permeabilized cells was increased under 
process relevant conditions and the residual initial rate was ~ 80 % after 5 cycles. 
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Although the immobilization strategies present certain advantages among which recovery, reuse and increased 
stability can be put forward, the loss of activity by immobilization and the immobilization process itself increase 
the cost of the enzyme for a given process42. To follow certain economic guidelines a high specific activity of a 
biocatalyst is required as long as possible92 and that can also be achieved by protein engineering93. Currently 
the only literature report of a protein engineering approach to increase the stability of the ω-transaminase, 
among other improvements made, is the production of Sitagliptin by Savile et al.68, where the authors showed 
impressive increase of the DMSO tolerance from 5 to 50 %. 
2.3.2.3.2 Thermodynamic Limitations 
One of the most challenging limitations concerning the asymmetric synthesis of optically pure amines by         
ω-transaminase are thermodynamic challenges. These challenges have been extensively documented and 
several approaches have been developed. This challenge arises from the low Keq values which in turn result in 
low thermodynamic yields. Keq or the thermodynamic equilibrium constant is the ratio between the product 
and the substrate equilibrium concentration quotients. For a general chemical reaction: 
 𝛼𝐴 + 𝛽𝐵 ⇌ 𝛾𝐶 + 𝛿𝐷 2.2 
Keq can be defined as: 
 𝐾𝑒𝑞 =
[𝐶]𝛾 ∙ [𝐷]𝛿
[𝐴]𝛼 ∙ [𝐵]𝛽
 2.3 
[A] – concentration of the component A; α – stoichiometric coefficient of the component A 
By knowing the Keq value, calculation of thermodynamic yield is fairly simple for given starting concentrations 
of the substrates. Comparing the calculated yield with the desired yield, one can decide whether an equilibrium 
shifting strategy is required and how effective it has to be. For the production of optically pure amines by        
ω-transaminase many cases exhibit unfavorable Keq values. The Keq is determined by the change of standard 
Gibbs free energy of reaction which is defined as the difference of standard Gibbs free energy of formation 
between products and substrates as shown in the Equation 2.4. 
 ∆𝐺0 = ∑ ∆𝐺𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑠
0 − ∑ ∆𝐺𝑓 𝑟𝑒𝑎𝑐𝑡𝑎𝑛𝑡𝑠
0  2.4 
The change of Gibbs free energy for the production of α-keto acids from amino acids is small and therefore 
the Keq is small. A similar change can be observed for the production of chiral amines starting from prochiral 
ketones. In one such example Shin and Kim reported the production of α-MBA starting from acetophenone 
yielding only 0.5 % α-MBA, even with a tenfold excess of alanine41. They reported the Keq value based on a 
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kinetic parameter estimation to be around 10-3. Truppo et al. reported that the equilibrium becomes more 
favorable when 2-propylamine is used as amino donor instead of alanine, , however the equilibrium still favors 
the substrates29.  It was clear that the Keq of production of chiral amines from prochiral ketones is highly 
unfavorable, and the need for knowing the Keq values for specific cases of interest was therefore emerging. 
Jankowski et al. developed a group contribution method for estimating the Gibbs free energy of formation for 
biochemical reactions in aqueous solutions at pH 7 and 25°C94. This methodology was applied in the work of 
Seo et al. for the comparison of the transamination potential of different amine donors95. Another possible 
method of determining the Keq value is the experimental method which allows reactants to reach the 
equilibrium from both directions of the reaction96, 97. Due to the slow reactions rates and low stability and/or 
volatility of reactants, a modified method was proposed by Tufvesson et al which in turn provided the first 
experimental values for different pairs of keto acceptors and amino donors for different ω-transaminase 
systems98. 
The majority of the research on ω-transaminase systems reported thermodynamic challenges and identified 
them as top challenge for the asymmetric synthesis approach. This was one of the reasons why the kinetic 
resolution approach gained much popularity in the earlier days of research in transaminase systems. However, 
the advantages of the asymmetric synthesis approach, e.g. higher theoretical yields and cheaper starting 
material, were soon recognized as well as the need for a powerful equilibrium strategy in order to fully utilize 
this approach. 
2.4 Strategies for Shifting the Thermodynamic Equilibrium 
To achieve desired process-relevant yields in thermodynamically challenged systems, strategies for overcoming 
thermodynamic limitations must be used. These strategies are based on process solutions and cannot be 
achieved by enzyme improvement. The reason for this is the fact that the enzyme catalyzes the forward 
reaction, but also the reverse reaction, meaning that the reaction will reach the equilibrium state faster using 
the enzymes. However the value of the equilibrium constant itself will not be shifted. There are two types of 
equilibrium shifting strategies: the first one is based on changing the Keq value by changing the chemistry of 
the reaction and therefore changing the Gibbs free energy of formation of components. This means that by 
selecting a more favorable amine donor a more favorable Keq value can be achieved. The second type of 
strategies do not change the Keq of the reaction but favor the formation of the product by manipulating the 
concentrations of reaction components. The latter can be achieved by excess substrate, in-situ product removal 
(ISPR) or in-situ co-product removal (ISCPR). The purpose of all equilibrium shifting strategies is to shift the 
thermodynamic equilibrium to achieve economically viable yields. Based on the desired yield and given Keq 
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value, it is possible to calculate the “workload” that the equilibrium shifting strategy has to achieve, and, 
depending on the investigated case, what type or combinations of several different strategies is necessary. 
2.4.1 Amino Donor Selection 
As mentioned before, amino donor selection is an equilibrium shifting strategy that actually changes the Keq 
value of the reaction system by choosing a different amino donor resulting in a more favorable Keq value. An 
amino donor which is more energy stable will have a lower Gibbs free energy of formation, and will according 
to Equation 2.4 increase the change of Gibbs free energy of the system and thus the value of Keq. However, it 
should be clear that the Keq value must be significantly increased to achieve industrially relevant yields. Taking 
the concentration ratio of substrates to be 1:1 and assuming a required thermodynamical yield of 95 %, the 
Keq value necessary to achieve such yields can be calculated using the Equation 2.3 and should be > 360. In the 
work by Tufvesson et al. Keq values were determined for two different substrates, acetophenone and 4-phenyl-
2-butanone, using several different amino donors98. The selection of a different amino donor indeed showed 
the change of Keq, e.g. when using acetophenone for the amino donors alanine and 2-propylamine Keq values 
have been found to be 4.03∙10-5 and 3.33∙10-2 respectively. Although the Keq was almost increased by a factor 
of 1000 in this example by the selection of a different amino donor, the yield was only increased from 0.6 to 
15.4 % as calculated on the basis of Equation 2.3. This example shows that more stable amino donors still have 
to be found. However, it should be kept in mind that they also have to be biocompatible and accepted by the 
enzyme. In the combination with other equilibrium shifting strategies the amino donor selection strategy may 
prove to be helpful in shifting the Keq value of thermodynamically challenged reactions. 
2.4.2 Excess of Substrate (Amino Donor) 
This equilibrium shifting strategy is based on Le Chatelier’s principle where by increasing the substrate 
concentration, the equilibrium concentration of the product is increased. In the case of the ω-transaminase, 
keto-substrates in most cases have low solubility and are more expensive compared to the amino donors, and 
the excess of substrate is therefore typically applied by providing an excess of the amino donor. This 
equilibrium shifting strategy is one of the first to be considered when developing a process due to its simplicity. 
By knowing the Keq and the maximum amount of the amino donor as a function of solubility, the equilibrium 
yield can be calculated using Equation 2.3. However, this method by itself can only be successfully when applied 
when the Keq is slightly unfavorable or near 1, as was demonstrated by Savile et al. in the case of Sitagliptin 
production where a 10-fold excess of 2-propylmine was used68. Due to the simplicity of this shifting strategy 
the combination with other equilibrium shifting strategies can be potent and reduce their “workload”. The 
possibilities for the implementation of this strategy, alone and in combination with other strategies, will be 
discussed in Section 3.4.1. 
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2.4.3 ISPR Technologies 
Another equilibrium shifting strategy based on Le Chatelier’s principle that manipulates the concentrations of 
reaction mixture components towards the product side is in-situ product removal or ISPR. This method is 
focused on the removal of the product as it is being produced by the reaction. The purpose of the ISPR can be 
either for shifting the equilibrium or alleviating the product inhibition. However, the focus of this thesis will be 
on the shifting of the equilibrium. The general approach of this technology is the removal of the product to a 
second phase (liquid, solid or gas) which then drives the reaction forward due to the equilibrium shift and 
facilitates the product recovery from the reaction mixture. The selection of the ISPR method in the case of ω-
transaminases depends on the physical properties of the amino product and other components in the reaction 
mixture. The most common properties used for ISPR are differences in solubility, volatility, charge, 
hydrophobicity and molecular size99. In general, a favorable ISPR technology is the one which can selectively 
remove the product and generate a significant driving force for successful removal. In the following sections a 
brief overview of possible ISPR technologies will be given, and the discussion about individual challenges of 
application and implementation will be discussed in the Chapter 5. 
2.4.3.1 Classical ISPR Technologies 
One of the most frequently used ISPR methods in the ω-transaminase reaction is a liquid-liquid extraction. By 
shifting the reaction medium to acidic or basic conditions to overcome the protonation of the amine product, 
it is possible to remove the formed amine from the reaction mixture and alleviate product inhibition and shift 
the thermodynamics of the system. This approach was demonstrated by Kim and Shin25 and Koszelewski et 
al.100. However, post-reaction recovery was only performed in the latter work. Integrated extractive recovery 
was applied by Yun and Kim79 using a solvent bridge. The equilibrium shift was obtained by employing an in-
vivo ALS cascade as an in-situ co-product (ISCPRR) removal strategy and the solvent bridge was used to 
alleviate product inhibition by (S)-α-MBA, as well as to achieve equilibrium shifting and as product recovery 
strategy. Another investigated method is the adsorption to a solid surface (resin) proposed by Woodley et 
al.101, and later demonstrated by Truppo et al.80 as an efficient strategy for overcoming both the product 
inhibition and thermodynamic constraints. Together with the LDH/GDH cascade system as an ISCPR strategy 
high yields were obtained starting from 50 g L-1 of substrate. The difference between the volatility of the 
compounds can also be used as a property that can be exploited for the removal of the product. One such 
example was reported by Hanson et al.30 where (R)-sec-butylamine was recovered by distillation of the reaction 
mixture under basic conditions. 
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2.4.3.2 Cascades for ISPR 
In the traditional organic synthesis route of the production of pharmaceutical compounds several production 
steps are present. The biocatalytic approach tries to reduce the number of these steps and the exact place of 
the substitution of a biocatalysis step in the synthesis route may vary. When the investigated biocatalytic 
reaction is not placed at the end of a synthesis route, the sequential reactions that follow can potentially be 
used as an ISPR technique. It is important to note that this approach has mainly been achieved by another 
sequential enzymatic reaction or reactions, and it is called multi-enzyme synthesis102 or synthesis by cascades, 
and in general it means combined biocatalytic reactions without intermediate recovery steps103. The concept 
is taken from nature where successive biocatalytic reactions in cells form a metabolic pathway network. This 
concept is possible due to the high selectivity of the biocatalysts and has been exploited for manufacturing 
purposes as well. Although the application of multi-enzyme synthesis can be applied in the production of many 
valuable products 103, 104, its application in the case of the production of optically pure amines by                            
ω-transaminase still has not been reported. Such approach could significantly decrease the thermodynamic 
challenges in the production of optically pure amines. However, the choice and viability of a sequential reaction 
will vary on a case-to-case basis. 
Biocatalytic cascades as an ISPR in the ω-transaminase system may not yet have been fully researched. 
However, the non-catalytic cascade has been reported. The work was done by Truppo et al. using ethyl 4-
acetylbutyrate as a substrate80. The resulting amine then spontaneously cyclized to 6-methyl-2-piperidone 
yielding > 99 % conversion starting from 50 g L-1 prochiral ketone. 
 
Figure 11 Possible ISPR strategies by implementing cascades 
Using cascades as an ISPR strategy (Figure 11) has many advantages, and one of the most important ones is 
shifting the equilibrium value by a sequential reaction. Having this in mind, together with the fact that an 
intermediate step can be avoided, inhibition by the chiral amine intermediate can be alleviated and two or 
more (non)enzymatic reactions can be performed in one pot, and reducing the number of steps in the total 
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synthesis route. The ISPR by cascades thus sounds very promising for overcoming challenges such are 
unfavorable thermodynamic equilibrium or product inhibition. Unfortunately, challenges in the implementation 
still remain, and further research on this topic is needed. 
2.4.4 ISCPR Technologies 
The in-situ co-product removal (ISCPR) strategy is a procedure of removing the co-product of the reaction as 
it is being produced. ISCPR can be used when the co-product is inhibitory or toxic to the biocatalyst, when 
shifting the equilibrium of thermodynamically challenged reactions or for the combination of the 
aforementioned reasons. Similar to the ISPR strategy, the ISCPR is based on the Le Chatelier’s principle, and, 
by removing the co-product, the formation of the product is favored. For achieving a certain thermodynamic 
yield, the usage of ISPR or ISCPR is theoretically indistinguishable meaning the same thermodynamic yield will 
be achieved if a given amount of product or co-product is removed from the reaction mixture. However, the 
major advantage of ISCPR over ISPR is that the co-product does not have to be recovered and it can therefore 
be reacted away into an inert compound. Several ISCPR approaches on the ω-transaminase system have been 
reported in the literature and will be mentioned. However, the applicability, challenges and compatibility with 
other equilibrium shifting technologies will be discussed in more detail in Chapter 5. 
2.4.4.1 Classical ISCPR Technologies 
As mentioned in the Section 2.4.4.1 on Classical ISCPR Technologies, there are several physical properties that 
can be exploited for successful separation of the co-product. However, only the difference in the volatility 
between the product and the co-product has been reported. When 2-propylamine or 2-butanamine is used as 
an amino donor, the resulting co-product, acetone or butanone respectively, is volatile and can be removed 
by evaporation as suggested by Yun et al.28 Recently a model was developed by Tufvesson et al.105 for assessing 
the feasibility of shifting the equilibrium by acetone removal for a given process. The authors discussed two 
removal models, sweeping and sparging. They defined operating windows for each approach and identified 
Keq and the volatility of the ketone substrate as the key parameters. This approach can be very successful in 
the early stages of process development for the evaluation of the viability of evaporation as the ISCPR strategy 
that is most suitable for overcoming the equilibrium challenges. 
2.4.4.2 Cascades 
As opposed to the ISPR cascades, using cascades in ISCPR has the purpose to remove the co-product, in this 
case a keto co-product, in order to shift the equilibrium concentrations towards the product formation. The 
cascades in the ISCPR approach can be non-catalytic and biocatalytic (Figure 12). The example of non-catalytic 
cascades was demonstrated by Fotheringham who showed that the pyruvate can be efficiently decarboxylated 
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with hydrogen peroxide106. However, this method has a major drawback of resulting in decreased enzyme 
stability in the presence of hydrogen peroxide, or alternatively the pyruvate removal by hydrogen peroxide has 
to be performed in a separate vessel. Another example of non-catalytic cascades was presented by Wang et 
al.107 In this work racemic 3-aminocyclohexa-1,5-dienecarboxylic acid was used as amino donor and the 
resulting ketone was effectively removed by spontaneous tautomerization to 3-hydroxybenzoic acid. 
 
Figure 12 Possible ISCPR strategies by implementing cascades 
Although the above-mentioned examples show the possibilities of non-enzymatic cascades for ISCPR 
purposes, the majority of the research for the implementation of ISCPR was done by biocatalytic cascades. The 
superb selectivity of the enzymes towards the keto co-product (pyruvate or acetone) together with the enzyme 
availability presented several interesting research opportunities which will be described in more detail in the 
following sections. 
2.5 ISCPR by Enzymatic Cascade Systems in an ω-transaminase System 
The metabolic pathway in living cells consists of a series of sequential enzymatic reactions leading to the 
production of life building blocks or energy. Since both acetone and pyruvate are part of this metabolic 
network, several natural enzymes exist capable of selective degradation. This biomimetic approach has been 
applied for an ISCPR in the ω-transaminase system and several cascade systems have been reported in the 
literature as a proof of concept of successfully overcoming thermodynamic limitations for the production of 
optically pure amines. There are two categories of the cascade systems: co-factor (NAD(P)H) recycling enzymes 
presented by the dehydrogenases and non co-factor recycling enzymes, e.g. thiamine pyrophosphate (ThPP) 
dependent enzymes. 
2.5.1 Co-factor Recycling Enzymes 
Dehydrogenases are enzymes which are involved in the removal of hydrogen from the substrate to an acceptor, 
most commonly NAD+, in oxidation and reduction reactions. The majority of all redox enzymes use 
nicotinamide adenine dinucleotide (NAD+ - NADH) as coenzyme while the other enzymes prefer the 
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corresponding phosphorylated co-factor (NADP+ – NADPH). These are known enzymes which have been 
researched extensively and used in the industry. The availability of wild type and improved enzymes has led to 
the successful implementation of dehydrogenases in many industrial processes108. Another advantage is the 
high selectivity of dehydrogenases towards the co-product, meaning that no side reactions will occur. 
2.5.1.1 Co-factor and co-factor regeneration methods 
Nicotinamide adenine dinucleotide, NAD+ is a coenzyme found in living cells and it consists of two nucleotides 
which are linked by two phosphate groups as depicted in Figure 13 A). In the reduction and oxidation reactions 
the co-factor acts as an electron carrier as shown in the Figure 13 B) and in contrast to the other co-factors e.g. 
FAD or FMN it is not covalently bound to the enzyme109. During the reaction the co-factor is chemically altered 
as well as stoichiometrically consumed by the reaction, and therefore it could also be called the co-substrate. 
 
Figure 13 a) structure of NAD+ and b) redox reactions of nicotinamide adenine dinucleotide 
Due to the high cost of the co-factor and the stoichiometrical consumption, in-situ co-factor regeneration 
methods have been developed to overcome this important challenge110-112. Several regeneration methods have 
been reported: enzymatic (both isolated enzyme and whole cell), chemical, electrochemical and photochemical 
methods. Based on its several advantages including outstanding enzyme selectivity and enzyme availability, 
the enzymatic regeneration method has been researched more extensively. Compared to the whole cell 
approach, processes catalyzed by isolated enzymes result in a higher volumetric productivity and no side 
reactions are observed given the high selectivity of the enzymes110. The isolated enzyme approach of co-factor 
recycling can be described by coupling the two reactions catalyzed by the dehydrogenases, one consuming 
the co-factor and one regenerating it111 as shown in Figure 14. In some cases only one dehydrogenase is used 
capable of accepting two different substrates, one in oxidized form and the other in its reduced form, with 
A B 
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obviously a clear advantage related to single enzyme usage. This approach is also called coupled enzyme 
approach. 
 
Figure 14 General scheme of enzymatic co-factor regeneration adapted from 111 
It is understandable that adding stoichiometric amounts of the co-factor is not economically feasible for an 
industrial process and that the recycling strategy must be put in place. The isolated enzyme approach has been 
given a lot of attention due to the advantages mentioned above and many successful examples have been 
implemented either as proof of concept or as a commercial process, e.g. the first commercial process of chiral 
synthesis of tert-L-leucine113, 114. More advantages of this approach can be seen when continuous ISCPR and 
ISSS via co-factor shuttling is achieved providing kinetic and thermodynamic advantages. However, this 
approach adds to the complexity of the overall reaction system, and is in many cases producing additional 
molecular species which have to be considered in DSP. The secondary or sacrificial reaction has to use cheap 
and available substrate, and both substrate and product have to be inert, non-toxic and biocompatible. 
2.5.1.2 Co-factor Stability 
When performing reactions using NADH dependent dehydrogenases, the stability of the co-factor plays a 
significant role. This important factor can influence the choice of reaction conditions and feasibility of the 
recycling methods. The reduced form is more stable in the basic solutions and the oxidized form is more stable 
in the acidic medium115, 116. However, both are quite unstable in vitro in aqueous solutions117. Degradation of 
the co-factor as well as enzymes can be described by a first order decay described by Equation 1. To achieve 
the desired reaction rates and to maintain them over the course of the reaction, the addition of the co-factor 
would be required. To avoid the replenishment of the co-factor, improving the stability has to be the most 
important objective. The first attempts of stabilizing nicotinamide co-factors began with the buffer selection 
and it was found that the Tris buffer improved stability considerably118. However, the application of the buffer 
in the industrial process is not common and other methods of increasing the stability of the co-factor 
stabilization e.g. immobilization or the use of co-factor analogues should be considered. Those and other 
methods will be discussed in detail in Section 5.3.3.2. 
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2.5.1.3 LDH/GDH system 
The lactate dehydrogenase (LDH) (E.C. 1.1.1.27) /glucose dehydrogenase (GDH) (E.C. 1.1.1.47) is one of the 
most used systems for shifting the equilibrium in the ω-transaminase reaction. It was first described as an 
equilibrium shifting strategy by Shin and Kim41. The authors realized the need of a powerful equilibrium shifting 
strategy via pyruvate removal and used solely LDH enzyme or a whole cell system expressing LDH to remove 
the co-product resulting in a significant increase of the yield from 2 % to 90.2 % and 92.1 % respectively. The 
first usage of the complete LDH/GDH system was reported by Koszelewski et al. as a means to overcome 
thermodynamic challenges and achieve high yields100. Due to the successful proof of concept and the 
availability of these enzymes, a considerable number of research projects, e.g. Höhne et al.119, Hwang et al.120, 
Koszelewski et al.88, 100, 121, Truppo et al.29, 80, 122, Fuchs et al.123, Mutti et al.67, 124 and Pressnitz et al.125 used this 
cascade system for pyruvate removal and shifting the unfavorable equilibrium toward the product formation. 
Both LDH and GDH enzymes are dehydrogenases and follow the Ordered Bi Bi mechanism72, 126 shown in the 
Figure 15. This mechanism can be explained on the example of the reaction catalyzed by LDH. The substrate A 
which is the co-factor NADH, binds to the active site of the enzyme forming an EA complex followed by the 
binding of the substrate B, in this example pyruvate. The formed product P (lactate) then leaves the active site 
followed by the product Q (co-factor NAD+) leaving the enzyme. The overall ω-transaminase system coupled 
to the equilibrium shifting LDH/GDH system is depicted in the Figure 16. The equilibrium is shifted by 
selectively removing the pyruvate via an LDH catalyzed reaction forming lactate. The regeneration of the NAD+ 
to NADH is performed by an auxiliary or sacrificial reaction catalyzed by the GDH. The auxiliary substrate 
glucose is transformed into glucono-1,5-lactone which then forms an equilibrium with glucono-1,4-lactone 
and gluconic acid via a hydrolysis reaction. 
 
Figure 15 Ordered Bi Bi mechanism of dehydrogenases 
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Figure 16 Proposed reaction scheme of the LDH/GDH system for shifting equilibrium of the ω-transaminase reaction 
The biggest advantage of this equilibrium shifting system is the selectivity of all enzymes present towards the 
desired substrates within the reaction mixture. Products of this cascade system, lactic acid, glucono-1,5-lactone, 
glucono-1,4-lactone and gluconic acid, are non-reactive components and they remain in the reaction mixture. 
However, the accumulation of these molecular species raises the possibility of occurrence of inhibitory effects 
for both LDH and GDH enzymes. Another issue is the downstream processing challenge resulting from the 
presence of more species which needs to be considered when removing the desired component from the 
reaction mixture. The work by Kaswurum et al.127 showed that the hydrolysis of glucono-1,5-lactone is not fast 
enough and significant quantities of this molecular species can be accumulated, thus inhibiting the reaction 
and making the downstream processing more complicated. Moreover, the buildup of gluconic acid causes a 
pH change which in turn requires pH control. Focusing on the concentration of media used for neutralization, 
two problems may occur. If the neutralization medium is highly concentrated, inadequate mixing could lead 
to high or low local pH values in the reaction medium leading to enzyme denaturation and co-factor 
degradation as well. If the neutralization medium is less concentrated, dilution of the reaction mixture can 
occur and concentration steps should then be applied which adds to the complexity of the overall process, and 
other challenges may occur, e.g. selective water removal. 
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2.5.1.4 LDH/FDH system 
Lactate dehydrogenase/formate dehydrogenase (E.C. 1.2.1.2) (FDH) is a cofactor recycling system depicted in 
Figure 17 that is used for shifting the equilibrium of the D-amino acids production catalyzed by D-
transaminase128, 129. This system has been reported by Koszelewski et al.88, 100, Mutti et al.124 and Pressnitz et 
al.125 as a conceptual system. However, no experimental reports in the literature were found that would 
document the use of this cascade system in ω-transaminase systems. 
 
Figure 17 Proposed reaction scheme of the LDH/FDH system for shifting equilibrium of the ω-transaminase reaction 
This system inherits all the advantages and disadvantages regarding the shared enzyme (LDH) from the 
previously described system. However, the co-factor recycling reaction has been substituted with FDH which 
should have several advantages. The product of this reaction is CO2 which reduces the requirement for 
downstream processing and pH control. The product inhibition for this reaction is practically negligible and 
the thermodynamic equilibrium is further shifted to the product side due to the fact that CO2 is leaving the 
system. The disadvantage of FDH is the lower enzyme activity compared to other enzymes, which means that 
more FDH should be added to achieve the same reaction rate, meaning a higher cost of the added enzyme. 
Dissolved CO2 can also cause a slight pH shift and can form carbonates which in turn can cause downstream 
issues due to scaling. 
2.5.1.5 AlaDH/GDH system 
Alanine dehydrogenase (E.C. 1.4.1.1) (AlaDH) is an enzyme which follows an Ordered Ter Bi mechanism 
depicted in Figure 18. Depending on the host organism differences in the order of pyruvate and ammonia 
binding have been reported130-132. AlaDH/GDH is a system previously reported by Truppo et al. where three 
methods for overcoming the unfavorable thermodynamic equilibrium of the ω-transaminase system have been 
used: LDH/GHD and AlaDH/GDH as an ISCPR equilibrium shifting strategy and the usage of 2-propylamine as 
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an amino donor selection strategy122.  The reported 96 % yield showed the thermodynamic ability of this system 
to overcome the undesired equilibrium for the given conditions. However, the reaction rates of the amine 
production were slower compared to the LDH/GDH system and the choice of 2-propylamine as amino donor. 
 
Figure 18 Ordered Ter Bi mechanism of AlaDH from Bacillus Subtilis adapted from Grimshaw and Cleland131 
 
Figure 19 Proposed reaction scheme of the AlaDH/GDH system for shifting equilibrium of the ω-transaminase reaction 
One of the biggest advantages and the point of interest of this system is the recycling of alanine, as depicted 
in Figure 19. This means that only catalytic amounts of alanine are required as amino donor, and that the 
inexpensive ammonia salts may be used as the primary amino donor choices. This approach makes the system 
extremely interesting from an economic point of view. However, several challenges have been observed 
regarding the use of a catalytic amount of alanine. If the ω-transaminase reaction starts with a minor amount 
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of alanine, the production of pyruvate will be slow due to the kinetic effects and thermodynamics of the 
reaction. It can be therefore be concluded that the regeneration of pyruvate back to the alanine will be a 
function of the reaction rate of the ω-transaminase reaction and will face the same kinetic and thermodynamic 
challenges. To overcome this bottleneck, more alanine has to be added to increase the reaction rate of the 
transamination. However, in this case a higher alanine concentration poses inhibition challenges for the AlaDH 
as well as unfavorable thermodynamic starting conditions meaning a high product concentration (alanine) and 
low substrate concentration (pyruvate). However, to fully utilize this enzyme and optimize the concentrations 
of the amino donors the properties of the given AlaDH and ω-transaminase have to be known, and the models 
including thermodynamic behavior have to be developed. In the reaction catalyzed by the AlaDH the 
production of additional molecular species is not an issue which makes DSP more practical. The advantages 
and disadvantages of the GDH reaction have been previously described in Section 2.5.1.3. 
2.5.1.6 AlaDH/FDH system 
This system has been reported in the literature by Koszelewski et al.88, 133 and Mutti at al.67, 124 As shown in 
Figure 20 pyruvate is recycled back to the alanine and co-factor by an auxiliary reaction catalyzed by the FDH. 
In all reported cases the amination was successful resulting in relative high yields showing that thermodynamic 
equilibrium can be shifted for the given conditions by recycling the alanine. 
 
Figure 20 Proposed reaction scheme of the AlaDH/FDH system for shifting equilibrium of the ω-transaminase reaction 
Earlier Sections 2.5.1.5 and 2.5.1.4 describe all the advantages and disadvantages of AlaDH and FDH catalyzed 
reactions respectively. However there are two unique advantages for this cascade system. The first is that only 
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one substrate can be used for both cascade reactions, the ammonium formate where the ammonium ion is 
used as one of the substrates for the AlaDH catalyzed reaction and formate serves as a substrate for the FDH 
catalyzed reaction. The second advantage is that the products of this cascade system are either utilized by the 
ω-transaminase reaction or leave the system in gaseous form facilitating the DSP significantly. 
2.5.1.7 YADH/GDH system 
All previously described cascade systems are based on the usage of alanine as an amino donor where the 
pyruvate was removed enzymatically. Previous investigations showed that pyruvate is the preferred substrate 
for the ω-transaminase, meaning that alanine is a rather thermodynamically poor amino donor. Another amino 
donor, 2-propylamine, was found to be more thermodynamically favorable98, cheaper and the resulting co-
factor acetone can be removed in several ways including an enzymatic cascade catalyzed by alcohol 
dehydrogenase (Figure 21). Possible selectivity issues of this alcohol dehydrogenase toward the two ketone 
substrates present in the reaction mixture, namely acetone and acetophenone, was pointed out. However, a 
selective alcohol dehydrogenase from Saccharomyces cerevisiae was found. This yeast alcohol dehydrogenase 
(E.C. 1.1.1.1) (YADH) possesses a narrow substrate range and the reactions with four carbon substrates or higher 
have very slow or no observable reaction rates134 
 
Figure 21 Proposed reaction scheme of the YADH/GDH system for shifting equilibrium of the ω-transaminase reaction 
30 
 
This cascade system can be used when other ISCPR methods, e.g. evaporation or pervaporation, cannot satisfy 
the requirements for the equilibrium shifting. Thus far, experiments on this particular cascade system have not 
yet been reported in the literature. 
2.5.1.8 YADH/FDH system 
This system was explored and reported in the work of Cassimjee et al. where the conversion of different ketones 
and 2-propylamine as an amino donor was compared135. The conversions without the cascade system were 
already high (60-90%) compared to the cases where alanine was used as amino donor. However when the 
YADH/FDH cascade was used complete conversion was observed. This cascade system is shown in Figure 22. 
 
Figure 22 Proposed reaction scheme of the YADH/FDH system for shifting equilibrium of the ω-transaminase reaction 
As shown in the work of Cassimjee et al. this cascade system can be applied to the systems using 2-propylamine 
as an amino donor where these systems are usually much more thermodynamically favorable compared to the 
ones where alanine is used as an amino donor. Sequentially, the required amount of the co-product removed 
to achieve a desired thermodynamic yield is less compared to the relating alanine systems, facilitating the 
application of potential ISCPR strategies. 
2.5.2 Non Co-factor Recycling Enzymes 
Previously described dehydrogenases used the co-factor as a co-substrate meaning that the co-factor was 
stoichiometrically consumed by the reaction and an additional recycling reaction was required. However, not 
all enzymes suitable for equilibrium shifting by ISCPR consume the co-factor stoichiometrically, e.g. thiamine 
diphosphate enzymes. Thiamine diphosphate (ThDP) or thiamine pyrophosphate (ThPP) co-factor is an active 
form of vitamin B1. The purpose of this co-factor is versatile and in different metabolic pathways it assists in 
making and breaking bonds between carbon and sulfur, oxygen, hydrogen and nitrogen, as well as breaking 
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and making carbon-carbon bonds. ThDP is a true cofactor and remains on the protein site, where a divalent 
metal ion, usually Mg2+ is used to bind the cofactor to the enzyme.  
 
Figure 23 The structure of thiamine pyrophospate (TPP or ThPP) or thiamine diphosphate (ThDP) adapted from Frank et. al.136 
A) ThDP in a solution B) intermediate imine form of ThDP C) activated form of ThDP 
The catalytic activity of thiamine diphosphate in ThDP dependent enzymes lies in the activation of a C2 carbon 
by deprotonation forming an activated form of ThDP shown in Figure 23 C). This is accomplished during the 
binding to the active site of the enzyme where the effects of conformation and electrostatics enable the 
removal of the proton from the C2 position. Tautomerization occurs in the intermediate step (Figure 23 B) and 
the nitrogen from the imine is responsible for proton removal. The activated form of ThDP then offers the 
activity of ThDP dependent enzymes and two such enzymes have been found capable of degrading pyruvate: 
pyruvate decarboxylase (PDC) and acetolactate synthase (ALS). 
2.5.2.1 Pyruvate decarboxylase system 
Pyruvate decarboxylase (E.C. 4.1.1.1) (PDC) is an enzyme that catalyzes the nonoxidative decarboxylation of 
pyruvate into acetaldehyde and CO2 (Figure 24). It requires ThDP as a cofactor and Mg2+ for catalytic activity137. 
This cascade has been reported by Höhne et al. for production of 1-N-Boc-protected –aminopyrrolidine and –
piperidine obtaining high yields. 
A 
B 
C 
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Figure 24 Proposed reaction scheme of the PDC system for shifting equilibrium of the ω-transaminase reaction 
The obvious advantage of this pyruvate removal system compared to the dehydrogenases is in its 
monoenzymatic simplicity; only one enzyme is required and no co-factor recycling method is needed. Both 
products are volatile and facilitate downstream processing. Both product inhibition and unfavorable 
thermodynamics are also facilitated by the properties of the products119. The only possible disadvantage of 
this system is the selectivity of the ω-transaminase towards the acetaldehyde which is the preferred substrate. 
The by-product of this side reaction is ethylamine which is an explosive gas causing health problems. 
2.5.2.2 Acetolactate synthase (ALS) system 
Acetohydroxyacid synthase (AHAS) and more generally acetolactate synthase (E.C. 2.2.1.6) (ALS) is an enzyme 
found in plants and microorganisms and it is responsible for valine, leucine and isoleucine synthesis138. 
Acetohydroxyacid synthase (AHAS) naturally catalyzes the carboligation of a hydroxyl-ethyl group, obtained 
by the decarboxylation of the pyruvate. The second substrate can be either pyruvate or 2-ketobutyrate giving 
2-acetolactate or 2-aceto-hydroxybutyrate. The active site is known to be promiscuous and accepts a wide 
range of substrates, It requires both divalent metal ions like Mg2+ providing linkage to the enzyme and a 
molecule of flavin adenine dinucleotide (FAD) which is not spent in the reaction139. However, some bacteria 
contain an FAD-independent form of the enzyme referred to as ALS. The ALS catalyzes the same reactions as 
the AHAS but with high preference to the pyruvate as a second substrate. As mentioned before, the ALS is one 
of the enzymes found in metabolic pathways of branched-chained amino acids and butanediol production. In 
in-vivo conditions one possible route is that the product (S)-2-acetolactate is decarboxylated by acetolactate 
decarboxylase (E.C. 4.1.1.5) to form acetoin. However, in in-vitro conditions (S)-2-acetolactate undergoes 
spontaneous non-enzymatic decarboxylation into acetoin and oxidative decarboxylation to diacetyl140, 141. The 
reaction mechanism in in-vitro conditions for ISCPR in the ω-transaminase reaction is depicted in Figure 25. 
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Figure 25 Proposed reaction scheme of the in vitro ALS system for shifting equilibrium adopted from 140and 141 and applied to 
the ω-transaminase reaction  
The ALS system was reported for shifting the thermodynamic equilibrium of the ω-transaminase system by 
Yun and Kim79. They co-expressed the ALS enzyme together with the ω-transaminase using recombinant E. 
coli cells and a 2.5 fold increase in the production of (S)-α-MBA was observed compared to the cells containing 
only ω-transaminase. 
Similar to the pyruvate decarboxylase approach, this system looks promising due to its simplicity using only 
one single enzyme system with no cofactor recycling. Thermodynamic equilibrium is facilitated by the fact that 
one of the products is CO2 and the sequential reactions of (S)-2-acetolactate follow. However, those reactions 
are also the main disadvantage of this approach. (S)-2-acetolactate, acetoin and diacetyl are ketones, and 
therefore they might potentially function as substrates for the ω-transaminase. The resulting mixture of amines 
would be very difficult to separate in order to recover the desired amino product. Another disadvantage is that 
this enzyme is currently not commercially available, therefore making this cascade option not very favorable. 
2.6 Discussion and Conclusions 
The use of biocatalysis in the pharmaceutical industry has already been established for some processes. 
However, still, more emerging biocatalytic processes are being developed due to the increasing availability of 
enzymes and reactions they can catalyze. The main advantage of biocatalysis as shown in this literature 
overview is result of its supreme stereo-, regio- and substrate selectivity which results in a simplification of the 
production process by reducing often complicated and demanding reaction steps. There are many examples 
of emerging technologies, and the focus of this thesis is the production of optically pure chiral amines by ω-
transaminase.  
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Understanding the process starts from identifying the challenges and one very important group of challenges 
presented in this overview are biocatalytic challenges. Finding an enzyme with sufficient activities towards the 
desired substrates with sufficient stability and e.e. has become a major research undertaking pushing the 
screening (in micro-scale) and protein engineering technologies to their very limit when trying to develop an 
enzyme tailored to the specific reaction conditions. Other important biocatalytic challenges are substrate and 
product inhibitions which have been identified as a major hindrance for many ω-transaminases. Many process 
options, e.g. ISSS or ISPR, have been applied for alleviating the substrate or product inhibition respectively. 
However, developing enzymes without substrate or product inhibition might be a more elegant solution. 
Another identified challenge for many asymmetric synthesis reactions catalyzed by ω-transaminase which are 
of industrial interest is the low Keq value. To achieve economic feasibility and make a biocatalytic process 
comparable to a chemocatalytic one, several targets have to be met, one of them being sufficient product 
concentration (> 50 g L-1). Achieving such high product concentrations requires high yields and in the case of 
thermodynamically challenged reactions, equilibrium shifting strategies are essential. Four equilibrium shifting 
strategies have been identified: Amino donor selection, Amino donor excess, ISPR and ISCPR. The selection of 
the equilibrium shifting strategy varies from case to case and it will partially depend on the Keq of the reaction. 
For higher Keq values, a less powerful equilibrium shifting strategy may be used, e.g. amino donor excess of 10 
times for Keq ≈ 1 to achieve the desired thermodynamic yields68. Moderately challenged reaction conditions 
(Keq < 1) require more efficient equilibrium shifting strategies, e.g. ISPR or ISCPR. A simple calculation based 
on Equation 2.3 can determine the allowed product or co-product concentration and determine how efficient 
ISPR or ISCPR, respectively, have to be. However, in the case of severely challenged reactions, e.g. an                    
ω-transaminase reaction where acetophenone and alanine are used and Keq is 4.03∙10-5, the choice of 
equilibrium shifting strategy narrows down to one extremely thermodynamically efficient strategy, namely 
ISCPR by enzymes. The choice of equilibrium shifting strategy also depends on the physical and chemical 
properties of the chemicals that need to be removed, as well as on other chemicals in the reaction mixture. For 
example, in the ω-transaminase reaction where acetophenone and 2-propylamine are used as a substrate, the 
resulting co-product is volatile acetone and ISCPR by evaporation might seem as a viable option for shifting 
the equilibrium. However, the study of Tufvesson et. al.105 indicated that the volatility of the keto substrate and 
Keq are important parameters in assessing the feasibility of ISCPR by acetone evaporation. Furthermore, this 
study showed that 30 % keto substrate loss may be expected for industrially relevant conditions making this 
equilibrium shifting strategy not selective enough towards the desired co-product. The thermodynamic yield 
is also a function of the selectivity of the equilibrium shifting strategy towards the desired component vs the 
similar substrates, and the lower the selectivity is, the lower the thermodynamic yield will be. The required 
selectivity towards the product (and not the substrate) increases with the severity of unfavorable 
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thermodynamic equilibrium. However, equilibrium shifting strategies can sometimes be utilized to overcome 
certain biocatalyst challenges as well. For example, when product inhibition is present, ISPR is sometimes 
possible to alleviate product inhibition and shift the equilibrium. 
 
Figure 26 An example of use of ISPR for alleviating both product inhibition and shifting the thermodynamic equilibrium: A) 
product inhibition and thermodynamic challenge appear at same product concentration; B) product inhibition is more 
pronounced than equilibrium challenge; C) equilibrium challenge is more pronounced than product inhibition 
Implementing ISPR or ISCPR technologies for tackling the challenges of product inhibition and/or 
thermodynamic challenge caused by unfavorable equilibrium will depend on which of these challenges are 
more expressed. If a reaction system is faced with both challenges, they can be expressed as following: A) 
product inhibition and thermodynamic challenge are expressed at similar product concentrations (low or high), 
B) product inhibition is much more severe than thermodynamic challenge and C) thermodynamic challenge is 
much more pronounced than product inhibition. Those three cases are displayed in the Figure 26 while showing 
how ISPR technology can be implemented in each case. Thermodynamic challenge is a term used here to 
describe the slowing down of the reaction due to the thermodynamic limitation. In the Figure 26 A) product 
inhibition and thermodynamic limitation are starting to slow down the reaction at similar product 
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concentration. In this case ISPR technique has to be powerful enough to reduce product concentration to the 
required levels which depend on the severity of product inhibition and thermodynamic challenge. Figure 26 B) 
describes a situation where product inhibition is much more pronounced than the thermodynamic challenge. 
For a successful implementation of this specific case an ISPR method must be powerful enough to alleviate 
product inhibition. The final example shown in the Figure 26 C) describes a case severely challenged by 
unfavorable thermodynamic equilibrium while product inhibition occurs at higher product concentrations. Two 
options can be used to overcome inhibition and thermodynamic challenges and the first one is using ISPR 
powerful enough to shift equilibrium to achieve the desired effect. If such ISPR technique is not applicable or 
nonexistent, second option may be considered. ISPR technique for alleviating product inhibition must be used, 
however the thermodynamic challenge can be overcome by powerful enough ISCPR technique. The best 
example of such case is the production of (S)-α-MBA by ω-transaminase using acetophenone and alanine as 
substrates. This reaction is highly thermodynamically challenged while most currently developed transaminases 
are product inhibited. Depending on the starting concentration of substrates and ω-transaminase used in the 
process, thermodynamic limitation is observed at μmol L-1 while product inhibition at mmol L-1 product 
concentrations, respectively. Powerful and selective ISPR technique is not known for this reaction, however, 
thermodynamic challenges can be successfully surpassed by implementing ISCPR by cascades. For a successful 
implementation of currently developed ω-transaminases, in addition, an ISPR method would be required. 
However, enzyme improvements by protein engineering might be an intelligent solution. 
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3 Considerations for a Cascade Selection 
3.1 Introduction 
In the previous chapter a description of potential cascade options has been presented. Moreover beneficial 
effects to the product yields have been documented on the basis of the available literature and positive as well 
as negative consequences of the use of the different cascade options have been discussed. However a major 
question has still not been answered: how to select a cascade for the process relevant implementation? The 
process of selecting the right cascade should be done by following as set of rules and guidelines based on 
industrially relevant conditions. However, no such guidelines have been proposed in the literature thus far. It 
is therefore the aim of this chapter to discuss such considerations and to develop a frame for selecting cascades 
for shifting the equilibrium in the ω-transaminase systems. Furthermore, the knowledge gathered by 
developing this selection process might be used in other reaction systems facing similar challenges. 
The first step in any selection process is gathering the information and describing the potential candidates. In 
this work the order of obtaining the information plays a significant role, and the different information collection 
tasks have been placed in such an order as to minimize the time and money spent in a selection process. The 
first step is the preliminary literature data collection, and the purpose of this step is to achieve a fast and 
descriptive understanding of the cascade systems. What are the properties of an enzyme and what are the 
consequences of its implementation are two very important questions, and the literature information gathered 
has been divided into two major groups, here termed considerations: enzyme considerations and process 
considerations. Economic considerations are briefly discussed at the end of the section. 
3.1.1 Enzyme Considerations 
The first type that has been investigated are enzyme related considerations which describe properties of the 
cascade enzymes. The collected data, e.g. from the enzyme databases BRENDA, IntEnz or PDB, can describe 
enzymes in a general fashion, and serve the purpose of acquiring knowledge about the applicability to and 
interaction with the investigated ω-transaminase system. However, it is important to understand that the 
collected data will not represent the exact properties of the enzymes that will be investigated in this work for 
two reasons. The first reason is that the enzymes used in the literature and the enzymes that will be used in 
the industrial process are rarely from the same supplier and/or host organism, and therefore will have different 
properties to a certain degree. The second reason is that the experimental conditions under which the literature 
data have been obtained do not represent the conditions of the industrial process. Enzyme considerations are 
divided into a number of sections and are listed in Table 5. 
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Stability of enzymes in a cascade system is an important parameter for reasons described in the previous 
chapter. However, the literature does not provide information on the stability of cascade enzymes under 
process relevant conditions. Instead it is possible to identify cascade systems that potentially contain unstable 
components as well as solutions for improving their stability. In the case of dehydrogenases, three possibly 
unstable components have been identified: two enzymes that form a typical dehydrogenase co-factor recycling 
system as shown in Figure 14 and the co-factor itself. Possible solutions for increasing the stability of enzymes 
and co-factor will be discussed in Section 5.3.3.2. 
Substrate selectivity is another important enzyme consideration that needs to be addressed when comparing 
different cascades. In this work two possible types of substrate selectivity issues have been identified. The first 
type of substrate selectivity is the selectivity of the co-product degrading enzyme towards the desired 
substrate. The desired substrate is the keto co-product pyruvate or acetone. However, if a cascade enzyme 
lacks selectivity, another ketone present in the reaction mixture can be converted in a parallel side reaction. 
The only possible ketone is the substrate of the ω-transaminase reaction, e.g. acetophenone. Such side reaction 
is highly undesirable and the depletion of the ketone substrate can have the consequence of a negative 
thermodynamic shift. However, such cases of cascade promiscuity have not been reported in the literature. 
Another type of insufficient selectivity is the substrate selectivity of the ω-transaminase towards the ketones 
or aldehydes produced by the cascade reactions. The products of PDC and ALS cascades are aldehydes and 
ketones respectively, which are possible substrates for ω-transaminase side reactions. A detailed overview of 
possible side reactions and their consequences will be given in the Section 3.4.2. 
pH range is an important consideration in the process development and it is used for determining the optimal 
pH of multi-enzymatic systems. Enzymes may be very sensitive to the pH changes and the activity of an enzyme 
as a function of the pH is most often a bell-shaped curve142. Comparing and overlaying the pH curves of two 
or more enzymes under similar conditions will define a pH range under which all enzymes in a multi-enzymatic 
system can perform.  
 
Figure 27 The possible positions of the pH profiles of two enzyme system 
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Table 5 Considerations for a cascade selection based on the enzyme properties 
  Enzyme Considerations 
  
Stability Substrate Selectivity pH range Kinetic parameters 
Number of possibly 
unstable components 
Selectivity of the      
co-product removal 
enzyme 
Selectivity of the              
ω-transaminase towards 
the cascade products 
pH range of the 
co-product 
removal enzyme 
pH range of the 
co-factor recycling 
enzyme 
"mild" conditions 
Vmax [mmol min-1 g-1] Km [mmol L-1] 
LDH/GDH 
3 
(2 enzymes + co-factor) 
No reaction observed 
No ketones or aldehydes 
produced  
Figure 64 A)  
Appendix 3A 
Figure 64 B)  
Appendix 3A 
LDH 
4.43143 0.016143 
GDH 
? 51144 
LDH/FDH 
3 
(2 enzymes + co-factor) 
No reaction observed 
No ketones or aldehydes 
produced  
Figure 64 A)  
Appendix 3A 
Figure 64 C)  
Appendix 3A 
LDH 
4.43143 0.016143 
FDH 
0.63145 0.47146 
AlaDH/GDH 
3 
(2 enzymes + co-factor) 
No reaction observed 
No ketones or aldehydes 
produced  
Figure 64 D) 
Appendix 3A 
Figure 64 B) 
Appendix 3A 
AlaDH 
? 0.49147 
GDH 
? 51144 
AlaDH/FDH 
3 
(2 enzymes + co-factor) 
No reaction observed 
No ketones or aldehydes 
produced  
Figure 64 D) 
Appendix 3A 
Figure 64 C) 
Appendix 3A  
AlaDH 
? 0.49147 
FDH 
0.63145 0.47146 
YADH/GDH 
3 
(2 enzymes + co-factor) 
No reaction observed 
No ketones or aldehydes 
produced  
Figure 64 E) 
Appendix 3A 
Figure 64 B) 
Appendix 3A  
YADH 
? ? 
GDH 
? 51144 
YADH/FDH 
3 
(2 enzymes + co-factor) 
No reaction observed 
No ketones or aldehydes 
produced  
Figure 64 E) 
Appendix 3A 
Figure 64 C) 
Appendix 3A 
YADH 
? ? 
FDH 
0.63145 0.47146 
PDC 1 
Theoretically no 
substrate promiscuity 
Possible ω-transaminase 
substrate promiscuity 
towards acetaldehyde 
Figure 64 F) 
Appendix 3A 
- 0.72148 2.29148 
ALS 1 
Theoretically no 
substrate promiscuity 
Possible ω-transaminase 
substrate promiscuity 
towards (S)-2-acetolactate, 
acetoin and diacetyl 
Figure 64 G) 
Appendix 3A 
- ? 1.1; 1.6; 8.7149 
40 
 
As shown in Figure 27 there are three possible positions of the pH profiles in a two-enzyme system. In the 
Figure 27 A) the pH profiles do not overlap and performing both reactions at the same pH is impossible while 
the choice of pH in the Figure 27 C) is obvious due to the fact that both enzymes have the highest relative 
activity at the same pH. Determining the optimal pH for the case shown in Figure 27 B) is more complicated 
and for the sequential reactions, e.g. ω-transaminase reaction → co-product removing reaction, the selection 
process is depicted in Figure 28. 
 
Figure 28 Narrowing the pH optimum of the two enzyme system 
Narrowing the pH optimum of a two enzyme system can be done by taking the following steps: 
Step 1: identify the bottleneck reaction and display its pH profile curve (enzyme 1)  
Step 2: identify the pH optimum 1 
Step 3: display the pH profile of an enzyme 2 and identify the overlapping pH range 
Step 4: identify the pH where the two pH curves intersect 
Step 5: the possible pH optimum range is between the line ‘pH optimum 1’ and the line ‘intersection of two 
pH profiles’ 
The exact value of the pH optimum of the system is determined as a value where the reaction rate of the 
slowest enzyme (enzyme 1, e.g. ω-transaminase) will be at maximum while the reaction rate of the faster 
enzyme (enzyme 2, e.g. LDH) is equal to or higher than the reaction rate of enzyme 1. However, the latter 
requirement can also be met by adding an additional amount of enzyme. 
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Kinetic parameters like Km and Vmax can give a rough estimation on the behavior of the enzyme and simple 
kinetic models (Michaelis-Menten) can be made to estimate the differences between reaction rates of different 
cascade enzymes. As mentioned before, most of the time the reported kinetic parameters have been estimated 
under mild conditions and models derived from those parameters do not represent industrially relevant 
conditions. 
3.1.2 Process Considerations 
The second type of considerations which have been gathered in the comparison are the process considerations. 
They describe either the considerations that are not linked to the enzyme properties or the consequences of 
using a given cascade, e.g. products formed or pH shift.  
Thermodynamic equilibrium is one of the most important considerations for cascade selection. The cascade 
selection will be based on how well a certain cascade can remove the co-product and what thermodynamic 
yield it will achieve. The thermodynamic consideration has been divided into three parts, of which the first is 
the Keq of a reaction catalyzed by a given cascade. The second part is the determination of the allowed amount 
of remaining co-product in the reaction mixture to achieve 95 % conversion, which is a reasonable limit for the 
thermodynamic efficiency. The last part represents the cascade ability expressed in the form of the remaining 
co-product concentration and the resulting thermodynamic yield. A detailed explanation will be given in 
Section 3.4.1. 
Downstream processing is an important consideration that describes and identifies all the products formed 
during the reaction as well as their quantities. The properties of the products and their concentrations will 
determine the type, effectiveness and cost of the DSP technologies. In some cases it is easy and straightforward 
to predict concentrations of all products. However, in some cases, e.g. in the case of ALS it is more difficult 
since side reactions take place and an unknown amount of byproduct is formed. 
pH shift is a consideration which tries to identify the change of pH value during the reaction indicating the 
need for pH regulation. A higher pH change will result in stronger pH regulation and addition of a bigger 
volume of acid or base resulting in a higher dilution of the reaction mixture. The determination of the possible 
pH value at the end of the reaction is quite difficult due to the multitude of components in the reaction mixture, 
each with different effect on the pH. Some components shift pH more to the acidic pH region and some others 
more to the basic pH region which is the result of a change in pKa value whilst some other components, e.g. 
alanine act as a buffer. The final pH value will be a function of changed pKa values, concentrations of 
compounds in the reaction mixture and buffer effect. However, an indication of the pH change that is to be 
expected can be made via estimation of the ΔpKa values of different reaction components. The ω-transaminase 
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reaction is typically a reaction that only slightly or not at all influences the pH: For alanine the pKa2 value is 9.69 
while the pKa of (S)-α-methylbenzymamine is 9.75 and the ΔpKa value is +0.06 meaning this reaction has a 
negligible basic pH shift. The same procedure for calculating the ΔpKa value of cascade components has been 
made for several systems and the values have been presented in Table 6. 
3.1.3 Economic Considerations 
The cost of cascade implementation will have an enormous impact on the selection process. When the viable 
cascade candidates are identified, the decision for an industrial implementation will most likely be based 
completely on the cost. For a given cascade candidate the cost will depend on the number of catalytically active 
components (enzymes and co-factors) and the cost of possible sacrificial (co-factor recycling) reactions. 
However, the goal of this chapter will be the identification of viable cascade options and in further chapters 
selection of cascade candidate will be driven by economic concepts e.g. optimization of enzyme (and co-factor) 
concentrations. 
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Table 6 Considerations for a cascade selection based on the process parameters 
Process parameters 
 
Thermodynamic equilibrium Downstream processing  
Calculated Keq 
Allowed concentration of the 
co-product for 95 % 
thermodynamic yield [μM] 
Cascade ability 
(remaining co-
product [μM]) 
Thermodynamic 
yield 
Cascade products 
pH shift 
ΔpKa 
LDH/GDH 
LDH GDH 
1.11 
1.46∙10-12 > 99.99 % 
Lactate [475 mM]  + 1.36 
2.12∙104 1.67∙1023 
glucono-1,4-lactone 
[475 mM]  
- 
glucono-1,5-lactone - 
gluconic acid - 3.14 
LDH/FDH 
LDH FDH 
1.76∙10-12 > 99.99 % 
Lactate [475 mM]  + 1.36 
2.12∙104 1.31∙1052 CO2 [475 mM]   
AlaDH/GDH 
AlaDH GDH 
2.11 
2.29∙10-8 > 99.99 % 
H2O [475 mM]  - 
1.73∙106 1.67∙1023 
glucono-1,4-lactone 
[475 mM]  
- 
glucono-1,5-lactone - 
gluconic acid - 3.14 
AlaDH/FDH 
AlaDH FDH 
2.37∙10-10 > 99.99 %  
H2O [475 mM]  - 
1.73∙106 1.31∙1052 CO2 [475 mM]   
YADH/GDH 
YADH GDH 
9.21∙102 
2.11∙10-8 > 99.99 % 
2-propanol [475 mM]  - 
10.3 1.67∙1023 
glucono-1,4-lactone 
[475 mM]  
- 
glucono-1,5-lactone - 
gluconic acid - 3.14 
YADH/FDH 
YADH FDH 
2.12∙10-8 > 99.99 % 
2-propanol [475 mM]  - 
10.3 1.31∙1052 CO2 [475 mM]   
PDC 1.80∙1030 
1.11 
7.89∙10-24 > 99.99 % 
Acetaldehyde [475 mM]  - 
CO2 [475 mM]   
ALS N.A. N.A. N.A. 
CO2 > [475 mM]  
(S)-2-acetolactate 
[475 mM]  
+ 9.90 
Acetoin - 
Diacetyl - 
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3.2 Feasibility Parameters – Base for Selection 
The aim of the above described data collection was to create an overview of the cascade systems, a cascade 
database, and the impact they would have on a process. However, for a selection process such data is 
insufficient because it does not clearly indicate what the best cascade candidate for process implementation 
is. To identify the viable cascade option, the feasibility of process implementation of a given cascade must be 
challenged. Therefore, three feasibility parameters have been identified by which a comparison can be made, 
and a potential candidate for implementation can be identified. The three feasibility parameters are the 
thermodynamics of the system which is determined by the thermodynamic ability of a cascade system which 
represents the remaining equilibrium concentration of the co-product after a cascade has been implemented. 
The second parameter is substrate selectivity of the enzymes in the system indicating possible side reactions 
and issues associated with these phenomena, e.g. loss of product or difficult separation of product from a 
mixture of amines created by side reactions. The third parameter is operational stability of cascade enzymes 
which was experimentally determined. The order in which parameters have been placed also plays a significant 
role potentially reducing the workload, as well as the time and the cost needed for the selection process as 
presented by the scheme shown in the Figure 29. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. The justification of order in which the steps in the selection process are placed resulting in fewer candidates going 
through more time and workload consuming steps 
  
lower impact on time, 
workload and cost 
 
higher impact on  
time, workload and 
cost 
Calculations and Simulations 
[calculating lowest thermodynamically possible co-
product concentraions of transaminase-cascade 
system]
Literature Research/Experimental Work
[discussion on substrate selectivity of ω-transaminase 
and substrate selectivity experiments] 
Experimental Work
[Experimental determination of stability of all cascade 
systems under industrially relevant conditions]
reducing the 
number of possible 
cascade candidates 
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3.3 Materials and Methods 
3.3.1 Materials 
The enzymes lactate dehydrogenase (LDH 1; EC 1.1.1.27), glucose dehydrogenase (GDH 1 and 2; EC 1.1.1.47) 
and formate dehydrogenase (FDH; EC 1.2.1.2) are obtained from Codexis (Redwood City, CA) in the form of 
crude extract. Another lactate dehydrogenase (LDH 2) and alanine dehydrogenase (AlaDH; EC 1.4.1.1.) were 
obtained from Evocatal (Düsseldorf, Germany). Yeast alcohol dehydrogenase (YADH; EC 1.1.1.1) was obtained 
from Sigma Aldrich (Brøndby, Denmark). Acetophenone, L-alanine, 2-propylamine, sodium pyruvate, acetone, 
ammonium formate, (D)-(+)-glucose, (D)-gluconic acid sodium, sodium lactate, β-nicotinamide adenine 
dinucleotide reduced dipotassium salt, β-nicotinamide adenine dinucleotide hydrate, 2-propanol Tris Sigma 7-
9 and hydrochloric acid were obtained from Sigma Aldrich (Brøndby, Denmark). (S)-α-methylbenzylamine and 
potassium hydroxide were obtained from Merck KGaA (Darmstadt, Germany) 
3.3.2 Simulations and Calculations 
3.3.2.1 Thermodynamic Calculations 
Keq of individual cascade reactions. Gibbs free energies of the formation (Δ𝐺𝑓
°) of reaction components at pH 7 
and 25 °C were taken from the literature150 and the Keq of individual cascade reactions was calculated by using 
Equation 2.4 and Equation 3.1. 
 𝐾𝑒𝑞 = 𝑒
−
∆𝐺°
𝑅𝑇  3.1 
Calculation of the allowed remaining co-product concentration for 95 % conversion was made using Equation 
2.3, and Keq values for the substrate pairs acetophenone-alanine and acetophenone-2-propylamine were 
obtained from the experimental work published by Tufvesson et al98. The initial concentration of acetone was 
500 mmol L-1 and a 1X excess of amino donor (1 mol L-1) was present, where excess is defined as: 
 𝑐1 = 𝑐2(1 + 𝑋) 3.2 
c1 – concentration of the component in excess (donor); c2 – concentration of the comparing component (ketone substrate); 
X – excess 
The allowed pyruvate concentration for 95 % conversion in the AlaDH case was calculated by modifying the 
Equation 2.3 by assuming the same alanine concentration for the initial value and the equilibrium value 
simulating the alanine recycle. 
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Cascade ability or how much of the co-product can a given cascade thermodynamically remove was calculated 
using an iterative procedure as suggested by the literature151. The thermodynamic equilibrium was postulated 
as described in Table 7. 
Table 7 Initial thermodynamic concentrations of ω-transaminase/LDH/GDH system 
ω-transaminase/LDH/GDH system 
ω-transaminase ACP + alanine ↔ pyruvate + MBA 
Initial conc. [mmol L-1] 500  1000  0  0 
Equilibrium conc. [mmol L-1] 500 - x  1000 - x  x  x 
LDH NADH + pyruvate ↔ NAD+ + lactate 
Initial conc. [mmol L-1] 0.1  x  0  0 
Equilibrium conc. [mmol L-1] 0.1 - y  x - y  y  y 
GDH NAD+ + glucose ↔ NADH + glucono-1,5-lactone 
Initial conc. [mmol L-1] y  550  0  0 
Equilibrium conc. [mmol L-1] y - z  550 - z  0.1 – y + z  z 
Based on the Equation 2.3, Keq values, initial concentrations and the assumptions stated at the end of this 
section, equations for calculating the equilibrium change in ω-transaminase (value x), LDH (value y) and GDH 
(value z), here were developed and are described by equations 3.3, 3.4 and 3.5: 
 
𝑥 =
𝑐𝑀𝐵𝐴 + 𝑐𝑃𝑌𝑅 + 𝐾𝑒𝑞
𝑇𝐴𝑚(𝑐𝐴𝐶𝑃 + 𝑐𝐴𝑙𝑎) −
−√(𝑐𝑀𝐵𝐴 + 𝑐𝑃𝑌𝑅 + 𝐾𝑒𝑞𝑇𝐴𝑚(𝑐𝐴𝐶𝑃 + 𝑐𝐴𝑙𝑎))
2
− 4(𝐾𝑒𝑞𝑇𝐴𝑚 − 1)(𝐾𝑒𝑞𝑇𝐴𝑚𝑐𝐴𝐶𝑃𝑐𝐴𝑙𝑎 − 𝑐𝑃𝑌𝑅𝑐𝑀𝐵𝐴)
2(𝐾𝑒𝑞𝑇𝐴𝑚 − 1)
 
3.3 
 
𝑦 =
𝑐𝑁𝐴𝐷+ + 𝑐𝐿𝐴𝐶 + 𝐾𝑒𝑞
𝐿𝐷𝐻(𝑐𝑃𝑌𝑅 + 𝑐𝑁𝐴𝐷𝐻) −
−√(𝑐𝑁𝐴𝐷+ + 𝑐𝐿𝐴𝐶 + 𝐾𝑒𝑞𝐿𝐷𝐻(𝑐𝑃𝑌𝑅 + 𝑐𝑁𝐴𝐷𝐻))
2
− 4(𝐾𝑒𝑞𝐿𝐷𝐻 − 1)(𝐾𝑒𝑞𝐿𝐷𝐻𝑐𝑃𝑌𝑅𝑐𝑁𝐴𝐷𝐻 − 𝑐𝐿𝐴𝐶𝑐𝑁𝐴𝐷+)
2(𝐾𝑒𝑞𝐿𝐷𝐻 − 1)
 
3.4 
 
𝑧 =
𝑐𝑁𝐴𝐷𝐻 + 𝑐𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶 + 𝐾𝑒𝑞
𝐺𝐷𝐻(𝑐𝑃𝑌𝑅 + 𝑐𝑁𝐴𝐷+) −
−√(𝑐𝑁𝐴𝐷𝐻 + 𝑐𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶 + 𝐾𝑒𝑞𝐺𝐷𝐻(𝑐𝑃𝑌𝑅 + 𝑐𝑁𝐴𝐷+))
2
− 4(𝐾𝑒𝑞𝐺𝐷𝐻 − 1) ∙
∙ (𝐾𝑒𝑞𝐺𝐷𝐻𝑐𝐺𝐿𝑈𝑐𝑁𝐴𝐷+ − 𝑐𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶𝑐𝑁𝐴𝐷𝐻)
2(𝐾𝑒𝑞𝐺𝐷𝐻 − 1)
 
3.5 
The equilibrium concentrations of reaction mixture components were calculated as shown in the Table 7  in 
the ‘Equilibrium conc.’ rows. Following the steps of calculation of equilibrium concentrations for each reaction, 
it can be observed that the equilibrium concentration of pyruvate in ω-transaminase was consumed by the 
LDH reaction which means that the equilibrium concentrations have to be recalculated. The next set of x, y and 
z values are calculated followed by calculations of new equilibrium concentrations of the reaction mixture. This 
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process continues iteratively until the whole cascade system reaches equilibrium. This equilibrium of the system 
can be defined as the case when the ω-transaminase reaction slows down and further MBA production is 
insignificant (iteration condition for stopping: e = |cMBA, n - cMBA, n-1| < 10-15). Figure 30 shows an example of flow 
diagram for above described procedure for the program developed in Matlab®.  
Initial values
Equilibrium concentrations of    
TAm components
Equilibrium concentrations of    
co-product removal reaction
Equilibrium concentrations of   
co-factor regeneration 
reaction
e =
|cMBA, n - cMBA, n-1| 
< 10
-15
NO
Co-product concentration, 
yield
YES
 
Figure 30 Flow diagram of calculating thermodynamic equilibrium concentrations of ω-transaminase coupled to a 
dehydrogenase cascade system 
An example of Matlab® program for calculating equilibrium co-product concentration and thermodynamic 
yield for LDH/GDH system is given in Appendix 3B. 
Several assumptions were made during the calculation: the concentrations of water and CO2 were kept constant 
at 55.52∙103 and 28.4 mmol L-1 respectively where these values represent the water concentration in aqueous 
solution and the equilibrium concentration of CO2 in water under standard conditions. In the reactions 
catalyzed by GDH, only transformation from glucose to the glucono-1,5-lactone is considered. 
Multiple equilibrium shifting strategies have been discussed and the effect of using ISPR, ISCPR and Amino 
donor excess was calculated using modified Equation 3.6 for two systems with different Keq values shown in 
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the Figure 32 and Figure 36. The concentrations of product removed by ISPR [%] or co-product removed by 
ISCPR [%] are termed as cISPR and cISCPR, respectively. 
 
𝐾𝑒𝑞
𝑇𝐴𝑚 =
(𝑐𝑃𝑌𝑅 − 𝑐𝐼𝑆𝐶𝑃𝑅)(𝑐𝑀𝐵𝐴 − 𝑐𝐼𝑆𝑃𝑅)
𝑐𝐴𝐶𝑃𝑐𝐴𝑙𝑎(1 + 𝑋)
 
3.6 
 
3.3.3 Experimental Studies 
3.3.3.1 Stability Studies 
Approximation of process relevant conditions. Three reaction mixtures representing three reaction systems, i.e. 
ω-transaminase-LDH/GDH, ω-transaminase-AlaDH/FDH and ω-transaminase-YADH/GDH, were prepared and 
termed reaction mixture 1, 2 and 3 respectively. The concentration of the components in the reaction mixtures 
was averaged between starting and ending concentrations of an industrial process (50 g L-1 of product ≈ 500 
mmol L-1). Reaction mixture 1 contained 30 mmol L-1 acetophenone, 1 mol L-1 L-alanine, 250 mmol L-1 (S)-α-
methylbenzylamine, 250 mmol L-1 sodium lactate, 250 mmol L-1 (D)-(+)-glucose and 250 mmol L-1 (D)-gluconic 
acid sodium salt. Reaction mixture 2 contained 30 mmol L-1 acetophenone, 1 mol L-1 L-alanine, 250 mmol L-1 
(S)-α-methylbenzylamine and 250 mmol L-1 ammonium formate. Reaction mixture 3 contained 30 mmol L-1 
acetophenone, 1 mol L-1 2-propylamine, 250 mmol L-1 (S)-α-methylbenzylamine, 250 mmol L-1 2-propanol, 250 
mmol L-1 (D)-(+)-glucose and 250 mmol L-1 (D)-gluconic acid sodium salt. The pH value of the reaction mixtures 
was adjusted to 7 with the addition of HCl or KOH. 
Enzyme assay. For determination of the initial reaction rates of the co-product removal enzymes an assay was 
used containing 0.1 mmol L-1 of co-factor NADH and 1 mmol L-1 of pyruvate for LDH and AlaDH or acetone 
for YADH. The LDH, AlaDH or YADH assay contained reaction mixture 1, 2 or 3 respectively. The concentration 
of enzymes in the assay of AlaDH, LDH and YADH was 0.001, 0.01 and 0.2 g L-1 respectively. The assay for 
determining the initial reaction rates of co-factor recycling enzymes GDH and FDH contained reaction mixture 
1 and 2 respectively and 0.1 mmol L-1 of NAD+ while the concentration of both enzymes was 0.01 g L-1. The 
assay mixtures lacking the co-factor NADH/NAD+ were incubated at 30 °C in 4 mL glass vials in the 
thermoshaker (HLC, TG Instrument AB, 300 min-1). Samples were taken at time 0, 4 and 24 h into 4 mL Quartz 
SUPRASIL® Precision cells and the reaction was started by addition of NADH or NAD+ solution. The reaction 
rates of all enzymes were followed by the change of adsorption of NADH at 340 nm using a Shimadzu UV-
1801 at 30 °C.  
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3.3.3.2 Selectivity studies 
The assay contained 0.1 mmol L-1 NADH and 30 mmol L-1 acetophenone and the concentration of AlaDH, LDH 
and YADH was 1 g L-1. The assay was carried out in 4 mL Quartz SUPRASIL® Precision cells by following the 
change of adsorption of NADH at 340 nm using a Shimadzu UV-1801 at 30 °C. The reaction was started by 
addition of the enzyme solution. The blank cuvette contained reaction mixture without the enzyme solution. 
An additional 100 μL of NADH solution was added to each cuvette during the reaction to verify that no 
observable reaction is occurring. 
3.4 Results and Discussion 
3.4.1 Thermodynamic Ability 
For thermodynamically challenged reactions an equilibrium shifting strategy is mandatory and possible 
strategies have been described in the Section 2.4. The usage of thermodynamic calculations described in 
section 3.3.2.1 enables the calculation of a desired yield as a function of the changed Keq value (amine donor 
selection), added substrate (amino donor excess) or allowed residual product or co-product (ISPR or ISCPR, 
respectively). Taking into account physical limitations of the system, e.g. solubility of amino donor, this 
approach can identify the applicable equilibrium shifting strategies as well as provide an estimation of how 
effective a strategy has to be to achieve the desired thermodynamic yield. 
One possible strategy for determining the requirement for achieving that desired thermodynamic yield is 
calculating the allowed co-product concentration that can remain in the reaction mixture as a function of 
thermodynamic yield as shown in Figure 31. This calculation is based on industrially relevant conditions (cACP 
= 500 mmol L-1 and one fold excess alanine calanine = 1 mol L-1). 95 % thermodynamic yield has been chosen as 
a relevant target resulting in a product concentration in the range defined in the guidelines for successful 
biocatalytic processes8 cMBA = 475 mmol L-1 or γMBA ≈ 50 g L-1. Under these conditions the allowed co-product 
concentration remaining in the reaction mixture is 1.11 μmol L-1 which means that any successful equilibrium 
shifting strategy must be able to remove the co-product to this value or lower. 
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Figure 31 The allowed co-product concentration remaining in the reaction mixture as a function of the desired yield for an 
equilibrium value Keq= 4.03·10-5 
The value of the allowed co-product concentration for the previously described case (cpyruvate = 1.11 μmol L-1) 
shows how strong the thermodynamic challenge is. To achieve a desired yield of 95 %, 474.998 mmol L-1 of 
the co-product have to be removed by a single equilibrium shifting strategy which would require for this 
strategy to be extremely efficient. To overcome this challenge, it is possible to implement multiple equilibrium 
shifting strategies to assist the primary one. In the Figure 32 the yield has been calculated as a function of 
product removed by ISPR [%], co-product removed by ISCPR [%] and Amine donor excess to investigate the 
additive effect of those strategies (Equation 3.6).  
 
Figure 32 Thermodynamic yield as a function of co-product removed by ISCPR [%], product removed by ISPR [%] and excess 
of amino donor; intersecting horizontal plane indicates 95 % conversion (Keq = 4.03·10-5) 
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The calculation showed that the use of ISPR (yz plane) or ISCPR (xz plane) applied individually result in the 
same effect meaning that the removed co-product required to achieve e.g. 95 % yield (Scenario 1) will 
correspond to the same amount of product removed to achieve 95 % yield (Scenario 2). However, if 95 % of 
possible co-product is removed by ISCPR together with an additional 80 % of the product removed by ISPR 
(Scenario 3), the resulting thermodynamic yield won’t be significantly changed. This result shows in this case 
that secondary ISPR equilibrium shifting strategy does not contribute considerably to the yield. The addition 
of the amino donor excess strategy will also not improve the thermodynamic yield significantly, and will result 
in closely packed calculated surfaces representing yields as shown in the Figure 32 in the enlarged window. 
The lower dark blue surface represents equimolar amount of amino donor, the white the excess of 10 and the 
upper blue the excess of 50. This type of calculation can prove to be very beneficial in the early stage of process 
development indicating viable equilibrium shifting strategies. Taking e.g. ISCPR as a primary equilibrium 
shifting strategy, calculations have been made to show how much of the remaining co-product is allowed in 
the reaction mixture, and results are shown in the Figure 33. As predicted assisted ISPR and assisted donor 
excess allow more co-product concentrations in the reaction mixture for achieving 95 % yield, however this 
information does not show the percentage of the assistance of secondary and tertiary strategy. Figure 34 shows 
percentage-wise the assistance of secondary and tertiary equilibrium shifting strategy and for the case of 99 
% assisted ISPR and 50X excess amino donor, the required co-product that needs to be removed was reduced 
only by 1 %. ISPR and excess amino donor in this case didn’t provide significant assistance. 
 
Figure 33 Allowed co-product concentration in the reaction mixture for achieving 95 % yield as a function of assisted ISPR 
and assisted excess donor (Keq = 4.03∙10-5) 
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Figure 34 Percentage of the required co-product removed as a function of assisted ISPR and assisted excess donor                      
(Keq = 4.03·10-5) 
Looking at the trends of ISPR and ISCPR at 95 % conversion (Figure 32) it is possible to plot a thermodynamic 
window of operation, i.e. a two-dimensional process map displaying regions of feasible operating ranges based 
on the boundaries of the system152, 153. In Figure 35 the drawn lines represent the intersection of yield surfaces 
with the 95 % plane. For the case of 94 % assisting ISPR and 50X donor excess (Scenario 4) the ISCPR 
requirement will be reduced from starting 95 % (no assisting strategies) to 94 % of removed co-product. 
 
 
 
 
 
 
 
 
 
 
Figure 35 Window of operation for achieving 95 % conversion as a function of ISCPR, ISPR and amino donor excess; the area 
above the lines shows the window of operation (Keq = 4.03·10-5) 
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The inability to reduce the requirements for achieving the desired yield by the assisting secondary and tertiary 
equilibrium shifting strategy is mainly a function of the Keq value,  which is extremely low in this example (Keq 
= 4.03·10-5). To prove this hypothesis, the same set of calculations have been made for a case where                      
2-propylamine is used as an amino donor (Figure 21) and the Keq value is 3.33·10-2. 
  
 
 
 
 
 
 
Figure 36 Thermodynamic yield as a function of co-product removed by ISCPR [%], product removed by ISPR [%] and excess 
of amino donor; intersecting horizontal plane indicates 95 % conversion (Keq = 3.33·10-2) 
 
Figure 37 Allowed co-product in the reaction mixture for achieving 95 % yield as a function of assisted ISPR and assisted 
excess donor (Keq = 3.33·10-2) 
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Figure 38 Percentage of the required co-product removed as a function of assisted ISPR and assisted excess donor                      
(Keq = 3.33·10-2) 
 
Figure 39 Operating window for achieving 95 % conversion as a function of ISCPR, ISPR and amino donor excess; the area 
above the lines shows possible window of operation (Keq = 3.33·10-2) 
Scenario 5 
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The results for the two different cases (Keq = 4.03·10-5 and Keq = 3.33·10-2) showed that the Keq value plays a 
significant role in determining the extent of assistance provided by the secondary and tertiary equilibrium 
shifting strategy. As seen in the Figure 37 the allowed remaining co-product concentration for achieving 95 % 
conversion is much higher when secondary (ISPR) and tertiary (amino donor excess) strategies are applied. 
Figure 38 supports that statement by showing that when the secondary strategy (ISPR) is at 99 % and the 
tertiary (amine donor excess) at 50X, the primary equilibrium shifting strategy (ISCPR) has to remove 85 % of 
the required co-product to achieve 95 % thermodynamic yield. An improved assistance of the secondary and 
tertiary equilibrium shifting strategies is shown in the Figure 39 where e.g. for 60 % assisted ISPR and 50X of 
amino donor (Scenario 5) the required co-product removal by ISCPR is lowered from 95% to ≈ 70 %. Observing 
these results, the conclusion can be drawn that for highly thermodynamically challenged reactions, e.g.             
ω-transaminase reaction with acetophenone and alanine as substrates, only one equilibrium shifting strategy 
will have a dominant effect on the equilibrium shift and it will have to be very efficient and extremely selective. 
Since the amino donor excess strategy is usually limited by solubility of the donor, the choice of equilibrium 
shifting strategies will have to be made between ISPR and ISCPR. Taking into account the properties of the 
components in the reaction mixture, currently no ISPR technology satisfies the exclusive selectivity towards the 
product and thus lacks the ability to remove it to low enough values (1.1 μmol L-1). However, due to the high 
substrate selectivity of enzymes and the ability to run the reactions at relatively high rates at low substrate 
concentrations (low Km), ISCPR by enzymes provides currently the only viable equilibrium shifting strategy for 
severely thermodynamically challenged reactions. Compared to the more classical approaches e.g. ISCPR by 
chemocatalytic reaction, the obvious advantage of the enzymatic approach is its supreme substrate selectivity 
and the importance of this parameter will be discussed in the next section. 
In the Figure 33 the allowed co-product concentration to obtain an industrially relevant 95 % thermodynamic 
yield was calculated. However, to choose a cascade capable of lowering the co-product to that concentration 
or even a lower concentration is a first step in a cascade selection process. This ability of achieving co-product 
removal is here termed the cascade ability and is represented in the system as the remaining co-product 
concentration [μmol L-1] after the cascade system reaches equilibrium. If a cascade system is 
thermodynamically unable to remove the co-product to the desired concentration, either lower yields have to 
be considered or the cascade system has to be discarded from the selection process. The process of calculating 
the allowed co-product concentration and the cascade ability was described in the Section 3.3.2.1 and the 
results are shown in Table 8. 
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Table 8 Cascade ability vs. allowed co-product concentration with their respective thermodynamic yields of different cascade 
system candidates 
Enzymatic cascade 
Allowed co-product 
[μmol L-1] 
Cascade ability 
(co-product [μmol L-1]) 
Thermodynamic 
conversion 
LDH/GDH 1.11 1.10∙10-7 > 99.99 % 
LDH/FDH 1.11 1.25∙10-7 > 99.99 % 
AlaDH/GDH 2.11 9.28∙10-2 99.77 % 
AlaDH/FDH 2.11 1.66∙10-8 > 99.99 % 
YADH/GDH 9.21∙102 1.65∙10-1 99.12 % 
YADH/FDH 9.21∙102 1.81∙10-1 99.12 % 
PDC 1.11 7.89∙10-25 > 99.99 % 
ALS 1.11 N.A. N.A. 
The calculations showed that all cascade systems have sufficient cascade ability and can reduce the co-product 
concentration to low enough levels to achieve thermodynamic yields > 99 %. The Gibbs free energy of 
formation for the (S)-2-acetolactate was unavailable in the literature so the calculation of Keq value for the 
reaction catalyzed by ALS (Figure 25) as well as its cascade ability was not possible. 
3.4.2 Substrate Selectivity 
The second step of a cascade selection process is determining the substrate selectivity of the enzymes present 
in the reaction system, and two types of undesired substrate selectivity can be observed. The first type of 
undesired substrate selectivity relates to the co-product degrading enzyme. In all ω-transaminase cases the 
co-product is a ketone and if a co-product degrading enzyme does not possess sufficient selectivity, another 
ketone, e.g. acetophenone might be consumed instead as shown in Table 9. 
Table 9 Possible reaction scheme of side reactions due to the insufficient substrate selectivity of the co-product removal enzyme 
Side Reaction Consequence 
 
 consumption of limiting substrate 
 undesired equilibrium shift 
Insufficient substrate selectivity of the co-product removing enzymes was never reported in the literature. 
However, a quick experimental verification described in Section 3.3.3.2 was made to confirm these results 
(Appendix 3C). 
The second type of undesired selectivity relates to the substrate selectivity of ω-transaminase towards the 
products of the cascade reactions. Two enzymes whose products might be substrate for the ω-transaminase 
reaction have been identified: PDC and ALS. These products are ketones and aldehydes and possible side 
reactions and their consequences for the PDC cascade have been listed in Table 10. 
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Table 10 Possible reaction schemes of side reactions due to insufficient substrate selectivity of the ω-transaminase towards 
the products of the PDC cascade 
Side Reactions Consequence 
 
 loss of amino donor 
 undesirable 
equilibrium shift 
 extra amine – harmful 
and flammable 
 
 loss of amino product 
 extra amine - harmful 
and flammable 
 
Table 11 Keto substrates and amino donors resulting in 18 possible side reactions in the ALS cascade system 
Possible Keto Substrates Possible Amino Donors 
  
  
  
  
  
In the ALS cascade system overall 18 possible side reactions catalyzed by ω-transaminase may occur (Table 
11) resulting in production of numerous unwanted amines, an undesirable equilibrium shift and, most 
importantly, a loss of the main amino product. The extent of each side reaction for both cascade systems will 
depend on its own specific Keq and kinetic parameters. However, certain predictions can be made after studying 
the literature. Aldehydes have been identified in the literature as a preferred substrate for the ω-transaminase52, 
and as a result the reactions shown in Table 10 are likely to take place. Regarding the promiscuity of                     
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ω-transaminase towards the products of the ALS cascade, acetoin, diacetyl and 3-aminobutan-2-one show 
high structural resemblance to pyruvate, and are also very favorable substrates of the ω-transaminase52, 154, 
and side reactions involving those molecules might be very likely to occur, however not yet experimentally 
confirmed. Due to the high probability of loss of product, the production of undesired amines which 
complicates DSP and the undesired equilibrium shift, the PDC and ALS cascade systems will be discarded from 
the selection process until an ω-transaminase with desired substrate specificity is developed. 
3.4.3 Enzyme Stability 
In the section 2.3.2.3.1.2 the reasons for requiring a high stability of the enzymes have been explained and 
justified and the same rules must be applied when selecting the cascade options for industrial implementation. 
The literature suggests the investigation of the operational stability of enzymes for industrial purposes155. This 
approach determines the stability of an enzyme throughout the course of the reaction. However, in this work 
industrially relevant conditions could not be met by application of the available ω-transaminase due to the 
lack of enzyme tolerance towards high concentrations of substrates and products. A compromise has been 
made and stability has been determined at simulated conditions. Knowing the concentrations of the reaction 
mixture at the beginning and the end of the reaction, averaged concentrations which do not change over time 
were chosen to represent process conditions of several processes with different cascades (reaction mixtures 1, 
2 and 3; see section 3.3.3.1). 
The stability results are usually presented in relative values, and are often fitted to first order kinetics (Equation 
2.1) given a certain half-life time. However, if the values are given as reaction rates, comparing those values 
with experiments done in neat conditions (substrates, buffer) for the same substrate concentrations, valuable 
information can be retrieved, e.g. the degree of inhibition by components in the reaction mixture. If this simple 
experiment can show that inhibition is too high, e.g. no reaction can be observed under industrial conditions, 
then this enzyme can be excluded from the selection process until it is improved to tolerate a higher 
concentration of inhibitory components. In this work this was the case with YADH which showed no observable 
reaction under process relevant conditions (reaction mixture 3). 
As shown in Figure 40 a certain fraction of the potentially realizable reaction rate was lost due to inhibition. 
However, a more detailed investigation and kinetic models are required to identify the inhibiting components 
and the strength of inhibition (Chapter 4). 
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Figure 40 Difference in the initial reaction rates between neat and industrially relevant conditions for LDH 1 and AlaDH 
enzymes 
Results of the investigated cascade enzymes represented as reaction rates are shown in Figure 41 and resulting 
half-time values in Table 12. Stabilities of individual enzymes fitted to a first-order decay model (Equation 2.1) 
are shown in Appendix 3D. This method does not only distinguish possible candidates between different types 
of enzymes, but also between the same enzymes from different sources and/or suppliers. For this reason, all 
cascade enzymes available for this project were tested for stability and were therefore also named for this 
purpose LDH 1, LDH 2, GDH 1 and GDH 2. 
 
Figure 41 Cascade enzyme stability under corresponding process relevant conditions 
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Table 12 Results of kd value and half-time for different cascade enzymes 
The exclusion criterion was set to a minimum reaction rate corresponding to 80 % of the initial reaction rate. 
However, in the future development of this method an exclusion criteria will be a function of the economic 
evaluation and the reaction rates. As shown in the Figure 41 LDH 1 and AlaDH have shown insufficient stability 
towards the process conditions. Their half-life time of 42 and 94 minutes respectively makes them very unstable 
and undesirable in a process. GDH 2 with a half-life time of 54 hours is showing a certain degree of instability 
with remaining activity ≈ 74 % after 24 hours. The last experimental point shows a higher degree of uncertainty 
meaning that this value could be higher than the exclusion criteria. The experiments with YADH showed no 
observable activity at time 0 hours, leaving only two possible cascade systems for industrial implementation: 
LDH 2/GDH 1 and LDH 2/FDH. Those enzymes showed no decrease of stability over the investigated period of 
time. 
3.5 Conclusions 
A novel strategy for selection of cascades for shifting the equilibrium of ω-transaminase systems was 
developed and successfully implemented on eight cascade systems. The selection process was based on three 
important feasibility considerations: thermodynamics, substrate selectivity and enzyme stability. The order of 
the different steps was carefully considered with the aim of decreasing the amount of time-consuming lab 
work. Therefore, calculation steps were scheduled first in the selection process, and experimental steps were 
put at the end. As shown in Figure 42 the first selection step is based on calculating the thermodynamic ability 
of the cascades. The exclusion criterion was ≥ 95 % thermodynamic yield and all cascade systems satisfied this 
criterion. The second step included considerations about substrate selectivity. The first element in these 
considerations was concerned with the substrate selectivity of the cascades, and it was experimentally 
confirmed that no observable reaction occurs with the acetophenone as an alternative keto substrate. The 
second element to be considered was related to the selectivity of ω-transaminase towards the products of the 
cascades. The aldehyde product of the PDC cascade is a preferable substrate of the ω-transaminase, and based 
on the structural similarity of the ALS products acetoin, diacetyl and 3-aminobutan-2-one with pyruvate, those 
side reactions have been identified as highly probable. Such reactions would result in an unfavorable 
equilibrium shift, the consumption of the main product and a more complicated DSP, and therefore the PDA 
and ALS cascade systems have been excluded from the selection process. The final selection step was the most 
laborious and time consuming, and therefore it was important to reduce the number of potentially feasible 
cascade options in the previous steps. This selection step was based on the enzyme stability under process 
 LDH 1 LDH 2 AlaDH GDH 1 GDH 2 FDH 
kd [h-1] 0.98 0 0.44 0 1.28∙10-2 0 
t1/2 [h] 0.71 - 1.57 - 54.09 - 
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AlaDH
GDH
LDH
relevant conditions where the exclusion criterion was set to 80 % of the initial reaction rate for the duration of 
the process envisioned here for 24 h. LDH 1, AlaDH, GDH 2 and YADH showed insufficient stability. 
Finally, the selection process resulted in two cascade systems as potential candidates for industrial 
implementation. Every cascade candidate offers certain advantages and disadvantages and to select one over 
another further investigation is required. 
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Figure 42 An overview of the selection process of the most promising cascades in ω-transaminase systems
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4 Developing Kinetic Models of LDH, GDH and FDH 
Enzymes to Assist the Selection Process 
4.1 Introduction 
In the previous chapter, a selection framework was developed and presented, identifying LDH/GDH and 
LDH/FDH cascade systems as the best candidates for potential industrial implementation. The aim of this 
chapter is to provide a more detailed description of both cascade systems via development of kinetic models. 
Such models can then assist the selection process since they allow optimizing the amount of required enzymes. 
Another goal of kinetic model development is identifying the necessary improvement of ω-transaminase 
activity to reach desired goal of final product concentration of 50 g L-1 within 24 h. The activity of the ω-
transaminase required for an industrial process will depend on the efficiency of the pyruvate removal, which is 
depending on the kinetic parameters of cascade enzymes, the concentrations of cascade enzymes and the 
concentration of co-factor. The investigation of cascade efficiency and its effect on the required ω-
transaminase activity is an important aspect of process development, and defining this correlation can be a 
crucial part of the decision making process. 
4.1.1 Multi-enzyme processes – one pot processes 
Traditionally the implementation of enzymatic reactions to pilot or industrial scale has been performed mostly 
in a single reaction step and following that concept, e.g. a three enzyme process would be carried out in three 
sequential reactors in series with a single step performed in each reactor. However, due to the high substrate 
selectivity of enzymes, it is theoretically possible to perform the process studied here in a single reactor. Instead, 
an approach known as a multi-enzyme one-pot process is a necessity for this type of multi-enzyme processes, 
and represents an innovative way of carrying out multi-enzymatic reactions. 
The implementation of a multi-enzyme one-pot process provides several advantages compared to the 
traditional one-step one-reaction approach. Provided that conditions of individual reactions (e.g. 
concentrations of reaction mixture components, temperature, pH) are well matched so that all enzymes can 
tolerate those conditions it is possible to exploit the cooperation between the enzymes in the one-pot process. 
The substrate consumed by the first reaction becomes the intermediate product, and then it can be consumed 
immediately by the second reaction and so on. Furthermore, the required reaction volume is reduced from 
multiple vessels to one reactor, and moreover the separation and isolation of intermediate products is 
eliminated103. This leads to a simplification of downstream processing and a reduction of operating costs. 
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4.1.2 Objectives of Model Development 
Development of mathematical models is increasingly important in the process of investigating enzymatically 
catalyzed reactions. A number of parameters influence the reaction rate, e.g. chemical and physical properties 
of substrates, products and external components at different concentrations, properties and concentrations of 
the biocatalyst, thermodynamic equilibrium, pH and temperature to name a few. 
There are several objectives for developing the kinetic model. One of the objectives is to analyze the dynamic 
process behavior by simulating the model while varying the input variables. This procedure allows better 
interpretation of the model, and will result in an improved understanding on how input variables, e.g. substrate 
concentrations, influence the process outputs. Another objective of such simulations is to provide a good plan 
for design of experiments when, e.g. the model needs to be validated. Furthermore, it is possible to optimize 
the process by adjusting the inputs and parameters in the model, e.g. optimal substrate concentrations, 
temperature, pH or process set-up. To achieve the desired objective, e.g. maximal yields, finding optimal 
conditions can be done utilizing either statistical or stochastic methods 156. Finally, well defined and reliable 
models can be used for prediction of the process output and for process control. All the above-mentioned 
objectives are valid and applicable for both single and multi-enzyme processes. However, multi-enzyme 
processes benefit highly from model development due to the complexity of the system to be studied. 
Development of multi-enzyme kinetic model can be a powerful tool to achieve all of the abovementioned 
model development objectives. 
4.1.3 Enzyme kinetics 
4.1.3.1 Michaelis-Menten kinetics 
The Michaelis-Menten equation (Equation 4.1) is the fundamental equation of enzyme kinetics and it was first 
derived for the simplest case of an irreversible enzyme reaction converting a single substrate into a product157. 
The rate of reaction as a function substrate concentration for the Michaelis-Menten kinetics is given in Figure 
43. 
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Figure 43 Initial reaction rates, r0, plotted against increasing substrate concentrations for a reaction obeying Michaelis-Menten 
kinetics 
 𝑟𝑆 =
𝑉𝑚𝑎𝑥𝑐𝑆
𝐾𝑚𝑆 + 𝑐𝑆
 4.1 
The kinetic model describes a rate of reaction as a function of a single substrate (Equation. 4.2). However, 
expressions for more complicated e.g. two, three or more substrate reactions have been developed. The two 
substrate Michaelis-Menten equation is shown in Equation 4.3 and similar equations can be obtained for e.g. 
three substrate reactions. 
 𝑟𝑆 =
𝑉𝑚𝑎𝑥𝑐𝑆1𝑐𝑆2
(𝐾𝑚𝑆1 + 𝑐𝑆1)(𝐾𝑚𝑆2 + 𝑐𝑆2)
 4.3 
The Equation 4.3 can be expanded further by observing the kinetic mechanism, including for example inhibition 
expressions caused either by substrates or products. It is quite often the case that enzymatically catalyzed 
reactions are inhibited by bonding of an undesired molecular species to the active site of the enzyme and thus 
blocking it. Three types of inhibition may occur: competitive, uncompetitive and noncompetitive inhibition 
described in Equation 4.4, 4.5 and 4.6 respectively. 
 
𝑟𝑆 =
𝑉𝑚𝑎𝑥𝑐𝑆
𝐾𝑚𝑆 (1 +
𝐼
𝐾𝑖
) + 𝑐𝑆
 
4.4 
 
𝑟𝑆 =
𝑉𝑚𝑎𝑥𝑐𝑆
𝐾𝑚𝑆 + 𝑐𝑆 (1 +
𝐼
𝐾𝑖
)
 
4.5 
 
𝑟𝑆 =
𝑉𝑚𝑎𝑥𝑐𝑆
(𝐾𝑚𝑆 + 𝑐𝑆) (1 +
𝐼
𝐾𝑖
)
 
4.6 
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4.2 Materials and Methods 
4.2.1 Materials 
The enzymes lactate dehydrogenase (LDH; EC 1.1.1.27), glucose dehydrogenase (GDH; EC 1.1.1.47) and formate 
dehydrogenase (FDH; EC 1.2.1.2) were obtained from Codexis (Redwood City, CA) in the form of crude extract 
and all chemicals used in this chapter are stated in Chapter 3.3.1. D-(+)-gluconic acid δ-lactone was obtained 
from Sigma Aldrich (Brøndby, Denmark). 
4.2.2 Activity Measurements 
The activity measurements for determining the initial reaction rates in this chapter were based on 
spectrophotometric methods following either consumption or production of the co-factor NADH at 340 nm at 
pH 7 and 30°C. The calculation from measured absorbance to NADH concentration was made via a previously 
prepared calibration curve containing known concentrations of NADH. All enzymes were pre-incubated at 30°C 
15 minutes prior to the experiments. The activity measurements were performed in a way that the 
concentration of the investigated component was varied over the desired range while concentrations of other 
components were fixed as shown by an example in Table 1. The final reaction medium was adjusted to pH 7 by 
addition of HCl or KOH solutions. The experiments were performed in disposable cuvettes. However, when 
acetophenone or (S)-α-methylbenzylamine were used 4 mL Quartz SUPRASIL® Precision cells were used. All 
experiments were done in triplicate. 
Table 13 An example of the experimental recipe with concentrations and volumes in the case of investigating the effect of 
lactate on the initial reaction rates of the LDH reaction 
lactate 
Components Concentrations [mmol L-1] 
lactictate 50 100 200 300 400 500 
pyruvate 0.5 0.5 0.5 0.5 0.5 0.5 
NADH 0.1 0.1 0.1 0.1 0.1 0.1 
LDH [g L-1] 0.01 0.01 0.01 0.01 0.01 0.01 
Volumes [μL] 
lactate 250 500 1000 1500 2000 2500 
pyruvate 500 500 500 500 500 500 
NADH 100 100 100 100 100 100 
enzyme 25 25 25 25 25 25 
water 4125 3875 3375 2875 2375 1875 
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4.2.3  Model Development 
LDH kinetic expression 
The model is comprised of kinetic and mass balance equations. The kinetic equation for the LDH enzyme was 
developed from the two substrate Michaelis-Menten expression described by Equation 4.3, and was expanded 
by adding competitive inhibition by pyruvate, NAD+, lactate and alanine observed from the results of initial 
reaction rate experiments. It was assumed that the reaction is irreversible due to the calculated Keq = 2.12∙104, 
and therefore no expression containing Keq was added. No observable loss in activity over a period of 24 h was 
observed in the experiments reported in Chapter 3, and therefore no stability expression was introduced in the 
equation. The final kinetic expression is given by Equation 4.7. 
 
𝑟𝐿𝐷𝐻 =
𝑉𝑚𝑎𝑥
𝐿𝐷𝐻𝑐𝑁𝐴𝐷𝐻𝑐𝑃𝑌𝑅𝛾𝐿𝐷𝐻
(𝐾𝑚𝑁𝐴𝐷𝐻 (1 +
𝑐𝑁𝐴𝐷+
𝐾𝑖
𝑁𝐴𝐷+
) + 𝑐𝑁𝐴𝐷𝐻) (𝐾𝑚𝑃𝑌𝑅 (1 +
𝑐𝐿𝐴𝐶
𝐾𝑖
𝐿𝐴𝐶 +
𝑐𝐴𝐿𝐴
𝐾𝑖,𝐿𝐷𝐻
𝐴𝐿𝐴 ) + 𝑐𝑃𝑌𝑅 +
𝑐𝑃𝑌𝑅
2
𝐾𝑖
𝑃𝑌𝑅)
 
4.7 
GDH kinetic expression 
The GDH reaction and its simplified sequential reactions can be presented by Figure 44: 
 
Figure 44 Simplified reaction scheme of GDH and its sequential hydrolysis reactions 
GDH, as well as LDH, follows ordered bi bi enzyme kinetics and a kinetic expression can be developed from the 
two substrate Michaelis-Menten equation expanded to include competitive inhibition by products and external 
components. The Keq for this reaction has been calculated (Keq=1.63∙1023) as relatively high, and taking into 
account that the equilibrium is even more facilitated by the sequential hydrolysis reaction, the assumption has 
been made that this reaction is irreversible. Stability experiments in Chapter 3 also showed no decrease in 
activity over 24 hours and the final kinetic expression is summarized in Equation 4.8. 
 
𝑟𝐺𝐷𝐻 =
𝑉𝑚𝑎𝑥
𝐺𝐷𝐻𝑐𝑁𝐴𝐷+  𝑐𝐺𝐿𝑈𝛾𝐺𝐷𝐻
(𝐾𝑚,𝐺𝐷𝐻
𝑁𝐴𝐷+ (1 +
𝑐𝑁𝐴𝐷𝐻
𝐾𝑖,𝐺𝐷𝐻
𝑁𝐴𝐷𝐻) + 𝑐𝑁𝐴𝐷+) (𝐾𝑚
𝐺𝐿𝑈 (1 +
𝑐𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶
𝐾𝑖
𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶 +
𝑐𝑀𝐵𝐴
𝐾𝑖,𝐺𝐷𝐻
𝑀𝐵𝐴 ) + 𝑐𝐺𝐿𝑈)
 
4.8 
The following reaction, the hydrolysis of glucono-1,5-lactone to gluconate, is described as pseudo-first order 
and it can be described by Equation 4.9. T The pseudo first-order rate constant as a function of pH is given by 
Equation 4.10 found in the literature158: 
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 𝑟𝐻𝑌𝐷_𝑓 = 𝑘𝐻𝑌𝐷_𝑓𝑐𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶  4.9 
 𝑘𝐻𝑌𝐷_𝑓 = {[𝐻
+] ∙ 4.7 ∙ 10−2 + [𝑂𝐻−] ∙ 4 ∙ 103 + 2.5 ∙ 10−4}𝑠−1 4.10 
Hydrolysis of glucono-1,5-lactone is a reversible reaction and the rate constant for the reverse reaction is a 
function of Keq_h = 5.04, found in the literature158 and the rate constant of hydrolysis as shown by Equation 
4.11: 
 𝑘𝐻𝑌𝐷_𝑟 =
𝑘𝐻𝑌𝐷_𝑓
𝐾𝑒𝑞_ℎ
 4.11 
Finally, the rate equation for reverse reaction can be summarized by Equation 4.12: 
 𝑟𝐻𝑌𝐷_𝑟 = 𝑘𝐻𝑌𝐷_𝑟𝑐𝐺𝐿𝑈𝐶  4.12 
FDH kinetic expression 
FDH kinetics, similar to GDH and LDH, follow an ordered bi bi mechanism. The reaction has been assumed to 
be irreversible due to the high calculated Keq=1.31∙1052, and due to the sequential reactions that follow 
CO2(aq)→CO2(g) and CO2(aq)+H2O→H2CO3. The stability of FDH has been determined by experiments in the 
previous chapter showing no decrease in activity over 24 h. The final kinetic expression is given by the Equation 
4.13. 
 
𝑟𝐹𝐷𝐻 =
𝑉𝑚𝑎𝑥
𝐹𝐷𝐻𝑐𝑁𝐴𝐷+  𝑐𝐴𝑀𝐹𝛾𝐹𝐷𝐻
(𝐾𝑚,𝐺𝐷𝐻
𝑁𝐴𝐷+ (1 +
𝑐𝑁𝐴𝐷𝐻
𝐾𝑖,𝐹𝐷𝐻
𝑁𝐴𝐷𝐻) + 𝑐𝑁𝐴𝐷+) (𝐾𝑚
𝐴𝑀𝐹 (1 +
𝑐𝐴𝐶𝑃
𝐾𝑖
𝐴𝐶𝑃) + 𝑐𝐴𝑀𝐹)
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ω-transaminase kinetic expression 
The ω-transaminase follows the ping pong bi bi kinetic mechanism and the equation defining the rate of 
reaction was taken from the literature72 and is shown in Equation 4.14. 
 
𝑟𝑇𝐴𝑚 =
𝑉𝑚𝑎𝑥,𝑓
𝑇𝐴𝑚 𝑉𝑚𝑎𝑥,𝑟
𝑇𝐴𝑚 (𝑐𝐴𝐿𝐴𝑐𝐴𝐶𝑃 −
𝑐𝑃𝑌𝑅𝑐𝑀𝐵𝐴
𝐾𝑒𝑞
) 𝛾𝑇𝐴𝑚
𝑉𝑚𝑎𝑥,𝑟𝑇𝐴𝑚 𝐾𝑚𝐴𝐶𝑃𝑐𝐴𝐿𝐴 + 𝑉𝑚𝑎𝑥,𝑟𝑇𝐴𝑚 𝐾𝑚𝐴𝐿𝐴𝑐𝐴𝐶𝑃 +
𝑉𝑚𝑎𝑥,𝑓
𝑇𝐴𝑚 𝐾𝑚𝑀𝐵𝐴
𝐾𝑒𝑞
𝑐𝑃𝑌𝑅 +
𝑉𝑚𝑎𝑥,𝑓
𝑇𝐴𝑚 𝐾𝑚𝑃𝑌𝑅
𝐾𝑒𝑞
𝑐𝑀𝐵𝐴 + ⋯
… + 𝑉𝑚𝑎𝑥,𝑟𝑇𝐴𝑚 𝑐𝐴𝐿𝐴𝑐𝐴𝐶𝑃 +
𝑉𝑚𝑎𝑥,𝑓
𝑇𝐴𝑚 𝐾𝑚𝑀𝐵𝐴
𝐾𝑖
𝐴𝐿𝐴𝐾𝑒𝑞
𝑐𝐴𝐿𝐴𝑐𝑃𝑌𝑅 +
𝑉𝑚𝑎𝑥,𝑓
𝑇𝐴𝑚
𝐾𝑒𝑞
𝑐𝑃𝑌𝑅𝑐𝑀𝐵𝐴 +
𝑉𝑚𝑎𝑥,𝑟𝑇𝐴𝑚 𝐾𝑚𝐴𝐿𝐴
𝐾𝑖
𝑀𝐵𝐴 𝑐𝐴𝐶𝑃𝑐𝑀𝐵𝐴
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Mass balance equations 
The ω-transaminase/LDH/GDH model is comprised of the following mass balance equations: 
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𝑑𝑐𝐴𝐿𝐴
𝑑𝑡
= −𝑟𝑇𝐴𝑚 4.15 
 
𝑑𝑐𝐴𝐶𝑃
𝑑𝑡
= −𝑟𝑇𝐴𝑚 4.16 
 
𝑑𝑐𝑃𝑌𝑅
𝑑𝑡
= 𝑟𝑇𝐴𝑚 − 𝑟𝐿𝐷𝐻 4.17 
 
𝑑𝑐𝑀𝐵𝐴
𝑑𝑡
= 𝑟𝑇𝐴𝑚 4.18 
 
𝑑𝑐𝑁𝐴𝐷𝐻
𝑑𝑡
= 𝑟𝐺𝐷𝐻 − 𝑟𝐿𝐷𝐻 4.19 
 
𝑑𝑐𝑁𝐴𝐷+
𝑑𝑡
= 𝑟𝐿𝐷𝐻 − 𝑟𝐺𝐷𝐻 4.20 
 
𝑑𝑐𝐿𝐴𝐶
𝑑𝑡
= 𝑟𝐿𝐷𝐻 4.21 
 
𝑑𝑐𝐺𝐿𝑈
𝑑𝑡
= −𝑟𝐺𝐷𝐻 4.22 
 
𝑑𝑐𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶
𝑑𝑡
= 𝑟𝐺𝐷𝐻 − 𝑟𝐻𝑌𝐷_𝑓 + 𝑟𝐻𝑌𝐷_𝑟 4.23 
 
𝑑𝑐𝐺𝐿𝑈𝐶
𝑑𝑡
= 𝑟𝐻𝑌𝐷_𝑓 − 𝑟𝐻𝑌𝐷_𝑟 4.24 
In the ω-transaminase/LDH/FDH model Equations 4.19, 4.20 and 4.22 are replaced by Equations 4.25, 4.26 and 
4.27 respectively. Furthermore, the product formation of FDH (CO2) is not considered by the kinetic model and 
Equation 4.23 and 4.24 are therefore excluded from the model. 
 
𝑑𝑐𝑁𝐴𝐷𝐻
𝑑𝑡
= 𝑟𝐹𝐷𝐻 − 𝑟𝐿𝐷𝐻 4.25 
 
𝑑𝑐𝑁𝐴𝐷+
𝑑𝑡
= 𝑟𝐿𝐷𝐻 − 𝑟𝐹𝐷𝐻 4.26 
 
𝑑𝑐𝐴𝑀𝐹
𝑑𝑡
= −𝑟𝐹𝐷𝐻 4.27 
 
4.2.4 Estimation of Kinetic Parameters 
4.2.4.1 Linear Regression 
The initial estimation of the kinetic parameters was done by plotting Hanes plots (Figure 45 A) of the 
experimental results (ccomponent/reaction rate vs. ccomponent) and for the estimation of the inhibition constant of 
pyruvate a Dixon plot (Figure 45 B) was used (ccomponent vs. 1/reaction rate). The fitting of experimental data was 
done by the least squares method in Excel. The linear regression plots with experimental data are shown in 
Appendix 4A, 4B and 4C.  
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Figure 45 A) Hanes plot for determining kinetic parameters; B) Dixon plot for determining substrate inhibition 
4.2.4.2 Nonlinear Regression 
The estimated kinetic parameters obtained by linear regression have been used as initial values for a nonlinear 
regression. A global fit of experimental data to expressions described by Equations 4.7, 4.8 and 4.13 has been 
made in the OriginPro software package which uses the Levenberg-Marquardt algorithm to adjust parameter 
values in an iterative model-fitting procedure. 
4.2.5 Calculating Required Improvement 
Kinetic models of ω-transaminase/LDH/GDH and ω-transaminase/LDH/FDH containing Equations 4.7 - 4.27 
have been simulated in Matlab®. Kinetic parameters of cascade enzyme models were estimated by nonlinear 
regression and kinetic parameters of ω-transaminase were taken from the literature71. However, Vmax_r was a 
derived parameter calculated by Equation 4.28 known as the Haldane relationship. The simulation of 
acetophenone feeding was designed to maintain 30 mmol L-1 fed concentration until 470 mmol L-1 has reacted 
away. Then the feeding stops and total acetophenone concentration added to the process is 500 mmol L-1The 
program was set to search for a Vmax_f,r value that will result in 95 % conversion for given concentrations of 
cascade enzymes where Vmax_f,r [mmol min-1 L-1] represents Vmax_f [mmol min-1 g-1] multiplied by the 
concentration of ω-transaminase [g L-1]. This procedure was repeated for desired range of concentrations of 
both cascade enzymes. An example of the program calculating Vmax_f,r as a function of cascade enzyme 
concentration, and representing the ω-transaminase/LDH/GDH model is given in Appendix 4D. 
 𝑉max _𝑟 =
𝑉max _𝑓
√𝐾𝑒𝑞
√
𝐾𝑚𝑃𝑌𝑅𝐾𝑚𝑀𝐵𝐴
𝐾𝑚𝐴𝐿𝐴𝐾𝑚𝐴𝐶𝑃
 4.28 
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4.3 Results and Discussion 
4.3.1 Estimation of kinetic parameters 
The initial rate experiments were performed as described in the section 4.2.2 where one investigated 
component was varied over a concentration range expected in an industrial process while concentrations of 
other components were fixed. In the industrial pharmaceutical processes buffers are usually not used and 
therefore the decision was made to adjust the pH by addition of acid or base. Furthermore, the pH change 
during the reaction is a function of the concentration of pH changing species, and in this particular case the 
limiting substrate (NADH or NAD+) was 0.1 mmol L-1. Therefore possible pH changes were disregarded as 
marginal. 
A first estimation of kinetic parameters was done by linear regression and the purpose of this step was to 
provide initial values of these parameters for later estimation by nonlinear regression which was performed in 
OriginPro as described in section 4.2.4.2. Results for kinetic parameters estimated by both methods are given 
in Table 14. 
Table 14 Kinetic parameters of LDH, GDH and FDH reaction estimated by linear and nonlinear regression 
Parameters Units Linear regression Nonlinear regression 
LDH 
𝑉𝑚𝑎𝑥
𝐿𝐷𝐻 [mmol min-1 g-1] 30.6908 39.0251 ± 1.5645 
𝐾𝑚
𝑁𝐴𝐷𝐻 [mmol L-1] 0.0386 0.0266 ± 0.0041 
𝐾𝑚
𝑃𝑌𝑅 [mmol L-1] 0.0203 0.0365 ± 0.0066 
𝐾𝑖
𝑃𝑌𝑅 [mmol L-1] 3.1649 2.8728 ± 0.3161 
𝐾𝑖
𝐿𝐴𝐶 [mmol L-1] 17.4114 5.1987 ± 0.9669 
𝐾𝑖
𝑁𝐴𝐷+ [mmol L-1] 1.4052 0.6288 ± 0.2470 
𝐾𝑖
𝐴𝐿𝐴 [mmol L-1] 233.3150 83.9268 ± 15.8071 
GDH 
𝑉𝑚𝑎𝑥
𝐺𝐷𝐻 [mmol min-1 g-1] 42.1053 53.4958 ± 1.9571 
𝐾𝑚,𝐺𝐷𝐻
𝑁𝐴𝐷+  [mmol L-1] 0.1380 0.1453 ± 0.0082 
𝐾𝑚
𝐺𝐿𝑈 [mmol L-1] 76.4760 75.7494 ± 9.4221 
𝐾𝑖
𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶
 [mmol L-1] 4.6691 32.2336 ±5.2846 
𝐾𝑖,𝐺𝐷𝐻
𝑀𝐵𝐴  [mmol L-1] 8.1615 13.9023 ± 1.7142 
𝐾𝑖,𝐺𝐷𝐻
𝑁𝐴𝐷𝐻 [mmol L-1] 0.0309 0.3443 ± 0.0350 
FDH 
𝑉𝑚𝑎𝑥
𝐹𝐷𝐻 [mmol min-1 g-1] 8.8106 15.5813 ± 0.9562 
𝐾𝑚
𝐴𝑀𝐹 [mmol L-1] 88.9427 78.6683 ± 7.1699 
𝐾𝑚,𝐹𝐷𝐻
𝑁𝐴𝐷+  [mmol L-1] 0.0671 0.0812 ± 0.0086 
𝐾𝑖,𝐹𝐷𝐻
𝑁𝐴𝐷𝐻 [mmol L-1] 0.9126 0.7795 ± 0.2223 
𝐾𝑖
𝐴𝐶𝑃 [mmol L-1] 50.2556 32.9580 ± 5.6376 
The kinetic parameters obtained by the nonlinear regression were reported together with the confidence 
intervals to indicate the reliability of the estimated values. For the LDH model, Vmax and Km values were 
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estimated accurately with very low confidence intervals meaning they can be trusted. However, the inhibition 
constants showed less reliability, especially Ki
ALA (83.9268 ± 15.8071 mmol L-1). Similar behavior in the reliability 
of estimated data can be noticed for GDH and FDH. 
The fitting of the estimated parameters obtained by nonlinear regression for the LDH, GDH and FDH kinetic 
expressions is shown in Figure 46, Figure 48 and Figure 50 respectively. 
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Figure 46 Investigation of the reduction of pyruvate catalyzed by LDH (30°C, pH 7 adjusted by HCl or KOH; γLDH = 0.01 g L-1, 
cpyruvate = 0.5 mmol L-1 and cNADH = 0.1 mmol L-1 if not varied). Initial reaction rates as a function of A) pyruvate, B) NADH, C) 
lactate, D) NAD+ E) glucose, F) gluconate, G) alanine, H) acetophenone, I) MBA, J) ammonium formate 
From Figure 46 A) it can be seen that LDH is highly inhibited by its substrate pyruvate, however this inhibition 
poses no challenge for the process. Experiments show that inhibition occurs from a substrate concentration 
cpyruvate = 0.2 mmol L-1 and upwards, but the model simulation shows that the maximum pyruvate 
concentrations during the reaction are equal to 37.71 μmol L-1 as shown in Figure 47. Therefore, the inhibition 
by substrate does not occur in practice. The conditions for this pyruvate concentration check have been 
selected to represent the highest accumulation of pyruvate for the process that still achieves 95 % conversion, 
meaning conditions for a low rate of pyruvate removal (γLDH = 9 g L-1, γGDH = 1 g L-1, cNADH = 0.1 mmol L-1) and 
a high rate of pyruvate production (Vmax_f,r = 597.94 mmol min-1 L-1). The model and its assumptions are 
described in section 4.3.2.  
 
Figure 47 The progress curve of pyruvate simulated by the ω-transaminase/LDH/GDH model in MatLab®; the kinetic 
parameters are shown in the Table 14 and initial concentrations are the same as in Section 3.3.2.1; Vmax_f,r = 597.94 mmol 
min-1 L-1, γLDH = 9 g L-1, γGDH = 1 g L-1, cNADH = 0.1 mmol L-1 
In the Figure 46 C) strong inhibition by the product lactate is observed meaning that the pyruvate removal will 
be more and more affected when approaching the end of reaction and inhibition by alanine shown in Figure 
46 G) shows that pyruvate removal will also be affected at the beginning of the reaction by high alanine 
concentrations. The inhibition by pyruvate, lactate and alanine can be explained by structural similarities of 
these molecules which vary only in the keto, hydroxyl and amino group on the α-carbon atom, respectively. 
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Figure 48 Investigation of the oxidation of glucose catalyzed by GDH (30°C, pH 7 adjusted by HCl or KOH; γGDH = 0.01 g L-1,  
cglucose = 300 mmol L-1 and cNAD+ = 0.1 mmol L-1 if not varied). Initial reaction rates as a function of A) glucose, B) NAD+,         
C) glucono-1,5-lactone, D) NADH E) alanine, F) pyruvate, G) lactate, H) acetophenone, I) MBA, J) gluconate 
The initial rate experiments showed no observable substrate inhibition of the oxidation of glucose by GDH and 
a slight inhibition by product NADH was observed. It has been found in the literature that the GDH reaction 
can also be inhibited by glucono-1,5-lactone127. To simplify the system the formation of glucono-1,4-lactone 
has been excluded from this research due to the literature report stating that it forms in very small 
concentrations 159. Based on the rates of the forward and backward hydrolysis of glucono-1,5-lactone, kinetic 
simulations showed that significant concentrations of glucono-1,5-lactone may accumulate in the system 
(Figure 49) and the decision was made to investigate the influence of this component on the reaction kinetics 
depicted by Figure 48 C). The inhibition by MBA was also observed as shown by Figure 48 I). 
 
Figure 49 Simulated progress curve of glucono-1,5-lactone with the ω-transaminase/LDH/GDH system: Vmax_f,r = 46.31 mmol 
min-1 L-1, γLDH = 12 g L-1, γGDH = 1 g L-1, cNADH = 0.1 mmol L-1; initial concentrations same as in the Figure 51 
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Figure 50 Investigation of oxidation of ammonium formate catalyzed by GDH (30°C, pH 7 adjusted by HCl or KOH; γFDH = 0.2 
g L-1, cammonium formate = 100 mmol L-1 and cNAD+ = 0.1 mmol L-1 if not varied). Initial reaction rates as a function of A) ammonium 
formate, B) NAD+, C) NADH, D) lactate E) pyruvate, F) alanine, G) acetophenone, H) MBA 
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The kinetic investigation of the oxidation of ammonium formate is shown in Figure 50 and a slight inhibition 
by the product NADH has been observed (Figure 50 C). A slight inhibition by acetophenone has been observed 
as well, as shown in Figure 50 G). Inhibition by NADH has been reported in many cases of kinetic investigation. 
However, the inhibition by acetophenone has never been published and structurally the closest occurrences of 
inhibition were reported in the literature for the o-nitrobenzaldehyde160 and diacetyl161. 
4.3.2 Transaminase of tomorrow 
The objective of this chapter is to develop kinetic models describing cascade enzymes and then to use the 
resulting model to assist the selection process. It is not only essential to estimate the feasibility and efficiency 
of the cascade enzymes applied to the currently developed ω-transaminase, but it is also important to evaluate 
the efficiency of cascade enzymes combined with the ‘transaminase of tomorrow’ – ω-transaminase developed 
to satisfy industrial requirements to produce 50 g L-1 of product. Currently, ω-transaminases are faced by 
several challenges described in Chapter 2, where product inhibition and activity are the most challenging 
bottlenecks. Even at the current activity of ω-transaminase and with the equilibrium shift provided by a cascade 
system, the reaction is usually challenged by product inhibition which in some cases occurs at concentrations 
as low as about 5 – 10 mmol L-1 of MBA. Such product inhibition requires an ISPR method to alleviate it. 
However, extremely low Keq also requires exclusive selectivity of this ISPR method towards the MBA. Such high 
selectivity ISPR method has not yet been described or tested. However another possibility for overcoming this 
challenge might be explored by developing new enzymes via protein engineering or discovering new enzymes 
from new host organisms. One such example was published by Park and Shin82 using ω-transaminase from 
Ochrobactrum anthropi which is devoid of both substrate and product inhibition for acetophenone 
concentrations up to 20 mmol L-1 and MBA concentration up to 500 mmol L-1, which covers the majority of the 
concentration ranges in an industrial process. Such ω-transaminase would then be faced by only two 
challenges: the thermodynamics of the system which can be facilitated by cascade systems and sufficient 
enzyme activity to ensure 50 g L-1 of product in e.g. 24 h assuming sufficient stability is achieved either via 
protein engineering or immobilization techniques. 
Inspired by these recent developments a ‘transaminase of tomorrow’ was envisioned to represent an enzyme 
suited for industrial conditions. The kinetic expression describing the reaction rate following the ping pong bi 
bi mechanism was taken from the literature (Equation 4.14). Taking into consideration the assumption that the 
Michaelis constants (Km) have not been improved by protein engineering from the current state of 
development, those parameters were taken from the work of Shin and Kim71. Based on the previously discussed 
example, inhibition constants were set to a high number (1000 mmol L-1) simulating no inhibition. Vmax_r was 
calculated by Equation 4.28 and kinetic parameters of the ‘transaminase of tomorrow’ are shown in Table 15. 
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Table 15 Kinetic parameters of the ’transaminase of tomorrow’ required by the kinetic expression described by Equation 4.14 
Parameter Value Unit 
𝐾𝑒𝑞 4.03∙10-5 [-] 
𝑉𝑚𝑎𝑥 _𝑓
𝑇𝐴𝑚  Calculated by Matlab program [mmol min-1 g-1] 
𝐾𝑚
𝐴𝐶𝑃 0.54 [mmol L-1] 
𝐾𝑚
𝐴𝐿𝐴 1.07 [mmol L-1] 
𝐾𝑚
𝑀𝐵𝐴 53.03 [mmol L-1] 
𝐾𝑚
𝑃𝑌𝑅 9.58 [mmol L-1] 
𝐾𝑖
𝐴𝐿𝐴 1000 [mmol L-1] 
𝐾𝑖
𝑀𝐵𝐴 1000 [mmol L-1] 
𝑉𝑚𝑎𝑥_𝑟
𝑇𝐴𝑚  Eq. 4.28 [mmol min-1 g-1] 
 
4.3.2.1 Required ω-transaminase Improvement 
To develop a valid industrial process one of the most important questions that has to be answered is: What is 
the activity of ω-transaminase required for the production of 50 g L-1 of optically pure amines? This required 
activity will depend on the required time period that is available to achieve the goal, e.g. 24 h, and on the 
kinetic parameters of the ω-transaminase itself. Furthermore, the required activity of ω-transaminase will 
depend on the kinetic parameters of the cascade enzymes as well as on the amount of added enzymes. Models 
for ω-transaminase/LDH/GDH and ω-transaminase/LDH/FDH have been developed using equations 4.7 - 4.27. 
It was attempted to simulate the process at conditions based on the reality. The acetophenone solubility in 
water (45.8 mmol L-1 at 25°C) is the limiting factor for the possible substrate concentrations. It has been also 
observed in the experiments that high concentrations of alanine (1 mol L-1) decrease the solubility of other 
components and that at cacetophenone = 40 mmol L-1 and calanine = 1 mol L-1 the maximum solubility of 
acetophenone was reached and a second phase was observed. Due to these observations a feeding strategy 
was assumed keeping the concentration of acetophenone constant at 30 mmol L-1. The amount of fed 
acetophenone was limited to the 500 mmol L-1, meaning that the feeding stopped when the total amount of 
acetophenone in the system reached this concentration (30 mmol L-1 dissolved in the reaction mixture and 470 
mmol L-1 expressed as produced MBA). When the concentration of the product MBA reached 470 mmol L-1 the 
feeding stopped. The feeding mechanism is described by the following reactions: 
 
 cMBA < 470 mmol L-1 cMBA ≥ 470 mmol L-1  
 
𝑑𝑐ACE
𝑑𝑡
= 0 Equation 4.16  
 
For the feeding of pure acetophenone the overall change of volume was ≈ 6 %, and therefore the volume 
change was neglected in the model simulation. The program described in section 4.2.5 has been developed to 
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calculate the required activity of ω-transaminase expressed as Vmax_f,r as a function of co-product removing 
enzyme concentration (LDH) and co-factor recycling enzyme concentration (GDH or FDH) for achieving 95 % 
conversion. The results of the simulations are shown in the Figure 51.
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Figure 51 Required Vmax_f,r of ω-transaminase for achieving 95 % conversion as a function of LDH/GDH and LDH/FDH 
concentrations based on initial concentrations: calanine = 1 mol L-1, cACP = 500 mmol L-1, (fed at 30 mmol L-1), cpyruvate = 0 mmol 
L-1, cMBA = 0 mmol L-1, cNAD+ = 0 mmol L-1, clactate = 0 mmol L-1, cglucose = 550 mmol L-1, cglucono-1,5-lactate = 0 mmol L-1, cgluconate 
= 0 mmol L-1,  cammonium formate = 550 mmol L-1 and A) cNADH = 0.1 mmol L-1 B) cNADH = 0.25 mmol L-1 C) cNADH =  0.5 mmol L-
1 
A 
B 
C 
Scenario 1 
Scenario 2 
Scenario 3 
ω-transaminase/LDH/GDH system ω-transaminase/LDH/FDH system 
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The above presented results show the required ω-transaminase improvement in Vmax_f,r [mmol min-1 L-1] as a 
function of the concentrations of added cascade enzymes. As seen from Figure 51 the investigated 
concentration ranges of cascade enzymes vary for LDH from 8.6 – 12 g L-1 and for GDH and FDH from 0.01 – 
0.5 g L-1. The Vmax_f,r value was investigated up to 100 mmol min-1 L-1 and this value has been as a reasonable 
limit for an enzyme development. It was also found that for a small further reduction in cascade enzyme 
concentrations Vmax_f,r values increased exponentially. 
The effect of all catalytically active components of a cascade system to the required ω-transaminase activity 
has to be explored to obtain complete information about system behavior. Therefore the influence of the co-
factor concentration was investigated. In the Figure 51 for both cascade options for the case A), B) and C) the 
co-factor concentration was increasing 0.1, 0.25 and 0.5 mmol L-1 respectively. It can be noticed that higher 
co-factor concentrations reduce required Vmax_f,r values for achieving 95 % conversion. 
To compare the effect of the concentration of the co-factor between the LDH/GDH and LDH/FDH system a 
scenarios have been chosen with fixed cascade enzyme concentrations, e.g. for LDH/GDH system LDH (γLDH = 
11 g L-1) and GDH (γGDH = 0.5 g L-1). For these enzyme concentrations and abovementioned co-factor 
concentrations (cNADH = 0.1, 0.25 and 0.5 mmol L-1) three scenarios were highlighted shown as Scenario 1, 2 
and 3 in the Figure 51. The same was done for the LDH/FDH system and the results as Vmax_f,r values at 
concentrations of LDH (γLDH = 11 g L-1) and GDH or FDH (γGDH = γFDH =0.5 g L-1) ac a function of co-factor 
concentration are plotted in the Figure 52. Comparing those to cascade systems indicates that the usage of 
FDH system requires less ω-transaminase improvement to achieve 95 % conversion at previously mentioned 
conditions. This difference is more expressed at lower co-factor concentrations and decreases at higher 
concentrations of the co-factor. 
  
Figure 52 Vmax_f,r as a function of added co-factor NADH at cascade enzyme concentrations for LDH/GDH system: γLDH = 11 
g L-1 and γGDH = 0.5 g L-1 and LDH/FDH system: γLDH = 11 g L-1 and γFDH = 0.5 g L-1
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4.3.3 Debottlenecking the Process 
Observing the results shown in Figure 51 it can be seen that acceptable enzyme improvement can be achieved 
at relatively low concentrations of GDH or FDH, i.e. 0.1 – 0.4 g L-1 depending on the enzyme used and the co-
factor concentrations. However, in both cases the concentration of LDH is considerably higher ranging from 9 
– 12 g L-1 which is a concentration that is more than one order of magnitude higher than for the co-factor 
recycling enzymes. This discrepancy in enzyme concentrations may hint towards the fact that the bottleneck 
of the process is the reaction catalyzed by LDH. Observing the kinetic behavior of LDH shown in Figure 46, 
inhibitions by pyruvate, lactate and alanine have been observed. It has been concluded in the previous 
discussion that inhibition by pyruvate does not occur under the investigated conditions, and therefore the 
inhibition by alanine and lactate must be responsible for the high concentrations of LDH required for achieving 
the industrial target. In order to observe the effects of those inhibition effects a slice from Figure 51 A) at γGDH 
= 0.5 g L-1 has been selected. The slice taken from Figure 51 is represented with the blue line showing the 
required Vmax_f,r at current inhibition levels of LDH. During the reaction lactate is accumulated in the reaction 
media and thus more and more inhibiting the removal of pyruvate when approaching the end of reaction. To 
overcome the increasing inhibition and achieve functional pyruvate removal, high LDH concentrations are 
required. When the inhibition by lactate was excluded from the model, a huge improvement in the reduced 
LDH concentration was observed (red line). Inhibition by alanine is not so severe and the effect on the rate of 
pyruvate removal is decreasing over time as the concentration of alanine is decreasing. When inhibition by 
alanine was removed from the model, a slight improvement (green line) was observed. The enzyme that would 
benefit from the lack of both inhibitions showed the largest improvement both in concentration of LDH and 
Vmax_f.r required for achieving the industrial target (purple line). 
 
Figure 53 Reducing the LDH concentration required for achieving the industrial target (50 g product L-1 in 24 h) by removing 
the inhibition by alanine and/or lactate; γGDH = 0.5 g L-1 and cNADH = 0.1 mmol L-1 
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4.4 Conclusions 
The goal of this chapter was to prove a set of tools to assist a cascade selection process via model development. 
By developing a model, a comparison can be made between viable cascade options for industrial 
implementation (LDH/GDH and LDH/FDH), e.g. based on the optimized concentrations of individual enzymes. 
The current state of ω-transaminase was not taken into consideration in model development due to the strong 
substrate and product inhibition, as well as the low activity. However, a ‘transaminase of tomorrow’ devoid of 
all inhibitions was envisioned as a possible industrially applicable enzyme. The required activity of the 
‘transaminase of tomorrow’, expressed as Vmax_f,r [mmol min-1 L-1] was calculated as a function of cascade 
enzyme concentrations, demonstrating how much of activity improvement is required to achieve 50 g L-1 of 
product within 24 h. Simulations have shown that the improved activity is a function of how well the cascade 
system removes the co-product pyruvate. This ability to remove pyruvate was evaluated here via three 
parameters: the concentration of pyruvate removing enzyme (LDH), the concentration of co-factor recycling 
enzyme (GDH or FDH) and the concentration of the co-factor. Significant improvements in reducing the LDH 
and GDH/FDH concentration required to achieve 95 % conversion in 24 h while having Vmax_f,r < 100 mmol  
min-1 L-1 were achieved by adding more co-factor. However, the final concentration of the co-factor will depend 
on the economic analysis considering the cost of co-factor vs. the cost of ω-transaminase improvement and 
the cost of the cascade enzymes. 
Another outcome of the model development was that the model allowed identifying current bottlenecks of 
the process, which in this case were the unreasonably high LDH concentrations required for the conditions 
corresponding to an industrial process. Further investigation revealed that inhibition caused by alanine and 
lactate requires high concentrations of LDH for the establishment of a successful process. Alleviating those 
inhibitions resulted in a huge decrease in LDH concentrations required for an industrial process. An important 
conclusion that can be drawn from investigating the model simulation results is that cascade enzymes must 
be devoid of inhibitions mainly caused by cascade products. As the reaction progresses, the accumulation of 
cascade products will reduce the activity and as a consequence significant amounts of that enzyme will be 
required to achieve the desired product concentrations. Therefore, the ‘cascade enzymes of tomorrow’ must 
also be devoid of all inhibitions, especially by cascade products or other components whose concentration 
builds up over the duration of the process. 
Based on the calculated GDH and FDH concentration required for successful industrial implementation the 
results vary at low and high co-factor concentrations. At low NADH concentrations the results clearly favor FDH 
as a choice of co-factor recycling. At higher NADH concentrations the differences between GDH and FDH 
concentrations are becoming smaller. However, taking into account the high price of the co-factor and the 
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cost of ω-transaminase improvement, the process optimization will favor processes aiming towards lower co-
factor concentrations where FDH shows significant benefits over GDH. As described in the previous paragraph, 
this result can be partially explained by inhibition of GDH caused by glucono-1,5-lactone and also by MBA 
(accumulating component) while FDH is devoid of such inhibitions. Due to the lower requirements for ω-
transaminase improvement in the presence of lower concentrations of NADH, the LDH/FDH system has been 
chosen as a best candidate for a potential industrial implementation. 
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5 Industrial Perspectives and Process Strategies for 
Implementation of ω-transaminase/LDH/FDH 
System 
5.1 Introduction 
Developing an industrial process is a complex and challenging procedure involving many features defined by 
many non-technical aspects, e.g. market, supply chain, safety, patents and regulatory aspects to name a few. 
The resulting overall process has to satisfy also economic, environmental and social impacts162. In the case of 
production of optically pure amines by ω-transaminase, this enzymatic process is usually not a standalone 
process but rather one step in the synthesis of valuable pharmaceutical products. This means that the ω-
transaminase process has to be integrated into an existing or a new synthesis route as shown in Figure 54. 
 
Figure 54 the integration of the ω-transaminase process in the overall synthesis route for API production 
Process System Engineering (PSE) tools and methods will play a core role in the development of an industrial 
process for production of optically pure amines by ω-transaminase, where the resulting solution for each 
process is strongly case dependent. Several major influences will dominate the process design and will have to 
be continuously reevaluated. As shown in Figure 55 the framework for process design of this particular process 
is focused on several important considerations. Physical and chemical properties of chemicals will e.g. 
determine feeding strategies for low soluble substrates or determine the type of DSP. The thermodynamic 
calculation will indicate the applicability of different equilibrium shifting strategies; however the viability 
implementation strategies have to be tackled via process design. To ensure optimal conditions for successful 
biocatalytic conversions, e.g. optimal temperature, pH, substrate and product concentrations a Process 
Analytical Technology (PAT) strategy, including suitable control and monitoring tools, will have to be applied. 
Finally, the biocatalyst performance will affect the potential biocatalyst formulation options, and therefore the 
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route
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process implementation. Process intensification via e.g. ISPR may also reduce the required biocatalyst 
performance, which is important to take into account during process design. 
    
Figure 55 Considerations for development of an industrial process for production of optically pure amines, specifically for 
thermodynamically challenged cases utilizing cascade systems 
There are several processes for production of optically pure chiral amines via ω-transaminases mentioned in 
the literature, and one of the most cited ones is the example of successful Sitagliptin production by Savile et 
al.68. However processes severely challenged by unfavorable equilibrium are not at all mentioned in the 
literature, and the same goes for processes utilizing cascade systems to overcome those challenges. It is 
therefore the objective of this chapter to discuss possible process solutions for such thermodynamically 
challenged processes. The potential process setup options are compared and a selection is made based on 
previous work, literature suggestions and in some cases supported by simulation of the previously developed 
models (Section 4.2.3).
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5.2 Materials and Methods 
5.2.1 Two Pot Strategy 
A kinetic model described in section 4.2.3 was implemented, and mass balance equations were modified to 
describe a two pot system. Each individual reactor was considered as a constant volume CSTR connected in a 
loop as shown in Figure 56 and mass balance equations of all components were established for both reactors. 
A general mass balance equation for component A in a reactor can be expressed by Equations 5.1 and 5.2: 
 
𝑑𝑛𝐴
𝑑𝑡
= 𝐹𝑖𝑛𝑙𝑒𝑡𝑐𝐴,𝑖𝑛𝑙𝑒𝑡 − 𝐹𝑜𝑢𝑡𝑙𝑒𝑡𝑐𝐴,𝑜𝑢𝑡𝑙𝑒𝑡 + 𝑟𝐴𝑉 5.1 
 𝑑𝑐𝐴
𝑑𝑡
=
𝑐𝐴,𝑖𝑛𝑙𝑒𝑡
𝜏
−
𝑐𝐴,𝑜𝑢𝑡𝑙𝑒𝑡
𝜏
+ 𝑟𝐴 
5.2 
The volume ratio was defined as shown in Equation 5.3 where V1 is the working volume of the ω-transaminase 
reactor, and V2 is the working volume of the external cascade reactor. V1 is fixed at 1 dm3 while Vr is varied over 
the investigated range. 
 𝑉𝑟 =
𝑉1
𝑉2
 5.3 
Mass balance equations used in the model are shown below: 
 ω-transaminase reactor External cascade reactor  
 𝜏1 =
𝑉1
𝐹
 𝜏2 =
𝑉2
𝐹
 5.4 
 
𝑑𝐶𝐴𝐿𝐴,1
𝑑𝑡
=
𝑐𝐴𝐿𝐴,2
𝜏1
−
𝑐𝐴𝐿𝐴,1
𝜏1
− 𝑟𝑇𝐴𝑚 
𝑑𝐶𝐴𝐿𝐴,2
𝑑𝑡
=
𝑐𝐴𝐿𝐴,1
𝜏2
−
𝑐𝐴𝐿𝐴,2
𝜏2
 5.5 
 
𝑑𝑐𝐴𝐶𝑃,1
𝑑𝑡
=
𝑐𝐴𝐶𝑃,2
𝜏1
−
𝑐𝐴𝐶𝑃,1
𝜏1
 
𝑑𝑐𝐴𝐶𝑃,1
𝑑𝑡
=
𝑐𝐴𝐶𝑃,2
𝜏1
−
𝑐𝐴𝐶𝑃,1
𝜏1
− 𝑟𝑇𝐴𝑚 
1 
 
2 
𝑑𝑐𝐴𝐶𝑃,2
𝑑𝑡
=
𝑐𝐴𝐶𝑃,1
𝜏2
−
𝑐𝐴𝐶𝑃,2
𝜏2
 5.6 
 
𝑑𝑐𝑃𝑌𝑅,1
𝑑𝑡
=
𝑐𝑃𝑌𝑅,2
𝜏1
−
𝑐𝑃𝑌𝑅,1
𝜏1
+ 𝑟𝑇𝐴𝑚 
𝑑𝑐𝑃𝑌𝑅,2
𝑑𝑡
=
𝑐𝑃𝑌𝑅,1
𝜏2
−
𝑐𝑃𝑌𝑅,2
𝜏2
− 𝑟𝐿𝐷𝐻 5.7 
 
𝑑𝑐𝑀𝐵𝐴,1
𝑑𝑡
=
𝑐𝑀𝐵𝐴,2
𝜏1
−
𝑐𝑀𝐵𝐴,1
𝜏1
+ 𝑟𝑇𝐴𝑚 
𝑑𝑐𝑀𝐵𝐴,2
𝑑𝑡
=
𝑐𝑀𝐵𝐴,1
𝜏2
−
𝑐𝑀𝐵𝐴,2
𝜏2
 5.8 
 
𝑑𝑐𝑁𝐴𝐷𝐻,1
𝑑𝑡
=
𝑐𝑁𝐴𝐷𝐻,2
𝜏1
−
𝑐𝑁𝐴𝐷𝐻,1
𝜏1
 
𝑑𝑐𝑁𝐴𝐷𝐻,2
𝑑𝑡
=
𝑐𝑁𝐴𝐷𝐻,1
𝜏2
−
𝑐𝑁𝐴𝐷𝐻,2
𝜏2
− 𝑟𝐿𝐷𝐻 + 𝑟𝐹𝐷𝐻 5.9 
 
𝑑𝑐𝑁𝐴𝐷+,1
𝑑𝑡
=
𝑐𝑁𝐴𝐷+,2
𝜏1
−
𝑐𝑁𝐴𝐷+,1
𝜏1
 
𝑑𝑐𝑁𝐴𝐷+,2
𝑑𝑡
=
𝑐𝑁𝐴𝐷+,1
𝜏2
−
𝑐𝑁𝐴𝐷+,2
𝜏2
+ 𝑟𝐿𝐷𝐻 − 𝑟𝐹𝐷𝐻 5.10 
 
𝑑𝑐𝐿𝐴𝐶,1
𝑑𝑡
=
𝑐𝐿𝐴𝐶,2
𝜏1
−
𝑐𝐿𝐴𝐶,1
𝜏1
 
𝑑𝑐𝐿𝐴𝐶,2
𝑑𝑡
=
𝑐𝐿𝐴𝐶,1
𝜏2
−
𝑐𝐿𝐴𝐶,2
𝜏2
+ 𝑟𝐿𝐷𝐻 5.11 
 
𝑑𝑐𝐴𝑀𝐹,1
𝑑𝑡
=
𝑐𝐴𝑀𝐹,2
𝜏1
−
𝑐𝐴𝑀𝐹,1
𝜏1
 
𝑑𝑐𝐴𝑀𝐹,2
𝑑𝑡
=
𝑐𝐴𝑀𝐹,1
𝜏2
−
𝑐𝐴𝑀𝐹,2
𝜏2
− 𝑟𝐹𝐷𝐻 5.12 
1 for cMBA,1 < 470 mmol L-1 
2 for cMBA,1 ≥ 470 mmol L-1 
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Reaction rates rLDH, rFDH and rTam are described by Equations 4.7, 4.13 and 4.14 respectively. The model assumes 
perfect mixing of both reactors, acetophenone feeding strategy described in Section 4.2.5 and the length of 
the connecting pipes is not taken into consideration. Initial concentrations were set: cACP = 30 mmol L-1, calanine 
= 1 mol L-1, cpyruvate = 0 mmol L-1, cMBA = 0 mmol L-1, clactate = 0 mmol L-1, cNADH = 0.1 mmol L-1, cNAD+ = 0 mmol 
L-1, cammonium formate = 550 mmol L-1. Enzyme concentrations were set to achieve 95 % conversion for the above-
mentioned conditions: Vmax_f,r = 55.33 mmol min-1 L-1, γLDH = 11 g L-1 and γFDH = 0.3 g L-1. 
5.2.2 Stability of the Co-factor 
Stability of the co-factor NADH has been investigated under conditions mentioned as reaction mixture 1 
described in the section 3.3.3.1 and for 100 mmol L-1 concentrations of pH 7 buffers (phosphate buffer, Tris, 
Hepes and wide range buffer163) while the initial NADH concentration was 0.5 mmol L-1. The experiment was 
performed at pH 7 and 30°C by following the adsorption of NADH at 340 nm in 4 mL Quartz SUPRASIL® 
Precision cells in a Shimadzu UV-1801 Spectrophotometer. The experiments were done in triplicate. The 
obtained values were fitted to the second-order decay kinetics described by Equation 5.13 with the OriginPro 
program which uses the Levenberg-Marquardt algorithm to adjust parameter values in the iterative parameter 
estimation / curve fitting procedure. 
 𝑐𝑡 =
𝑐0
1 + 𝑐0𝑘𝑑𝑡
 5.13 
ct – concentration at time t; c0 – initial concentration; kd – deactivation coefficient; t – time 
5.2.3 Downstream Processing 
The charge analysis was performed and plotted in the Excel CurTiPot program (pKa database and distribution 
diagram generation). 
The model developed in section 5.2.1 was modified to simulate the external ISPR unit. All kinetic expressions 
were previously developed and explained in the section 4.2.3 and the mass balances were modified in such a 
way that all enzymes and co-factors are present in UFMR (UltraFiltration Membrane Reactor) where all 
biocatalytic reactions take place. The external ISPR unit is modelled in such a way that 50 % of the inlet MBA 
concentration is removed and the corresponding mass balance equation 5.2 becomes now: 
 𝑑𝑐𝑀𝐵𝐴
𝑑𝑡
=
𝑐𝑀𝐵𝐴,𝑖𝑛𝑙𝑒𝑡
𝜏
−
𝑐𝑀𝐵𝐴,𝑜𝑢𝑡𝑙𝑒𝑡
𝜏
− 0.5
𝑐𝑀𝐵𝐴,𝑖𝑛𝑙𝑒𝑡
𝜏
= 0.5
𝑐𝑀𝐵𝐴,𝑖𝑛𝑙𝑒𝑡
𝜏
−
𝑐𝑀𝐵𝐴,𝑜𝑢𝑡𝑙𝑒𝑡
𝜏
 
5.14 
Mass balance equations for the model are shown below: 
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 UFMR External ISPR unit  
 𝜏1 =
𝑉1
𝐹
 𝜏2 =
𝑉2
𝐹
 5.15 
 
𝑑𝐶𝐴𝐿𝐴,1
𝑑𝑡
=
𝑐𝐴𝐿𝐴,2
𝜏1
−
𝑐𝐴𝐿𝐴,1
𝜏1
− 𝑟𝑇𝐴𝑚 
𝑑𝐶𝐴𝐿𝐴,2
𝑑𝑡
=
𝑐𝐴𝐿𝐴,1
𝜏2
−
𝑐𝐴𝐿𝐴,2
𝜏2
 5.16 
 
𝑑𝑐𝐴𝐶𝑃,1
𝑑𝑡
=
𝑐𝐴𝐶𝑃,2
𝜏1
−
𝑐𝐴𝐶𝑃,1
𝜏1
 
𝑑𝑐𝐴𝐶𝑃,1
𝑑𝑡
=
𝑐𝐴𝐶𝑃,2
𝜏1
−
𝑐𝐴𝐶𝑃,1
𝜏1
− 𝑟𝑇𝐴𝑚 
1 
2 
𝑑𝑐𝐴𝐶𝑃,2
𝑑𝑡
=
𝑐𝐴𝐶𝑃,1
𝜏2
−
𝑐𝐴𝐶𝑃,2
𝜏2
 5.17 
 
𝑑𝑐𝑃𝑌𝑅,1
𝑑𝑡
=
𝑐𝑃𝑌𝑅,2
𝜏1
−
𝑐𝑃𝑌𝑅,1
𝜏1
+ 𝑟𝑇𝐴𝑚 − 𝑟𝐿𝐷𝐻 
𝑑𝑐𝑃𝑌𝑅,2
𝑑𝑡
=
𝑐𝑃𝑌𝑅,1
𝜏2
−
𝑐𝑃𝑌𝑅,2
𝜏2
 5.18 
 
𝑑𝑐𝑀𝐵𝐴,1
𝑑𝑡
=
𝑐𝑀𝐵𝐴,2
𝜏1
−
𝑐𝑀𝐵𝐴,1
𝜏1
+ 𝑟𝑇𝐴𝑚 
𝑑𝑐𝑀𝐵𝐴,2
𝑑𝑡
= 0.5
𝑐𝑀𝐵𝐴,1
𝜏2
−
𝑐𝑀𝐵𝐴,2
𝜏2
 5.19 
 
𝑑𝑐𝑁𝐴𝐷𝐻,1
𝑑𝑡
= −𝑟𝐿𝐷𝐻 + 𝑟𝐹𝐷𝐻 Not present in ISPR unit 5.20 
 
𝑑𝑐𝑁𝐴𝐷+,1
𝑑𝑡
= 𝑟𝐿𝐷𝐻 − 𝑟𝐹𝐷𝐻 Not present in ISPR unit 5.21 
 
𝑑𝑐𝐿𝐴𝐶,1
𝑑𝑡
=
𝑐𝐿𝐴𝐶,2
𝜏1
−
𝑐𝐿𝐴𝐶,1
𝜏1
+ 𝑟𝐿𝐷𝐻 
𝑑𝑐𝐿𝐴𝐶,2
𝑑𝑡
=
𝑐𝐿𝐴𝐶,1
𝜏2
−
𝑐𝐿𝐴𝐶,2
𝜏2
 5.22 
 
𝑑𝑐𝐴𝑀𝐹,1
𝑑𝑡
=
𝑐𝐴𝑀𝐹,2
𝜏1
−
𝑐𝐴𝑀𝐹,1
𝜏1
− 𝑟𝐹𝐷𝐻 
𝑑𝑐𝐴𝑀𝐹,2
𝑑𝑡
=
𝑐𝐴𝑀𝐹,1
𝜏2
−
𝑐𝐴𝑀𝐹,2
𝜏2
 5.23 
1 for cMBA,1 < 470 mmol L-1 
2 for cMBA,1 ≥ 470 mmol L-1 
Initial concentrations of components are the same as in the section 5.2.1, as well as the enzyme concentrations. 
The volume of the reactor was 1 L and the volume of the ISPR unit was 0.2 L while the flow was 0.1 L min-1. 
Vmax_f,r was in the range 15 – 55 mmol min-1 L-1 and for each value the corresponding KiMBA was determined 
such that the conversion reached 95 %. Perfect mixing was assumed in the UFMR and the length of connecting 
pipes was disregarded. 
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5.3 Results and Discussion 
5.3.1 Type of Process: Batch or Continuous? 
Indeed, one of the most important decisions while designing a process is to decide whether the process should 
be run in batch or continuous mode. The use of decision making tools for this particular problem has been 
described in the literature; however the authors of that study focused on lab scale processes 164. For an 
industrial scale case, a more detailed approach is required including reuse of all possible process streams, e.g. 
recycling of nonconverted substrate, recycling of possible solvents, heat integration, monitoring, control and 
automation and complete economic and environmental assessment. 
Traditionally, the use of batch and fed-batch processes in the pharmaceutical industry has been predominant 
despite the higher costs165. However, a continuous mode of operation has been emerging within the 
pharmaceutical industry as a new field with benefits including a significant reduction in cost, energy 
consumption, use of solvents and leading to the production of purer products to name a few165, 166. Taking into 
consideration recent trends and developments in continuous processing using e.g. microreactors167, 168, 
microseparators169, 170 and continuous product formulation165, 171, 172 the change of established batch processes 
into continuous processes is slowly reshaping the pharmaceutical industry. However, switching from batch to 
continuous mode of operation is not applicable to all pharmaceutical processes. This decision will largely 
depend on the implementation of continuous processing throughout the stages of drug production as well as 
supply and demand of the final product. 
For the investigated case of production of MBA using the ω-transaminase/LDH/FDH system the choice of batch 
or continuous favors the batch, and more precisely the fed batch mode of operation. This choice is mainly 
justified by the fact that his type of reactions is still a 1st generation process, meaning that the industrial 
implementation has not been established, and transaminases are still under development. As the ω-
transaminase with required activity has not been engineered yet (see section 4.3.20), developing a processes 
might require an even longer reaction time than previously assumed (24 h) making a batch process an excellent 
choice due to its suitability for slowprocesses173. 
Temperature and pH monitoring and control are both required for this process. A suitable pH regulation can 
be achieved with a reliable pH meter and the addition of acid or base while a temperature regulation can be 
achieved via a standard thermostat. In both cases efficient mixing is required to avoid temperature and pH 
gradients. Due to the low solubility of the substrate acetophenone (45.8 mmol L-1 at 25°C) a suitable feeding 
strategy must be devised, and therefore the fed batch mode is considered as a viable option. In this work 
simulations were performed assuming the continuous presence of an acetophenone concentration of 30 mmol 
91 
 
L-1, meaning that the acetophenone dosing compensated for consumption by the reaction. The use of analytical 
methods for acetophenone detection is unfortunately limited to at-line HPLC. Taking into consideration the 
residence time of the HPLC method, this type of process monitoring and regulation might have a slow 
response. Another option are model-driven soft sensors which are based on mass balances, however they have 
to be developed specifically for a given case and often result in a long development period 174. However, the 
effort and time required to develop a suitable soft sensor might be acceptable, especially when considering 
how long time the overall ω-transaminase/LDH/FDH process development will take. 
5.3.2 One Pot vs. Two Pot Process 
One of the challenges facing the multi-enzyme processes can be the different operational stability of individual 
enzymes. In the particular case of the production of optically pure amines by ω-transaminases where the 
reaction is thermodynamically challenged and equilibrium shift is achieved by cascade enzymes, it could be a 
favorable operating strategy to separate, e.g. via two-pot process, enzymes with different stabilities. In this 
case it is possible to selectively remove unstable enzyme (e.g. ω-transaminases) from the stable enzymes 
(cascade enzymes). Applying this operating strategy could result in prolonging the reusability of stable 
enzymes while more unstable enzymes are replaced after the activity has dropped. One such example is 
external co-product removal shown in the Figure 56 B) while Figure 56 A) shows a one pot system.  
 
 
Figure 56 Process design options for a reactor: A) one pot system, B) external co-product removal; (○) – ω-transaminase,         
(□) – LDH, (Δ) – FDH 
A model representing two pot system was developed as described in section 5.2.1. The kinetic model is 
developed for the enzyme in the soluble formulation, and thus the system represented in the Figure 56 B) is 
envisioned as two UFMRs with perfect mixing while the biocatalyst loading of the ω-transaminase was 
A B 
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expressed as Vmax_f,r = 55.33 mmol min-1 L-1, and the LDH and FDH loading was 11 and 0.3 g L-1 respectively, 
representing conditions under which the yield of 95 % is achieved in 24 h in a one pot system. 
For a fixed V1 volume of 1 L the yield was calculated as a function of the volume ratio range, where the latter 
was allowed to vary from 0.2 to 5, and considering a flow rate range from 0.5 to 10 L min-1 as depicted in Figure 
57. 
 
Figure 57 Simulated yield of the ω-transaminase/LDH/FDH system in the two pot process as a function of volume ratio and 
flow rate; simulation conditions are stated in section 5.2.1  
Simulated results showed that an external co-product removal significantly reduces the yield, and it is not a 
viable option for the operation of the investigated ω-transaminase/LDH/FDH case. As shown in Figure 57 the 
yield is a function of the volume ratio up until value of approximately 3 and a further increase of the volume 
ratio does not influence the yield significantly. This can be explained by the fact that at higher volume ratios 
the external cascade reactor will have a larger volume and a higher residence time which will result in a more 
efficient pyruvate removal. Another investigated operating variable is the recycle flow rate of the system. At 
lower flow rates the pyruvate buildup in the ω-transaminase reactor will cause the reaction to slow down due 
to the highly unfavorable Keq. For present initial conditions (cacetophenone = 30 mmol L-1 and calanine = 1 mol L-1) 
the reaction can proceed at best to an equilibrium value of cMBA = 1.08 mmol L-1 without pyruvate removal. 
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Reducing the residence time by increasing the recycle flow rate the buildup of pyruvate in the ω-transaminase 
reactor is decreased and the yield that can be achieved is improved. One should indeed remember that a very 
high recycle flow rate yields a two pot system that will have a behavior that is close the behavior of the one 
pot system. However, those flow rates are impractical in reality and simulations have been performed for 
recycle flow rates up to 10 L min-1 which represents a flow rate corresponding to 10 working volumes of the 
ω-transaminase reactor that are exchanged per minute. 
Based on these simulations, it is concluded that the external co-product removal for thermodynamically 
challenged reactions is undesirable. To prevent slowing down the reaction rate due to the thermodynamic 
challenge, in-situ co-product removal (ISCPR) is absolutely necessary for successful industrial implementation. 
However, the two pot system may be considered for other cases, e.g. systems which are much more 
thermodynamically favorable, in which case ISCPR can be used for both shifting the thermodynamic equilibrium 
and alleviating possible co-product inhibition. 
5.3.3 Biocatalyst Formulation 
Biocatalyst formulation plays an important role in the process development and for the case of production of 
(S)-α-methylbenzylamine different possibilities of formulation of three biocatalysts and one co-factor are 
discussed in the following sections. 
5.3.3.1 Soluble Enzymes vs Immobilized Enzymes 
In recent years, the impact of protein engineering has played a significant role in achieving significantly 
increased enzyme yields while further reducing enzyme production cost and increasing performance via 
improved stability and productivity162. To enable reuse and stabilization of enzymes immobilization techniques 
are often introduced. However, there are still industries where soluble enzymes are dominant, e.g. detergents, 
food manufacturing, biofuel production from starch and synthesis of chiral compounds e.g. Sitagliptin. The 
reason for using soluble enzymes in some of the above mentioned cases is that achieving a high efficiency of 
hydrolysis processes for high molecular weight, or insoluble, or adsorbed substrates is only possible with 
soluble enzymes. In the case of production of Sitagliptin a novel ω-transaminase has been tailored for the 
process conditions where among other improvements a significant effort has been placed in increasing the 
activity, and eventual immobilization would probably not bring further improvements. The general advantages 
and disadvantages of application of soluble and immobilized enzymes are shown in Table 16 and the main 
principles of enzyme immobilization are summarized in the Figure 58. 
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Table 16 Advantages and disadvantages of application of soluble and immobilized enzymes, adopted from Buchholz et. al.162 
Advantages of soluble 
enzymes 
Disadvantages of 
soluble enzymes 
Advantages of 
immobilized enzymes 
Disadvantages of 
immobilized enzymes 
Low enzyme price High enzyme price High enzyme price 
requires immobilization 
High cost of 
immobilization 
Singular application Limited productivity Continuous processes, 
high productivity 
 
Low amounts (analytical, 
therapeutic application) 
   
Efficiency with insoluble, or 
adsorbed, or high molecular 
weight substrates)a 
 Fewer by-productsb More by-productsc 
Complex systems with coupled 
reaction path 
  Low efficiency with 
complex systems 
Co-factor dependent reactions 
easy to implement 
  No co-factor retention 
Application of membrane 
reactor systems (retention or 
recycling of enzymes) 
 Easy reuse  
a – enzyme remains in the product 
b – example: less trisaccharides due to decreasing lactose gradient in the carrier in lactose hydrolysis 
c – example: more reversion products due to increasing product gradient in the carrier with amyloglucosidase (dextrin hydrolysis) 
 
The overview given in the Table 16 may hint towards a favorable enzyme formulation for both the ω-
transaminase and the cascade system. As mentioned before, the ω-transaminase processes are still 1st 
generation processes and are not widely established as industrial processes. Still, much effort is put into 
developing transaminases with sufficient activity, and immobilization techniques usually do not contribute to 
the desired enzyme productivity. Therefore, to exploit the ω-transaminase activity optimally, a soluble form of 
the enzyme is preferred. The implementation of such processes requires an UFMR (UlraFiltration Enzyme 
Membrane Reactor) whose advantages and drawbacks are given in Table 17. 
 
 
 
95 
 
Table 17 Advantages and drawbacks of UFMR adopted from 175  
Advantages Drawbacks 
Continuous mode (substrate feeding) 
Decrease of enzyme activity (loss of catalyst, shear 
stress…) 
Free enzyme Membrane fouling 
Retention and reuse of catalyst Pressure drop 
Reduction of substrate/product inhibition  
Enzyme free product  
Control of product properties by enzyme and/or 
membrane choice 
 
Integrated process (single step reaction/enzyme 
separation) 
 
Another issue that needs to be discussed is the formulation of the cascade system. The previously mentioned 
conclusions in section 5.3.2 defined a one pot system as the only viable mode of operation, and therefore the 
formulation of the cascade system has to be compatible with the ω-transaminase formulation. The options for 
cascade immobilization are presented in Figure 58. 
 
Figure 58 Main principles of enzyme immobilization, adopted from Buchholz et. al.162 
The use of CLEAs and binding to the carrier as an immobilization method could cause the soluble ω-
transaminase to adsorb to the carrier surface which would result in decreased transaminase activity. Previous 
attempts of covalently binding the co-factor and co-immobilizing two dehydrogenases has indeed proved to 
increase reusability and stability of the system176-178. However the mobility was severely hindered as well, 
resulting in reduced activity. The main objective of the cascade system in the production of optically pure 
amines via ω-transaminase is the fast and in-situ removal of the co-factor, and therefore the reduced activity 
of the immobilized form as well as the possible formation of concentration gradients make immobilized carriers 
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an impractical choice. The inclusion of the cascade in soluble form in separate compartments is not practical 
as a consequence of the earlier conclusion that one pot is the necessary mode of operation. The inclusion into 
carrier (microorganisms) could prove to be a viable option if all three enzymes (ω-transaminase, LDH and FDH) 
are co-expressed to avoid mass transfer limitations through the cell wall. However, due to the relatively low 
activity of the still developing ω-transaminase, the process would be limited by cell loading within the reactor 
and the amount of possible protein expression within the cell, while risking the formation of inclusion bodies 
at higher protein expressions179. The literature suggest that the method of choice for co-factor dependent two 
or multi-enzyme systems is the application of membrane reactors which retain or recycle all catalytically active 
components162. To retain the co-factor within the membrane usually immobilization on to polymers is used, 
e.g. PEG with sufficiently high molecular weight180-182. 
5.3.3.2 Co-factor stability 
When utilizing dehydrogenase cascades for shifting the equilibrium, the stability of the co-factor NADH is in 
most cases not discussed or neglected. However, it has been found that the co-factor NAD(P)H is very unstable 
in in-vitro conditions117 and its stability under working conditions has to be investigated. Experiments showed 
that the kinetics of degradation vary with changing the pH environment, and that in pH regulated media, e.g. 
buffers, the degradation follows first-order kinetics (Equation 2.1). In media without pH regulation, e.g. water 
or reaction mixture 1 (see section 3.3.3.1), degradation followed second order kinetics (Equation 5.13). The 
stability of the co-factor in different buffers is shown in the Appendix 5A, and the stability in the reaction 
mixture 1 is shown in Figure 59. 
 
Figure 59 Stability of NADH in the reaction mixture 1 (see section 3.3.3.1) at 30°C and starting pH 7; t1/2 = 2 h 28 min 
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It is clear that the above shown poor stability of the co-factor represents a major challenge for successful 
industrial implementation. One way to tackle this challenge is the use of nicotinamide analogues which has 
recently resurfaced as a very interesting topic in biocatalytic redox chemistry. A recent extensive overview of 
the use of synthetic co-factors by Paul et. al.183 demonstrated a versatile role of co-factor analogues in 
biocatalytic and organic synthesis. A study by Ma et. al.184 showed increased activity of LDH when 8-(6-
aminohexyl)-amino-NADH was used compared to the native co-factor. 
5.3.4 Downstream Processing 
5.3.5 Introduction 
Usually, in the reactions catalyzed by ω-transaminases substrates and products are very similar due to the 
reaction mechanism where keto- and amino- groups are exchanged. Additionally, the substrates and products 
of the cascade system have to be taken into consideration when defining a suitable product separation 
technique. This similarity in size, hydrophobicity and volatility makes the product separation challenging, as 
shown in Table 18. 
Table 18 Physical and chemical properties of compounds in the investigated ω-transaminase/LDH/FDH system 
 Mw [g mol-1] Tm [°C] pKa logP pvap [mm Hg] Saq [g L-1] 
acetophenone 120.15 -9.86 - 1.58 3.97∙10-1 6.1 
alanine 89.09 292.0 2.35; 9.87 -2.96 2.68∙10-8 165.0 
MBA 121.18 -65.0 9.75 1.49 5.00∙10-1 43.0 
pyruvate 88.06 11.8 2.3 -1.24 9.68∙10-1 soluble 
lactate 90.08 16.8 3.86 -0.72 8.13∙10-2 soluble 
ammonium 
formate 
63.06 116.0 3.771; 9.252 -0.27 - soluble 
1 pKa of formic acid 
2 pKa of ammonia 
 
However, it is important to distinguish product recovery from ISPR and recognize possibilities, advantages and 
challenges of both approaches. Product recovery describes a procedure where both reaction and downstream 
operation are performed in batch mode. When a biocatalytic process has reached the desired yield, the 
biocatalyst has been removed, preferably by techniques which will allow reuse of the biocatalyst, and the 
reaction mixture is manipulated to allow selective recovery of a product. Although no ω-transaminase process 
utilizing cascades has been found in the literature, for the purposes of demonstration, an industrial process 
has been envisioned based on the work of Koszelwsk et. al.185 and the process flow diagram is shown in Figure 
60. 
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Figure 60 Envisioned industrial process setup for production of optically pure amines fitted to the product recovery method developed by Koszelewski et.al.185; For substrates BA 
(benzylacetone) and ala (alanine), the Keq is 6.07∙10-4 (Tufvesson et al.98), and the LDH/GDH cascade system is deployed to shift the equilibrium; APB – 3-amino-1-phenylbutane; 
pyr – pyruvate; gluc – glucose; gluco – gluconate; gluclac – glucono-1,5-lactone; DCM – dichloromethane; UFMR – UlfraFiltration Membrane Reactor 
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The product recovery procedure developed by Koszelewski et. al.185 was applied to the ω-
transaminase/LDH/GDH system at laboratory scale with benzylacetone and alanine as substrates, and it 
involved pH regulation of the reaction medium after the completion of the reaction. First, the pH was adjusted 
to a pH value of 1 causing the protonation of alanine and the product APB. The extraction of acetophenone 
with dichloromethane (DCM) as a solvent was carried out, after which the pH was again adjusted to a value of 
12. Under those conditions the product is neutrally charged and extraction with DCM is possible. In this process 
demonstration the final product is obtained by distillation of the DCM-APB mixture and the solvent is recycled 
back to the process. Also, the distillation of the DCM-BA mixture has been considered where both the solvent 
and the substrate benzylacetone are recycled back to the process. 
However, applying ISPR to the process may bring many advantages to the given process, but first numerous 
challenges have to be tackled. ISPR techniques are based on in-situ removal of product during the reaction, 
either by removing the product directly within the reactor or by means of an external unit where the removal 
occurs. In the latter case a recirculation is established and a reaction medium containing less product is 
returned back to the reactor. In the investigated ω-transaminase/LDH/FDH case where acetophenone and 
alanine are substrates a severe thermodynamic limitation (Keq = 4.03∙10-5) requires exquisite selectivity of the 
ISPR technique, since otherwise even trace quantities of the removed substrates would shift the 
thermodynamics in the opposite direction and make the process unfeasible. 
 
Figure 61 Charge analysis of the components of the ω-transaminase/LDH/FDH system as a function of pH 
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Based on the charge analysis shown in Figure 61, it is possible at operating pH 7 to selectively remove the 
product based on the differences in charge, meaning that separation either by ion exchange or electrodialysis 
should be possible. To avoid adsorption of enzymes to the ion exchange resins or fouling of the membranes 
in the electrodialysis module the application of ISPR techniques will have to be external as a consequence of 
the soluble form of the enzymes. Possible process implementations are shown in Figure 62. 
 
Figure 62 Possible process configurations based on separation on the basis of charge of individual compounds in the reaction 
medium 
Both ion exchange and electrodialysis can be performed in batch and continuous mode. The batch mode of 
operation of both techniques would consist of several steps where the first step would be running the reaction 
the reaction until the desired yield is achieved. The second step is then the product recovery by ion exchange 
or electrodialysis while the final steps include e.g. washing the resins, extraction and purification of the product. 
However, the continuous mode of product removal or ISPR can prove to be very beneficial. 
To illustrate the benefits of ISPR a theoretical case has been envisioned where the process of production of 
MBA via the ω-transaminase/LDH/FDH system is established and the ISPR method (either ion exchange resin 
or electrodialysis) is successful in selectively removing 50 % of the inlet MBA concentration. The volume of the 
UFMR is 1 L and the volume of the ISPR unit is 0.2 L, while the flow rate is 0.1 L min-1. The concentrations of 
catalytically active components were selected such that they represent 95 % conversion under fed batch 
conditions (Vmax_f,r = 55.33 mol min-1 L-1, γLDH = 11 g L-1, γFDH = 0.3 g L-1 and cNADH = 0.1 mmol L-1). Simulations 
showed that a 100 % conversion is achieved after approximately 8 hours when above described ISPR techniques 
is applied. This illustrative example shows that significant improvements of the yield can be achieved by process 
intensification. The outcomes of using an ISPR will result in either decreased required value of Vmax_f,r for 
achieving a desired 95 % conversion within 24 h or higher allowed product inhibition, or combination of both. 
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Figure 63 Possible values of KiMBA as a function of Vmax_f,r in the case of 50 % ISPR for 95 % conversion; conditions for the 
simulation are stated in the section 5.2.3. 
In the Figure 63 the combination of the required ω-transaminase activity, expressed as Vmax_f,r, and the 
inhibition by MBA, expressed as KiMBA are shown for the above described illustrative example of ISPR. It is for 
example possible to achieve 95 % conversion when Vmax_f,r = 30 mmol min-1 L-1 and the allowed MBA inhibition 
is approximately KiMBA = 0.6 mol L-1. This example clearly shows how process design and clever use of selective 
ISPR technologies can yield a significant reduction of the requirements for ω-transaminase development 
(activity, product inhibition). 
5.4 Discussion 
In this chapter the industrial implementation of processes of optically pure amine synthesis facing severe 
thermodynamic challenges was discussed, focusing on a specific case of MBA production from acetophenone 
and alanine with the use of the LDH/FDH cascade system. 
It was concluded that the fed batch operating mode fits the best to the process, due to the fact that this is a 
relatively slow reaction and the activity of the ω-transaminase still has to be improved further. To exploit the 
developed activity of the ω-transaminase, the few industrially established processes, e.g. the Sitagliptin 
process, use the soluble enzyme. The literature suggests that the co-factor and multi-enzyme processes should 
be in the soluble form, enabling mobility of catalyst molecules. An UltraFiltration Membrane Reactor (UFMR) 
is currently an option for the ω-transaminase/LDH/FDH system. The possibility of external ISCPR was dismissed 
due to the significantly decreased yields when applying external ISCPR, which only confirmed the fact that 
ISCPR has to be performed internally. Another very important issue was the stability of the co-factor, which at 
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in-vitro conditions, especially at conditions predicted for the investigated case, has a very low stability and 
therefore stabilization measures e.g. immobilization will be required. 
Two types of DSP – product recovery and ISPR, were also discussed in this chapter showing that product 
recovery is easier to perform by changing the reaction mixture conditions once the reaction is finished. 
However this procedure puts more demands to the performance of the ω-transaminase in terms of activity 
and requirements for reduced product inhibition. Using ISPR is extremely challenging in the investigated case 
and requires exquisite selectivity of product removal. 
Charge analysis showed that selective removal of the product MBA is possible via charge separation techniques, 
e.g. by means of ion exchange resins or electrodialysis. Indeed, each technology will have to pass rigorous 
selectivity testing before it can be implemented as ISPR technique. A showcase was developed to indicate 
possible benefits of such an integrated approach where 50% of the inlet product was removed. The results for 
that particular case showed that both the required ω-transaminase activity expressed as Vmax_f,r and the 
resistance towards product inhibition can be significantly reduced by means of process intensification. 
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6 Thesis Discussion and Conclusions 
The focus of this thesis was the biocatalytic synthesis of optically pure chiral amines, small molecule building 
blocks for many important pharmaceutical compounds. Furthermore, equilibrium shifting strategies for the 
thermodynamic “worst case scenario” with Keq = 4.03∙10-5 were investigated, concluding that only ISCPR by 
enzymes is a possible solution due to the selectivity of this method. Although literature suggested several 
options of ISCPR by enzymes, no attempts on industrial scale have been reported, and information on how to 
select between proposed cascades is also not available in the literature. The developed selection procedure 
was focused on the feasibility of the implementation of cascade enzymes into an industrial process. A first 
consideration was described as the thermodynamic ability of a cascade to remove the co-product to low 
enough concentrations to allow achieving 95 % conversion. The justification for this selection step lies in the 
fact that thermodynamic equilibrium of a cascade reaction cannot be improved by protein engineering, and if 
a cascade is thermodynamically unable to achieve the desired yield, it should be disregarded. The second step 
included a discussion about substrate selectivity of either cascades or ω-transaminase and identified outcomes 
of possible side reactions. The final step was based on experimental determination of the operational stability 
of cascade enzymes identifying viable options. This selection process yielded two promising implementation 
candidates: LDH/FDH and LDH/FDH. 
Model development took the investigation another step forward, predicting for the two cascade candidates 
and under the given conditions – e.g. starting concentration of reaction mixture compounds, concentrations 
of catalytically active components and reaction time to name a few – the required future development of the 
ω-transaminase. Since process design, e.g. ISPR, was not taken into consideration at that point, the envisioned 
ω-transaminase had to be devoid of product inhibition. A second crucial development of the ω-transaminase 
was the required activity expressed as Vmax_f,r [mmol min-1 L-1] as a function of cascade efficiency to remove 
pyruvate expressed in mass concentration of cascade enzymes and molar concentration of the co-factor. Based 
on its higher performance for lower co-factor concentrations, the LDH/FDH system was chosen. 
For long lasting reactions and due to the low solubility of the substrate acetophenone, the most suitable mode 
of operation proved to be fed batch. Simulations showed that external co-product removal is not a viable 
option, and therefore a one pot process was selected where all catalytically active components are present. 
The biocatalyst formulation was discussed at length and it was concluded that the soluble form of the ω-
transaminase is required provided that its stability is satisfactory. The soluble form of the cascades was chosen 
based on previous similar process implementations, and immobilizing only the co-factor to retain it with the 
membrane of the UFMR. 
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A DSP technique has been proposed, based on a lab scale procedure obtained from the literature185, where the 
final reaction mixture is modified via pH change to enable relatively selective extractions and final product 
separation and recovery. However, when ISPR is applied it was demonstrated that this comes along with several 
potential advantages, e.g. the required ω-transaminase activity for achieving 95 % conversion within 24 h can 
be reduced or an enzyme with product inhibition may be used. Additional charge analysis of the species 
indicated that at operating pH value a charge separation via ion exchange or electrodialysis is possible. 
Based on the investigations done in this thesis, the key findings, the main novelties and conclusions are 
highlighted below: 
 Shifting the equilibrium of a thermodynamically challenged reaction is possible and industrially 
applicable. Thermodynamically challenged extremes require powerful and more important selective 
strategies making ISCPR by enzymes the only solution. However a major challenge, especially for the 
investigated case, is not the low Keq value but the inadequate activity of the enzyme e.g. the ω-
transaminase. As a general rule that can be applied: lower Keq requires higher enzyme activity. 
 The cascade systems have to fulfill the following requirements: 
o Thermodynamic ability of a cascade system (ability of a cascade to remove thermodynamically 
the product to such concentrations that the required yield can be achieved) 
o Substrate selectivity: a) of cascades b) of the “main” enzyme, here ω-transaminase, towards 
the products of cascade reaction(s). For possible outcomes, see section 3.4.2 
o Operational stability of cascade enzymes and co-factors has to be investigated, and eventually 
the operational stability of the “main” enzyme needs to be evaluated as well 
o All cascade enzymes must be devoid of inhibition by accumulating components i.e. products 
of all present reactions 
o Co-product removing enzymes require low Km which enables fast removal at low 
concentrations using reasonable enzyme concentrations 
 If the “main” enzyme has a sufficiently high activity and possibly a low stability, immobilization is 
encouraged to achieve enzyme recycle and reuse 
 Immobilization of cascade enzymes should be considered only when the immobilization technique 
does not create significant concentration gradients and mass diffusion issues 
 Immobilization of co-factor recycling systems should involve only the immobilization of the cofactor 
to ensure retention within the membrane(s) 
 Immobilization efforts must aim at compatibility between the “main” enzyme formulation and the 
cascade enzyme formulation, e.g. the soluble form of the enzyme might adsorb to the carrier of the 
immobilized enzyme if soluble and immobilized enzyme forms are mixed in a reactor. 
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 External ISCPR is not an option for severely thermodynamically challenged reactions, and therefore 
internal methods must be applied meaning that the place of co-product removal has to be in the 
micro-environment where its production takes place. 
 The developed procedure for cascade selection is a generic procedure and can be applied not only to 
other systems catalyzed by an ω-transaminase, but also to any thermodynamically challenged reaction 
using ISCPR by enzymes as an equilibrium shifting strategy. 
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7 Future Work and Final Remarks 
There are several challenges that still have to be addressed in the future. 
Open challenges remaining for the current work: 
A lot of time and energy was put into LDH, GDH and FDH characterization and model development. However, 
a validation of these models in a coupled mode, e.g. LDH/GDH and LDH/FDH and under process relevant 
conditions was not performed, and analytical methods need to be developed. Model validation would 
significantly increase the reliability and potential future use of the model in the development of a model based 
soft sensor for establishing a reliable acetophenone feeding. 
Immobilization of the co-factor has been identified as one of the required steps for process implementation, 
followed by experimental re-estimation of kinetic parameters of the cascade enzymes. This is also work that 
needs to be done in the future. 
Immobilization of cascade enzymes when there are no significant concentration gradients. Such aspects could 
be investigated in more detail using techniques such as computational fluid dynamics. 
Ion exchange resins or electrodialysis were identified as the most feasible DSP options. One possible 
bottleneck, as seen in Figure 61, could be that two positively charged species are present at pH 7, i.e. MBA and 
a cation of a formate salt (NH4+). At the beginning of the reaction the ammonium concentration is 
approximately 550 mmol L-1 while the concentration of the MBA is 0. The ion exchange resin would quickly be 
saturated with ammonium ions, thus rendering the ISPR inoperable and pointing towards electrodialysis as the 
most suitable ISPR technique. 
Running the proposed system in an UFMR together with characterization of the electrodialysis unit in a lab 
scale setup, and demonstrating the production of > 50 g L-1 of product still remains to be done in the future, 
as well as further process optimization and implementation to pilot and industrial scale. 
Final remarks 
This thesis is focused on the possibilities of ISCPR by currently developed enzymes and possible 
implementation options represent the currently viable options. However, the future enzyme development will 
surely allow other cascade options to become an interesting alternative to the current LDH/FDH. On that list 
of cascade options considered here, the AlaDH/FDH system will surely emerge offering alanine recycling and 
possibly also cheap amine sources to be used. However, the stability has to be improved and inhibition by 
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alanine has to be alleviated (Appendix 7A). Other processes / companies might go for “less is more” by 
eliminating the use and recycling of the expensive co-factor by using PDC or ALS cascades if more substrate 
selective transaminases are developed in the future. 
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Appendix 
Appendix 3A – pH profiles of cascade enzymes found in the literature 
  
  
  
 
Figure 64 pH profile of ω-transaminase ATA-040 at 30°C, cacetophenone = 10 mmol L-1,c2-propylamine = 100 mmol L-1, γTAm = 3 g  
L-1 at wide range buffer163 pH 2-12 compared to pH profile of: A) LDH adopted from Li et. al.186, B) GDH adopted from 
Kobayashi et. al.187, C) FDH adopted from Ding et. al.188, D) AlaDH adopted from Yoshida et. al.189, E) YADH adopted from 
Drewke et. al.190, F) PDC adopted from Hiromasa et. al.191 and G) ALS adopted from Yoon et. al.192 
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Appendix 3B – An example of Matlab® code for calculating equilibrium 
concentrations of reaction components and the corresponding yield for 
the LDH/GDH system 
clc 
clear all 
  
% Tolerances 
tol     = 1e-15; 
diff    = 1; 
  
% Initial values 
ACP         = 500;  % mM 
Alanine     = 1000; % mM 
MBA         = 0;    % mM 
Pyruvate    = 0;    % mM 
NADH        = 0.1;  % mM 
lac         = 0;    % mM 
NAD         = 0;    % mM 
Keq1        = 1/24800; 
Keq2        = 2.12e4; 
Glucose     = 550;  % mM 
Gluc15lac   = 0;    % mM 
Keq3        = 1.67e23; 
x = 1; y = 1; z = 1; 
while (diff > tol) 
prev = MBA; 
  
% transaminase reaction 
x = (MBA + Pyruvate + Keq1 * (ACP + Alanine) – sqrt((MBA + Pyruvate + Keq1 * 
(ACP + Alanine))^2 – 4 * (Keq1 – 1) * (Keq1 * ACP * Alanine – Pyruvate * 
MBA)))/(2 * (Keq1 – 1)); 
  
ACP         = ACP – x; 
Alanine     = Alanine – x; 
Pyruvate    = Pyruvate + x; 
MBA         = MBA + x; 
  
%LDH reaction 
y = (NAD + lac + Keq2 * (Pyruvate + NADH) – sqrt((NAD + lac + Keq2 * (Pyruvate + 
NADH))^2 – 4 * (Keq2 – 1) * (Keq2 * Pyruvate * NADH – lac * NAD)))/(2 * (Keq2 – 
1)); 
  
Pyruvate    = Pyruvate – y; 
NADH        = NADH – y; 
lac         = lac + y; 
NAD         = NAD + y; 
  
% GDH reaction 
z = (NADH + Gluc15lac + Keq3 * (Glucose + NAD) – sqrt((NADH + Gluc15lac + Keq3 * 
(Glucose + NAD))^2 – 4 * (Keq3 – 1) * (Keq3 * Glucose * NAD – Gluc15lac * 
NADH)))/(2 * (Keq3 – 1)); 
  
Glucose     = Glucose – z; 
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NAD         = NAD – z; 
Gluc15lac   = Gluc15lac + z; 
NADH        = NADH + z; 
 
diff = abs(prev – MBA) 
end 
  
Pyruvate 
Conversion = MBA / 500 * 100 
 
Appendix 3C – Substrate selectivity of dehydrogenases towards the 
acetophenone 
 
Figure 65 Progress curves for reduction of acetophenone catalyzed by LDH, AlaDH and YADH at pH 7 and 30°C at initial 
concentrations of substrates cacetophenone = 30 mmol L-1 and cNADH = 0.1 mmol L-1 and with the concentration of all enzymes at 
1 g L-1. Additional 100 μL of NADH standard solution was added in the period from about 250 to 400 s to speed up the reaction 
if it is occurring slowly or to observe consumption of the cofactor if the reaction is too fast and any observable change in 
adsorption happened before the measurement in the spectrophotometer started 
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Appendix 3D – Relative stability of investigated cascade enzymes 
  
  
  
Figure 66 Relative stabilities of the investigated enzymes at pH 7 and 30°C and in the reaction mixture 1 and 2 defined in 
section 3.3.3.1 over a period of 24 h: A) stability of LDH 1 in reaction mixture 1; B) stability of LDH 2 in reaction mixture 1; C) 
stability of AlaDH in reaction mixture 2; D) stability of GDH 1 in reaction mixture 1; E) stability of GDH 2 in reaction mixture 
1; F) stability of FDH in reaction mixture 2 
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Appendix 4A – Linear regression plots for LDH catalyzed reaction 
  
  
  
Figure 67 Linear regression plots of initial rate experiments shown in Figure 46 for estimating kinetic parameters of reaction 
catalyzed by LDH: A) Hanes plot over pyruvate range 0.05 – 0.4 estimating 𝐾𝑚
𝑃𝑌𝑅, B) Hanes plot estimating 𝑉𝑚𝑎𝑥
𝐿𝐷𝐻 and 𝐾𝑚
𝑁𝐴𝐷𝐻, 
C) Dixon plot estimating 𝐾𝑖
𝑃𝑌𝑅; D) Hanes plots of increasing lactate concentrations estimating 𝐾𝑖
𝐿𝐴𝐶 ; E) Hanes plots of 
increasing NAD+ concentrations estimating 𝐾𝑖
𝑁𝐴𝐷+; F) Hanes plots of increasing alanine concentrations estimating 𝐾𝑖
𝐴𝐿𝐴 
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Appendix 4B – Linear regression plots for GDH catalyzed reaction 
Figure 68 Linear regression plots of initial rate experiments shown in Figure 48 for estimating kinetic parameters of reaction 
catalyzed by GDH: A) Hanes plot over estimating 𝐾𝑚,𝐺𝐷𝐻
𝐺𝐿𝑈 , B) Hanes plot estimating 𝑉𝑚𝑎𝑥
𝐺𝐷𝐻 and 𝐾𝑚
𝑁𝐴𝐷+ , C) Hanes plots of 
increasing glucono-1,5-lactone concentrations estimating 𝐾𝑖
𝐺𝐿𝑈𝐶−1,5−𝐿𝐴𝐶 ; D) Hanes plots of increasing NADH concentrations 
estimating 𝐾𝑖,𝐺𝐷𝐻
𝑁𝐴𝐷𝐻; E) Hanes plots of increasing MBA concentrations estimating 𝐾𝑖,𝐺𝐷𝐻
𝑀𝐵𝐴  
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Appendix 4C – Linear regression plots for FDH catalyzed reaction 
  
  
Figure 69 Linear regression plots of initial rate experiments shown in Figure 50 for estimating kinetic parameters of reaction 
catalyzed by GDH: A) Hanes plot over estimating 𝐾𝑚
𝐴𝑀𝐹 , B) Hanes plot estimating 𝑉𝑚𝑎𝑥
𝐹𝐷𝐻 and 𝐾𝑚
𝑁𝐴𝐷+, C) Hanes plots of increasing 
NADH concentrations estimating 𝐾𝑖,𝐹𝐷𝐻
𝑁𝐴𝐷𝐻; D) Hanes plots of increasing ACP concentrations estimating 𝐾𝑖
𝐴𝐶𝑃 
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Appendix 4D – An example of Matlab® code calculating Vmax_f,r of ω-
transaminase to achieve 95 % conversion within 24 h and as a function of 
cascade enzyme concentrations 
clear all 
close all 
clc 
  
Vmax = zeros(100,35); 
for i = 1:35 
    for j = 1:100 
  
% Transaminse parameters 
K       = 1/24800;  % [-] 
Enz     = 1;        % [g L-1] 
Vmax_f  = 10;       % [mmol min-1 L-1] 
KmACP   = 0.54;     % [mmol L-1] 
KmAla   = 1.07;     % [mmol L-1] 
KmMBA   = 53.03;    % [mmol L-1] 
KmPy    = 9.58;     % [mmol L-1] 
KiMBA   = 1000;     % [mmol L-1]  no inhibition 
KiAla   = 1000;     % [mmol L-1]  no inhibition 
Vmax_r = Vmax_f / sqrt(K) * sqrt(KmMBA * KmPy / KmACP / KmAla);%[mmol min-1 L-1] 
  
% Cascade parameters (LDH & GDH) 
Enz1    = [8.6 8.7 8.8 8.9 9 9.1 9.2 9.3 9.4 9.5 9.6 9.7 9.8 9.9 10 10.1 10.2 
10.3 10.4 10.5 10.6 10.7 10.8 10.9 11 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 
11.9 12];       % [g L-1] 
Vmax1   = 39.0251;  % [mmol min-1 g-1] 
KmNADH  = 0.0266;   % [mmol L-1] 
KmPyr   = 0.0365;   % [mmol L-1] 
KiPyr   = 2.8728;   % [mmol L-1] 
Kilac   = 5.1967;   % [mmol L-1] 
KiNAD   = 0.6288;   % [mmol L-1] 
KiAlan  = 83.9268;  % [mmol L-1] 
Enz21   = [10 9.9 9.8 9.7 9.6 9.5 9.4 9.3 9.2 9.1 9 8.9 8.8 8.7 8.6 8.5 8.4 8.3 
8.2 8.1 8 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7 6.9 6.8 6.7 6.6 6.5 6.4 6.3 6.2 
6.1 6 5.9 5.8 5.7 5.6 5.5 5.4 5.3 5.2 5.1 5 4.9 4.8 4.7 4.6 4.5 4.4 4.3 4.2 4.1 
4 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2 
1.9 1.8 1.7 1.6 1.5 1.4 1.3 1.2 1.1 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1];       
% [g L-1] 
Enz2    = Enz21/10; 
Vmax2   = 53.4958;  % [mmol min-1 g-1] 
KmNAD   = 0.1453;   % [mmol L-1] 
Kmgluc  = 75.7494;  % [mmol L-1] 
Kiglucl = 32.2336;  % [mmol L-1] 
KiMBAc  = 13.9023;  % [mmol L-1] 
KiNADH  = 0.3443;   % [mmol L-1] 
Khy     = (10^-7*4.7*10^-2+10^-7*4*10^3+2.5*10^-4)*60; %[min-1] 
Keqhy   = 1/0.185; 
Khyr    = Khy/Keqhy; %[min-1] 
  
par  = [K Enz Vmax_f Vmax_r KmACP KmAla KmMBA KmPy KiAla KiMBA Enz1(i) Vmax1 
KmNADH KmPyr KiPyr Kilac KiNAD KiAlan Enz2(j) Vmax2 KmNAD Kmgluc Kiglucl KiMBAc 
KiNADH Khy Keqhy Khyr]; 
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init = [1000 30 0 0 0.1 0 0 550 0 0]; 
Vmax(j,i) = fminsearch(@cost,Vmax_f,[],par,init); 
    end 
end 
 
function j = cost (Vmax_f, par, C) 
  
par(3) = Vmax_f ; 
[t,C] = ode15s(@F_enzyme,[0:10:1440],C,[], par); 
yield = C(end,4) / 500 * 100; 
  
r = (95 - yield); 
j = r^2; 
 
function dC = F_enzyme(t,C,par) 
  
K       = par(1); 
Enz     = par(2); 
Vmax_f  = par(3); 
Vmax_r  = par(4); 
KmACP   = par(5); 
KmAla   = par(6); 
KmMBA   = par(7); 
KmPy    = par(8); 
KiMBA   = par(9); 
KiAla   = par(10); 
Enz1    = par(11); 
Vmax1   = par(12); 
KmNADH  = par(13); 
KmPyr   = par(14); 
KiPyr   = par(15); 
Kilac   = par(16); 
KiNAD   = par(17); 
KiAlan  = par(18); 
Enz2    = par(19); 
Vmax2   = par(20); 
KmNAD   = par(21); 
Kmgluc  = par(22); 
Kiglucl = par(23); 
KiMBAc  = par(24); 
KiNADH  = par(25); 
Khy     = par(26); 
Khyr    = par(27); 
  
% Transaminase 
r = (Enz  * Vmax_f * Vmax_r * (C(1,1) * C(2,1) - C(3,1) * C(4,1) / K)) / (Vmax_r 
* KmACP * C(1,1) + Vmax_r * KmAla / K * C(2,1) + Vmax_f * KmMBA / K * C(3,1) + 
Vmax_f * KmPy / K * C(4,1) + Vmax_r * C(1,1) * C(2,1) + Vmax_f * KmMBA / KiAla / 
K * C(1,1) * C(3,1) + Vmax_f / K * C(3,1) * C(4,1) + Vmax_r * KmAla / KiMBA * 
C(2,1) * C(4,1)); 
  
% Cascades 
r1 = Enz1 * Vmax1 * C(5,1) * C (3,1) / ((KmPyr * (1 + C(7,1) / Kilac + C(1,1) / 
KiAlan) + C(3,1) + C(3,1)^2 / KiPyr)*(KmNADH * (1 + C(6,1) / KiNAD) + C(5,1))); 
r2 = Enz2 * Vmax2 * C(8,1) * C (6,1) / ((Kmgluc * (1 + C(9,1)/Kiglucl + C(4,1) / 
KiMBAc) + C(8,1)) * (KmNAD * (1 + C(5,1) / KiNADH) + C(6,1))); 
r3 = Khy * C(9,1); 
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r4 = Khyr * C(10,1); 
  
if C(4,1) <= 470 
     
% differential equations 
dC(1,1) = -r;           % alanine 
dC(2,1) = 0;            % ACP 
dC(3,1) = r - r1;       % pyruvate 
dC(4,1) = r;            % MBA 
dC(5,1) = r2 - r1;      % NADH 
dC(6,1) = r1 - r2;      % NAD 
dC(7,1) = r1;           % lactate 
dC(8,1) = -r2;          % glucose 
dC(9,1) = r2 - r3 + r4; % glucono-1,5-lactone 
dC(10,1)= r3 - r4;      % gluconate 
  
else 
     
% differential equations 
dC(1,1) = -r;           % alanine 
dC(2,1) = -r;           % ACP 
dC(3,1) = r - r1;       % pyruvate 
dC(4,1) = r;            % MBA 
dC(5,1) = r2 - r1;      % NADH 
dC(6,1) = r1 - r2;      % NAD 
dC(7,1) = r1;           % lactate 
dC(8,1) = -r2;          % glucose 
dC(9,1) = r2 - r3 + r4; % glucono-1,5-lactone 
dC(10,1)= r3 - r4;      % gluconate 
  
end 
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Appendix 5A – Stability of the co-factor NADH in different buffers 
  
  
 
Figure 70 Stability of the co-factor NADH in different media (cbuffer = 100 mmol L-1) at pH 7 and 30°C (○) – experiment, (-) – 
model: A) in water, fitted to second order kinetics t1/2 = 40.67 h; in buffers following first order kinetics B) in phosphate buffer, 
t1/2 = 21.09 h; C) in TRIS buffer, t1/2 = 343.16 h; D) in hepes buffer, t1/2 = 59.18 h; E) in wide-range163 buffer, t1/2 = 56.34 h 
 
 
 
 
 
0
0,02
0,04
0,06
0,08
0,1
0 10 20 30 40 50 60 70
c N
A
D
H
[m
m
o
l 
L-
1
]
time [h]
0
0,02
0,04
0,06
0,08
0,1
0 10 20 30 40 50 60 70
c N
A
D
H
[m
m
o
l 
L-
1
]
time [h]
0
0,02
0,04
0,06
0,08
0,1
0 10 20 30 40 50 60 70
c N
A
D
H
[m
m
o
l 
L-
1
]
time [h]
0
0,02
0,04
0,06
0,08
0,1
0 10 20 30 40 50 60 70
c N
A
D
H
[m
m
o
l 
L-
1
]
time [h]
0
0,02
0,04
0,06
0,08
0,1
0 10 20 30 40 50 60 70
c N
A
D
H
[m
m
o
l 
L-
1
]
time [h]
A 
C 
D 
E 
B 
132 
 
Appendix 7A – Inhibition profile of AlaDH by alanine 
 
Figure 71 Inhibition profile of AlaDH by alanine at 30ºC and pH 7 at cpyruvate = 1 mmol L-1, cNADH = 0.1 mmol L-1 and cammonium 
formate = 250 mmol L-1; (○) – experiment; (-) – model described by equation below: 
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